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ABSTRACT
Fraser syndrome is a multisystem malformation, the main features being 
cryptophthalmos, syndactyly and renal defects. Mouse blebbed mutants provide a 
model for Fraser syndrome, with mutations in five blebbed loci giving similar 
phenotypes to Fraser syndrome. The condition is genetically heterogeneous and the 
first disease locus to be identified, FRAS1, encodes a protein with similarity to the 
sea urchin extracellular matrix blastocoelar protein ECM3. The domain structure of 
FRAS1 suggests a structural role within the extracellular matrix as well as in cell 
signalling. Mutations in FRAS1, and Frasl in the blebbed (bl) mouse, have been 
identified that result in the premature termination of the protein. Mutations in the 
Freml gene have been shown to underly the head blebs (heb) phenotype.
In this thesis, a missense mutation at a second human locus is described, the affected 
gene FREM2, having homology to a gene closely linked to the murine 
myelencephalic blebs (my) locus. A genetrap within Frem2 is shown to have a 
similar phenotype to the other blebs mutants. The expression pattern of Frem2 is 
studied and auditory defects in the my mice are identified and analysed. Some 
functional analyses of Frasl was carried out suggesting a role for Frasl in binding 
BMPs.
It is also shown that the loss of the cytoplasmic multi-PDZ domain protein glutamate 
receptor interacting protein 1 (GRIP1) results in a phenotype similar to that of Fraser 
syndrome. In the eye blebs (eb) mouse a deletion has been detected covering two 
coding exons that disrupts the (Grip!) gene, resulting in a premature termination.
These mouse models for Fraser syndrome should provide important insights into the 
development of epithelial structures, as well as eye and kidney development and 
enable us to study the role of Fras-Frem proteins in other organs such as the heart 
and ear.
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CHAPTER 1. INTRODUCTION
1.1 FRASER SYNDROME
In the First century AD Pliny the Elder described a family with three children born 
with a membrane over the eye, which may well be the first reported description of 
autosomal recessive cryptophthalmos. In 1962 Dr. George Fraser described two 
sibships in which the affected children had cryptophthalmos, among other 
malformations. Initially the condition was known as cryptophthalmos syndrome, but 
a review of cases by Thomas et al. in 1986 noted that cryptophthalmos was not 
necessary for the constellation of features to be seen together, and the condition was 
subsequently known as Fraser Syndrome.
Fraser Syndrome (OMIM; 219000) is a very rare autosomal recessive condition with 
incidence estimated as one case per two hundred and fifty thousand live births, or 
eleven cases per one hundred thousand stillbirths (Martinez-Frias et al. 1998). 
Diagnosis of Fraser Syndrome is currently based on the presence of either two major 
and one minor characteristic or one major and four minor characteristics, however a 
recent extensive study of Fraser syndrome patients has revealed that malformations 
of the larynx and renal agenesis are more common than originally thought and 
should be regarded as major characteristics. All figures regarding the incidence of 
these characteristics are from that study (Mieke van Haelst, personal 
communication).
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MAJOR
CHARACTERISTIC
MINOR
CHARACTERISTIC
Cryptophthalmos 
Syndactyly 
Abnormal genitalia 
Sibling with Fraser Syndrome
Congenital malformation of nose 
Congenital malformation of ears 
Congenital malformation of larynx 
Cleft lip +/- palate 
Skeletal defects 
Umbilical hernia 
Renal agenesis 
Mental retardation
Table 1.1: The diagnostic criteria for Fraser Syndrome, as defined by Thomas et al. 
1986.
1.1.1 Clinical Features
1.1.1.1 Cryptophthalmos and eye development
The most striking feature of Fraser syndrome is cryptophthalmos, which is present in 
85% of cases. This is a congenital absence of the palprebal fissures (eyelids), with 
skin passing continuously form the forehead to the cheek (Figure 1.2).
The developing eye begins as a single eye field located centrally in the head, which 
then separates into two lateral optic vesicles. These extend toward the overlying 
surface ectoderm resulting in the formation of the lens placode, a thickening of the 
surface ectoderm that comes into contact with the optic vesicle. The interaction of 
the lens placode with the optic vesicle results in the invagination of the 
neuroectoderm and the formation of the lens vesicle and double-layered optic cup, 
the inner layer giving rise to the neural retina and the outer layer giving rise to the 
retinal pigment epithelium. The ciliary body and iris are derived from the distal tip of 
the optic cup, at the point where the neural retina and retinal pigment epithelium 
meet.
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Once the lens has formed, it detaches from the ectoderm and two waves of neural 
crest cells migrate into the space between the lens and epithelium, forming the 
corneal epithelium and stromal keratocytes. Following fusion of the eyelids the 
corneal epithelium enlarges and matures. Further developmental events occur 
succeeding the opening of the eyelids to result in the mature cornea (Chow and Lang 
2001; Graw 2003; Cvekl and Tamm 2004; Zieske 2004).
Cryptophthalmos can be bi- or unilateral, complete, incomplete or congenital 
symblepharon (abortive). The complete form is more common in Fraser syndrome, 
and involves the primitive epithelium overlying the lens, which normally 
differentiates into the cornea and conjunctiva, becoming a part of the skin. The 
eyelids do not form and the eyelid skin grows continuously from the forehead to the 
cheek, covering the underlying globe, which is usually abnormal (Zieske
2004). Incomplete cryptophthalmos has the presence of a rudimentary lateral lid and 
conjunctival sac. Facial skin fuses to the medial aspect of the globe with no eyelid 
structures in that area. The congenital symblepharon variety presents with fusion of 
the upper eyelid skin to the cornea, often with a small globe. The eyelid in this area 
is absent but there may be a small amount of normal eyelid laterally (Egier et al.
2005).
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Figure 1.1: a) Invagination of the optic vesicle results in the formation of the lens 
vesicle (LV) and presumptive neural retina (NR). The point at which the retinal 
pigment epithelium (RPE) and neural retina meet gives rise to components of the 
ciliary body and iris (C/I), b) The mature eye. C, cornea; LE, lens epithelium: LF, 
lens fibre cells; I, iris; CB, ciliary body; GCL, ganglion cell layer; INL, inner nuclear 
layer; ONL, outer nuclear layer: ON, optic nerve; DOS, dorsal optic stalk; VOS, 
ventral optic stalk (Chow and Lang 2001).
In 17% of cases a tongue of hair extending from the anterior hairline to the orbital 
margin accompanies the cryptophthalmos. The prognosis for vision in patients with 
cryptophthalmos is poor, though surgical correction is possible in cases of 
incomplete cryptophthalmos, where the eyelids can be reconstructed with oral 
mucous membrane grafts. Other ocular abnormalities include microphthalmia, 
anophthalmia and corneal opacification (Slavotinek and Tifft 2002).
28
1.1.1.2 Syndactyly and limb development
Cutaneous syndactyly occurs in 95% of cases and varies in severity from a mild 
interdigital webbing to a more severe glove-like appearance (Figure 1.3). 
Occasionally, syndactyly involving the fusion of one or more digits occurs. 
Syndactyly is caused by defects in limb morphogenesis.
Limb buds grow out from the flanks of the body as mesenchymal cell masses 
covered by simple ectoderm. The position, number and identity of the limbs is 
dependent on the expression of specific Hox genes. Limb morphogenesis occurs 
along three axes, the anterior-posterior, dorso-ventral and proximo-distal axes 
(Tickle 2000). The growth process of the limb relies on mutual interactions between 
the mesoderm and ectoderm. The main interactions necessary for limb development 
are between the apical ectodermal ridge (AER) and the underlying mesenchyme, 
which mediates limb bud outgrowth; the ectodermal-mesenchymal interactions that 
control dorso-ventral patterning and mesenchymal-mesenchymal interactions which 
control anterior-posterior patterning (Altabef et al. 1997; Koussoulakos 2004). 
Growth of the limb depends on the formation of the AER, which secretes fibroblast 
growth factors (FGFs) to attract lateral plate and somitic mesodermal cells which are 
kept in the progress zone for proliferation and prevented from differentiating until 
the appropriate time (Pizette et al. 2001; Lonai 2003; Koussoulakos 2004).
Another major characteristic of Fraser Syndrome is abnormal genitalia, occurring in 
approximately 66% of cases. In severe cases, sex assignment can be difficult at birth. 
Of cases with genital anomalies, approximately 37% of females have cliteromegaly, 
with bicornuate uterus, uterine hypoplasia, vaginal atresia and synechiae/ hypoplasia 
of the labia also occasionally being present. Approximately 32% of males have 
cryptorchidism (Slavotinek and Tifft 2002).
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Figure 1.2: Two patients with complete cryptophthalmos. The tongue of hair from 
the anterior hairline to the orbital margin is visible in both.
Figure 1.3: Cutaneous syndactyly of the hand and foot. Both cases are quite severe, 
with individual digits being indistinguishable.
1.1.1.3 Renal development and agenesis
The most common of the minor characteristics is renal agenesis and occurs in 
approximately 76% of cases, and if bilateral, is commonly the cause of neonatal 
death. Cystic renal dysplasia or renal cysts and absent, hypoplastic bladders also 
occur in 17% of patients.
Mammals form three excretory organs during development, all derived from the 
intermediate mesoderm. The pronephros, which has no obvious function in 
mammals; the mesonephros, which serves as an excretory organ during 
embryogenesis and contributes to the testis; and the metanephros which differentiates 
into the permanent kidney. Kidney development begins with the pronephric tubules 
and duct forming from the intermediate mesoderm and fusing to form the pronephros 
(Lelongt and Ronco 2003; Ribes et al. 2003). The Wolffian duct (an extension of the 
pronephric duct) then grows caudally to reach the mesonephric mesenchyme and 
induce the formation of the mesonephros (Vainio and Lin 2002).
Induction of metanephric development involves two steps; firstly the ureteric bud, an 
epithelial tissue, is induced by the metanephric blastema to grow out from the 
mesonephric (Wolffian) duct and invades the metanephric blastema. Secondly, the 
mesenchymal cells of the blastema become polarised and form the nephric 
epithelium. Once the ureteric bud invades, the metanephric blastema grows, branches 
and stimulates nephron formation by inducing the mesenchymal cells surrounding it 
to condense. The condensed mesenchyme in turn induces the ureteric bud to branch, 
forming two ureteric tips. The condensing mesenchyme forms pretubular aggregates 
that undergo transition from mesenchyme to epithelium to form an epithelial tubule. 
These tubules develop into nephrons in several stages of development, which see the 
tubule developing into a comma-shaped body and subsequently into an S-shaped 
body. The S-shaped body forms the glomerulus and proximal and distal tubules, 
which fuse to the ureteric bud (Schedl and Hastie 2000; Vainio and Lin 2002; 
Lelongt and Ronco 2003; Ribes et al. 2003; Yu etal. 2004).
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The life expectancy of Fraser syndrome patients varies according to the severity of 
their phenotype. Approximately 24% of Fraser syndrome cases die within the first 
year of life with bilateral renal agenesis often the cause of death in early neonates 
(Slavotinek and Tifft 2002). However, cases of patients living into their twenties are 
known, with the oldest Fraser Syndrome patient (one of Dr. Fraser’s original 
patients) still living into her fifties.
1.2 MOUSE BLEBBED MUTANTS
The mouse blebbed mutants are a group of five mouse strains with similar 
phenotypes (Table 1.2). They all present with cryptophthalmos, syndactyly and clear 
embryonic liquid filled blebs/ blisters. As a result of the similarity of the blebbed 
phenotype to Fraser Syndrome, the blebbed mutants were, proposed as a mouse 
model for Fraser Syndrome (Winter 1990; Darling and Gossler 1994).
There are five blebbed mutants. The best characterised of these mutants is 
myelencephalic blebs (my), which was originally thought to be an x-ray induced 
mutant created by Little and Bagg in 1923, though subsequently it has been thought 
to have been present in the original stock of mice (Little and Bagg 1923). The term 
myelencephalic blebs arose through the original interpretation of the anomalies being 
due to the overproduction of cerebrospinal fluid leaving the myelencephalon in the 
form of blebs (Gruneberg 1952). The my mice present with hydronephrosis, 
syndactyly of the fore- and hindlimbs, renal agenesis and anophthalmia, my has been 
mapped to chromosome 3.
The head blebs mutant {heb) maps to chromosome 4 and has blebs restricted mainly 
to the head of the mouse, hence its name (Varnum and Fox 1981). It is characterised 
by anophthalmia, and absent eyelids, occasionally with syndactyly of the fore- and 
hindlimbs.
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The eye blebs (eb) has been mapped to chromosome 10. The eb mice are reported to 
have the most severe kidney phenotype, on the background studied. As well as renal 
agenesis, mice can also have cystic kidneys. The neural tube can fail to close and eye 
development is severely disrupted, resulting in open eyelids, partial lens detachment 
and folded irises (Swiergiel et al. 2000).
The fetal haematoma strain (fh) has absent digits, as well as syndactyly of the fore- 
and hindlimbs. The cornea is opaque and microphthalmia is sometimes present 
(Center 1977). There are no renal abnormalities reported. The fh  strain has not been 
maintained and therefore its chromosomal location remains unknown.
BLEBBED
MUTANT
MOUSE
CHROMOSOMAL
LOCATION
HOMOLOGOUS 
REGION IN 
HUMANS
blebbed (bl) 5 4q
myelencephalic (my) 3 13
eye blebs (eb) 10 12
head blebs (heb) 4 9
foetal haematoma (fh) Not mapped Unknown
Table 1.2: The chromosomal locations of the mouse blebbed mutants and their 
human orthologues.
The blisters in the blebbed strains first arise at day 11.5 of embryonic development. 
The location of the bleb was the feature that originally said to characterise each of 
the blebbed mutants. All of the mutants have blisters on the head region, mainly over 
the eyes. Blebs also occur on the limb extremities, tail, forebrain and hindbrain. As 
development proceeds the blebs become hemorrhagic, though they resolve before 
birth.
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1.2.1 Possible Mechanisms
Carter (1959) observed that blebs occur on the shoulder, tail and back and migrate to 
the extremities of the limbs, snout and tail. The formation of the blebs may be due to 
epidermal fragility combining with the mechanical friction of the head and limb 
extremities with the uterine wall. These blisters can then physically interfere with the 
development of eyes and limbs. The presence of a large bleb over the eye region 
could prevent eyelid fusion from taking place, resulting in the skin growing 
continuously over the face (cryptophthalmos). When the bleb is present over the limb 
bud, where the mutated genes are most highly expressed (McGregor et al. 2003), this 
could disrupt the interactions between the ectoderm (AER) and underlying 
mesoderm, resulting in syndactyly (Carter 1956). The asymmetry of the lesions and 
inconsistency of the digital malformations involved lend support to this theory. 
However this does not explain the renal defects as there are no blebs in the kidney.
Another potential mechanism by which Fraser Syndrome and the blebbed mutants 
could arise is through a defect in apoptosis. The most characteristic malformations in 
Fraser Syndrome involve areas temporarily fused in utero, including the eyes, digits 
and vagina. Apoptosis plays an important role in kidney development and in the 
separation of the digits and eyelids. A defect in apoptosis could well explain the 
limb, eye and kidney defects in Fraser Syndrome and the blebbed mutants.
Other mouse models exist that have a similar phenotype to some of the blebbed 
mutants. Mice with a knockout of Bmp7 exhibit anophthalmia, renal dysplasia and 
polydactyly (Dudley et al. 1995; Luo et al. 1995). Mice with a knockout of Pax2 also 
exhibit retinal defects and have kidney abnormalities (Torres and Giraldez 1998). 
Pdgfc knockout mice also exhibit a similar phenotype to the bleb mice, including 
subepithelial blistering of the head, limb and spinal chord (Ding et al. 2004).
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1.3 EXTRACELLULAR MATRIX DISORDERS AND MOUSE MODELS
The extracellular matrix (ECM) has four major components, collagens, 
proteoglycans, non-collagenous glycoproteins and elastin fibres. The ECM plays a 
role in building a scaffold for maintaining the structural integrity of many tissues. 
The ECM is also involved in cellular functions such as cell adhesion, proliferation 
and differentiation through its interactions with cells via integrins and cell surface 
proteoglycans, and acts as a reservoir for growth factors involved in these processes. 
The interaction of adhesion molecules with the ECM results in activation of 
intercellular signalling pathways and the rearrangement of the cytoskeleton, and 
ensures proliferation, differentiation and survival of cells (Gustaffson and Fassler 
2000). Cell-matrix interactions have biological functions in all tissues including 
internal organs such as the kidney, eye, skeleton and muscles. Defects in the 
development of these organs can be caused by abnormalities of growth factors or 
their receptors, which play an important role in signal transduction. For example, 
mutations in FGFR3 can be responsible for achondroplasia, hypochondroplasia and 
thanatophoric dysplasia type I (Bruckner-Tuderman and Bruckner 1998).
The most abundant ECM components are the collagens which give connective tissue 
its tensile strength and structural integrity. Fibrillar collagens consist of homo- or 
heterotrimeric polypeptide chains with a repetitive triplet repeat of Gly-X-Y, where 
X and Y represent proline or hydroxyproline amino acid residues (Wallner et al.
1998).
Laminins are also components of the ECM and are heterotrimeric glycoproteins 
consiting of a , (3 and y chains, forming at least twelve laminin isoforms. Laminins 
are essential for ECM and basement membrane formation (Bruckner-Tuderman and 
Bruckner 1998).
The ECM is also involved in platelet function. Upon injury, platelets are recruited to 
the sites of injury where they are linked together to form a platelet clot to stop 
bleeding. The two main ligands to mediate platelet adhesion to ECM components are 
fibrinogen and von Willebrand factor (VWF). The VWF binds the glycoprotein Ib-
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V-IX complex and integrin allbp3 on the platelet surface and is involved in 
coagulation by stabilising factor VIII. Deficiency of VWF causes von Willebrand 
disease, one of the most common bleeding disorders in man (Gustaffson and Fassler 
2000).
Mutations in genes encoding ECM proteins in mice provide new insights regarding 
their role in development and disease. Many mouse strains have helped to verify the 
link between mutation and disease in humans and help to identify new functions for 
ECM proteins (Gustaffson and Fassler 2000). Mutations in various collagen genes 
have been found to underlie diseases such as Osteogenesis imperfecta (collagen type 
I), Alport syndrome (type IV), Ehlers-Danlos syndrome (type V), and dystrophic 
epidermolysis bullosa (type VII) (Aszodi et al. 1998; Bruckner-Tuderman and 
Bruckner 1998; Gustaffson and Fassler 2000). Mutations in Laminin 5 result in 
epidermolysis bullosa junctionalis lethalis and mutations in Laminin 2 result in 
muscular dystrophies (Aszodi et al. 1998). The study of these mouse models has 
enabled the function of otherwise unknown proteins to be elucidated and has aided 
the understanding of these disorders. Understanding of the role of ECM molecules in 
disease and development has been greatly enhanced by studying these mouse 
models, therefore they are a valuable tool in the analysis of ECM proteins.
Basement membranes are a specialised form of the ECM and are thin sheets of 
extracellular proteins that assemble into highly organised three-dimensional 
structures that are in contact with cells, compartmentalising tissues and organs. 
Basement membranes have barrier functions, polarise epithelial cells, shape tissue 
structures and guide and support migrating cells. They can form specialised 
structures such as the glomerular basement membrane of the kidney, which has a role 
in filtration.
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1.4 THE SKIN BASEMENT MEMBRANE ZONE (BMZ) AND SKIN 
BLISTERING DISORDERS
The skin BMZ has unique features, which enable it to carry out its function of 
anchoring the skin layers together. There are several attachment structures, which 
help to maintain association of the epidermis to the dermis, including the 
hemidesmosomes, anchoring filaments and anchoring fibrils (Figure 1.4). The 
hemidesmosomes extend from the basal keratinocytes to the lamina lucida and are 
composed of at least four proteins grouped into the inner plaque and outer plaque. 
The inner plaque consists of BPAG1 and plectin, which are involved in the binding 
of intermediate filaments. The outer plaque is composed of BPAG2 and integrin 
a6p4, transmembrane proteins which anchor the basal keratinocytes to the basement 
membrane (Pulkkinen and Uitto 1999; Uitto and Richard 2004). Anchoring filaments 
are thread-like structures which extend from the lamina lucida to the lamina densa. 
The anchoring fibrils are attachment complexes composed of collagen VII and 
extend from the lamina densa to the underlying mesenchyme (Bruckner-Tuderman 
1999; Mellerio 1999).
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Figure 1.4; Schematic to represent the skin basement membrane zone (BMZ) 
showing the basal keratinocytes overlying the papillary dermis, separated by the 
BMZ. The attachment structures are indicated on the left, with the individual protein 
components off these structures on the right. Also shown on the far right is the level 
of tissue separation in the different forms of Epidermolysis bullosa (Pulkkinen and 
Uitto 1999).
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The position of blister formation in Fraser Syndrome can be compared to that in 
other skin blistering disorders in mice, such as Collagen VIIA inactivation, and 
human diseases such as epidermolysis bullosa (EB) (Pulkkinen and Uitto 1999; Das 
and Sahoo 2004; Uitto and Richard 2004). Mice with Collagen VIIA inactivation 
have large ventral blisters, often extending to the extremities. Examination of the 
blisters shows dermal-epidermal separation, below the lamina densa (Heinonen et al.
1999).
EB can be characterised according to the level of the defect in the skin. In the first 
form, EB simplex, the defect is at the level of the keratinocyte and is caused, for 
example, by mutations in keratins. In junctional EB, the cells separate from the 
basement membrane and is caused by mutations in proteins such as laminin 5 
(Pulkkinen and Uitto 1999; Uitto and Richard 2004). The dystrophic form of EB 
involves a separation of the dermis from the epidermis, with the plane of disruption 
below the basement membrane (Das and Sahoo 2004).
Figure 1.5: Transmission electron micrographs showing the dermal-epidermal 
junction in wt and bl/bl embryos at different points during embryonic development. 
Bleb formation begins at El 1.5 and the basement membrane segregates with the 
epidermal cell layer. In higher power is a bl embryo bearing a hemorrhagic blister 
over the eye (blister cavity = c). The lamina lucida (LL) and lamina densa (LD) 
segregate with the epidermis (e) (McGregor et al. 2003).
E14.5
+ +
El 1.5
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Therefore, the blebbed mutation is most similar to the dystrophic form of EB as the 
plane of disruption is below the basement membrane (Figure 1.5). It is of interest that 
in EB the blisters occur post-natally and in Fraser syndrome and the blebbed mutants 
they occur embryonically. Post-natally the skin doesn’t blister and the response to 
healing is normal. Perhaps Frasl is not required post-natally as other proteins can 
compensate and healing occurs by other mechanisms.
1.5 HOMOZYGOSITY MAPPING
Homozygosity mapping uses consanguineous families to trace a common ancestral 
gene to the affected individual. A fraction of the genetic loci of affected offspring of 
consanguineous matings are expected to be homozygous by descent. This fraction 
should be random between offspring from different families, except at a common 
disease locus shared by affected individuals.
Homozygosity mapping is frequently carried out within our lab to identify the genes 
mutated in various rare disorders. Therefore, homozygosity mapping was carried out 
by Lesley McGregor to identify a possible locus for Fraser Syndrome (McGregor et 
al. 2003). Offspring from several consanguineous matings were genotyped using 
polymorphic markers to assign haplotypes. This lead to the identification of the 
region most likely to be linked to Fraser Syndrome. Using families less closely 
related this region was narrowed down to a 2cM region at chromosome 4q, syntenic 
to the region of mouse chromosome 5 to which the bl gene maps to. Four positional 
and functional human candidate genes in this region were identified by Lesley 
McGregor.
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Concurrent research by Prof. George Chalepakis produced a mutant mouse following 
a gene targeting event in which a lacZ cassette was inserted into the gene they were 
studying by homologous recombination (Vrontou et al. 2003), resulting in an 
identical phenotype to the bl mouse. The murine cDNA sequence of this gene (which 
was 120,300bp in length with 74 coding exons) was obtained and found to map to 
chromosome 4q21, within the region of synteny to the Fraser Syndrome loci 
identified by Lesley McGregor. This murine sequence was BLASTed against the 
human chromosome 4 genomic sequence. It was found to encompass three of the 
four human candidate genes originally identified.
The human cDNA sequence was generated by Blast2 alignment of the mouse cDNA 
with human BAC genomic sequences spanning the region. BACs AC026931, 
AL160235, AC104808 and AC025806 were used. Any gaps in the sequence were 
filled by using human EST databases, Ensembl mRNA transcripts and the Celera 
sequence, resulting in the determination of the full human cDNA sequence. The 
intron/ exon structure was determined by comparison with genomic DNA. The 
coding region of the gene (named FRAS1) is 120,224bp and comprises 75 exons.
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1.6 MUTATION SCREENING
Intronic primers were designed to amplify all 75 coding exons and mutation 
screening was carried out for families with linkage to the FRAS1 locus. Mutations 
were identified in five families, all of Asian background (Table 1.3), all of which 
result in a premature termination. No correlation has been identified between the 
positions of the mutations identified and the phenotype of the affected patients 
harbouring them.
Mutation screening was carried out in a similar manner for the bl mouse. Genomic 
DNA was isolated from bl/bl embryos and the 74 coding exons were amplified for 
direct sequencing. A premature stop codon pS2200X caused by the mutation 
c7313CC-»AA was detected (Figure 1.6).
EXON TYPE OF MUTATION MUTATION
58 Nonsense 8620 C—»T 
Q2863X
29 Nonsense 3829 C-»T 
Q1266X
41 Frameshift/ 
Premature Termination
5605insT 
1868+3aa
61 Nonsense 9031 C-»T 
Q3000X
27 Nonsense 4301 C->G 
S1423X
Table 1.3: The mutations identified in FRAS1 and their type.
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affected
control
n r T R G 
0
R fl
exon 58 Family 1 
(8620 C->T) Q2863X
exon 61 Family 2 
(9031 C->T) Q3000X
R R C R G T
R T T T T  T T T T
exon 41 Family 3 
5605msT (Irameshift)
affected
control
fl C T G R G R T R R C C
exon 29 Family 4 
(3829 C->T) Q1266X
T T C fl G
A
exon 31 FamBy 5 
(4301 C->G) S1423X
R C T C fl G
2 d
H
exon 47 bl mouse 
(7313 CC->AA) S2200X
R T C C C C
Figure 1.6: Chromatograms showing the four nonsense mutations (a, b, d, e) and 
frameshift mutation (c) detected in FRAS1 and the nonsense mutation in Frasl (f). 
(McGregor et al. 2003).
42
1.7 THE FRAS1 PROTEIN
FRAS1 encodes a protein of 4012 amino acids. The predicted protein structure of 
FRAS1 was determined using SMART (Simple Molecular Architecture Research 
Tool). This protein sequence was used to search protein databases to enable the 
identification of a similar protein of known function, which would indicate the 
possible function of FRAS1, and to determine whether there are any proteins that 
share the same domains as FRAS1, indicating possible functions for the FRAS1 
domains.
TM
Bl mutation S
NG2-like I Calx-PVWFC Furin
Signal
peptide Chordin-like
S S FS S S
4012aa
Human mutations
Figure 1.7: The FRAS1 protein, showing the different domains and mutations 
identified until July 2002. The mutations seem to be clustered in the NG2-like and 
calx-P domains. S, stop; FS, frameshift.
The most similar protein to FRAS1 was identified as the extracellular matrix protein 
ECM3 of the sea urchin, therefore FRAS 1 was predicted to also be an extracellular 
matrix protein. ECM3 is a component of a distinct class of extracellular matrix fibre, 
which undergo dramatic reorganisation during sea urchin gastrulation (Hodor et al.
2000). The different domains of FRAS 1 were identified (
Figure 1.7). There is a small intracellular region, but the majority of the protein is 
extracellular and it is this extracellular region that is homologous to ECM3. 
However, the N-terminus contains cysteine rich domains, including chordin-like 
domains, of which the type C domains of the coagulation factor von Willebrand 
factor are a subset. FRAS 1 also contains furin-like domains, proteoglycan NG2-like 
domains, calx-P domains and a transmembrane domain.
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The N-terminal domains of FRAS1 have motifs suggesting that they are involved in
BMP signalling. Calx-P is predicted to be cytoplasmic in integrins and ion
exchangers. It has a series of P-strands and turns as well as high affinity calcium 
binding site (Schwarz and Benzer 1997).
The domain structure suggests that FRAS1 interacts with other extracellular matrix 
molecules and is also involved in cell signalling. The von Willebrand factor type C 
domain is known to bind integrins, which help molecules to interact with the 
extracellular matrix (Sadler 1998). Proteoglycans participate in a broad range of cell­
cell and cell-matrix interactions and regulate cell adhesion, proliferation, motility and 
differentiation (Iozzo and Murdoch 1996).
NG2 is a transmembrane chondroitin sulphate proteoglycan expressed in immature 
progenitor cells and some types of malignant cells (Nishiyama and Stallcup 1993; 
Nishiyama et al. 1995). The NG2-like domain has high affinity binding sites for
fibroblast growth factor 2 (FGF2) and platelet derived growth factor-AA (PDGF-
AA), which are ubiquitous growth factors with profound effects on proliferation, 
differentiation and survival of cells from different tissues (Hodor et al. 2000). NG2 
proteoglycans also bind collagens V & VI, which are an integral part of the cell 
matrix (Tillet et al. 1997). The binding of collagen and perhaps also FGF and PDGF 
could be communicated to the cytoskeleton, affecting cell movement and shape.
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1.8 FRAS1 EXPRESSION
FRAS1 is expressed at low levels in many adult tissues but at higher levels in the 
kidney, pancreas and thalamus. It is also expressed in the foetal kidney and heart at 
high levels. At the RNA level, Frasl is expressed in the epithelium of the entire 
embryo, particularly the apical ectodermal ridge (AER) of limb buds, which is an 
ectodermal thickening, that plays an important role in the patterning of the limb. 
Frasl is also expressed in the interdigital spaces and there is also expression in the 
epithelia of the skin, peritoneal lining, mesonephric duct and the posterior cardinal 
vein, as well as in the developing eye (McGregor et al. 2003).
Figure 1.8 shows basement membrane zone (BMZ) expression. In wt mice, Frasl is 
detected in the BMZ and is absent in knockout mice. Other extracellular matrix 
proteins in the BMZ are also affected by the loss of Frasl. The laminin-a5 chain is 
expressed in both wt and knockout mice. Collagen VI localisation in the skin BMZ 
of knockout mice is lost. This may be due to a lack of interaction with the NG2-like 
domain of Frasl.
Frasl
Figure 1.8: The dermal-epidermal junction of wt and F raslA E l5.5 mice. The 
arrows mark the outer edge of the epidermis. BMZ expression is indicated by the 
dense red staining parallel to the epidermis. Frasl expression is lost in F raslA mice 
(a, b). Laminin-a5 expression is not affected by the loss of Frasl expression (c, d), 
however collagen VI localisation is lost in Frasl'/~ mice (e,f) (Vrontou et a l 2003).
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1.9 OTHER FRASER SYNDROME LOCI
Linkage to FRAS1 was determined in only 45% of the families studied, suggesting 
that like the blebbed mutants, the condition is genetically heterogeneous. Given the 
mouse model, the remaining blebbed mutants may provide models for further Fraser 
Syndrome loci. The myelencephalic blebs locus lies on murine chromosome 3, just 
telomeric to the trrp4 gene. Blast searches carried out to find genes similar to FRAS 1 
identified a human gene on chromosome 13 that had greater homology to ECM3 
than FRAS1 did. A mouse homologue was found in the region of the murine genome 
linked to the my locus. Screening was carried out to determine whether this gene is 
mutated in the my mutant. Further Fraser syndrome genes could also be identified 
using murine mutants.
1.10 AIMS
The blebbed mutants phenocopy, and therefore provide a model for Fraser syndrome. 
As a mutation in Frasl underlies the bl phenotype and mutations in FRAS1 are 
responsible for some types of Fraser syndrome, mutations in the genes responsible 
for the other blebbed mutants should also result in Fraser syndrome. If this is the case 
then there should be a further four Fraser syndrome loci, each corresponding to one 
of the remaining blebbed mutants. This is supported by the fact that not all Fraser 
syndrome patients have linkage to the FRAS1 locus. The aims of this project are to 
identify the genes responsible for the remaining blebbed mutants and their human 
orthologues responsible for Fraser syndrome, to confirm that Fraser syndrome is a 
heterogeneous disorder.
Frasl is a novel protein with a domain structure that suggests that it plays a role in 
different pathways, interacting with different ECM molecules and possibly being 
involved in cell signalling. Therefore determining the interacting partners of Frasl 
and the other Fraser syndrome proteins would help to establish the function of the 
protein and understand how mutation of the protein causes disease.
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1.11 GENE NOMENCLATURE
The following list gives the names of the genes in the Fras-Frem family that were 
identified by us and/ or our collaborators during the course of this project.
HUMAN GENE MOUSE GENE BLEBBED MUTANT
FRAS1 Frasl bl
- Freml heb
FREM2 Frem2 my
- GRIP1 eb
Table 1.4: The human Fraser syndrome and mouse blebbed mutant genes.
FREM; Frasl Related Extracellular Matrix gene/ protein 
GRIP; Glutamate Receptor Interacting Protein
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CHAPTER 2. FREM2 HUMAN MUTATION SCREENING
2.1 INTRODUCTION
Only 45% of our families showed evidence of linkage to the FRAS1 locus. This, 
along with the existence of a total of five blebbed mutants suggested that there were 
further Fraser syndrome loci. BLAST searches identified a gene on chromosome 
13ql3.3 thought to contain the novel gene FREM2 (Frasl related extracellular matrix 
protein 2), identified through homology with ECM. The murine orthologue of this 
gene lies on chromosome 3, near the region to which the myelencephalic blebs 
mutant mapped.
Families not consistent with identity via descent to the FRAS1 locus were genotyped 
for FREM2 using the markers in Table 2.1. Initially, three families were identified 
that had a region of homozygosity across the region on chromosome 13ql3.3 
containing FREM2. These families were then screened for mutations in FREM2.
2.2 RESULTS
Of the large cohort of patients collected, three were initially identified with 
homozygosity across the region of chromosome 13 containing FREM2. These three 
families were genotyped for FREM2 using suitable microsatellite markers around the 
region. PCR reactions were carried out using the DNA of the affected patient and, 
where available, parental samples. These were then run on the MegaBACE 1000. 
Where homozygosity was identified, sequencing was carried out using intronic 
primers and again run on the MegaBACE 1000. Analysis of the results was carried 
out using the Sequencher 4.1 programme.
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Calcium binding assays using “Stains-all” and Ruthenium red staining were carried 
out to test the affect of the mutation on calcium binding. For full details of the 
methodology used, see Chapter 8.
A second locus (FREM2) for Fraser syndrome was identified on chromosome 13 
through BLAST searches for proteins similar to FRAS1. Three families from our 
cohort were selected which have a region of homozygosity across the region on 
chromosome 13ql3.3 containing FREM2 (Table 2.1). These were subsequently used 
for mutation screening.
Fa
m
ily D13S1491
(tetra)
D13S218
(di)
D13S138
(tetra)
FR
EM
2
D13S1288
(di)
D13S139
(di)
D13S1253
(di)
1 151 151 190 190 69 69 187 187 129 129 134 136
2 151 151 190 190 69 69 195 195 131 131 130 130
3 155 155 194 194 128 128 138 138
Table 2.1: Allele sizes determined for the affected individual of each family found to 
have linkage to FREM2. Families 1 and 2 are both of Spanish gypsy ancestry and, as 
they have the same haplotype across three markers, may have inherited the disease 
causing allele from the same ancestor. The FREM2 gene lies between markers, 
D13S138 and D13S1288.
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2.2.1 Gene structure determination
In order to commence mutation screening, the intron/ exon boundaries needed to be 
determined for FREM2. This was done by analysing the mRNA transcripts predicted 
for the region around FREM2 using the Ensembl and UCSC genome browsers.
It was established that FREM2 was composed of the three GeneScan transcripts;
ACO17111.4.1.193787.1602.89821 
AL590007.5.1.148828.36407.140434 
AL354819.15.1.153149.11725.88731.
These have subsequently been combined into the one Ensembl novel gene 
ENSG00000150893. The coding sequence of FREM2 is 9510bp in length and has 23 
exons. It encodes a protein of 3098 amino acids. Intronic primers were designed 
using the Primer3 programme to amplify the exons and to screen the gene for 
mutations. The third exon is very large (5001bp) and therefore 8 sets of amplimers 
were used to amplify across the entire exon.
2.2.2 Mutation screening
PCR amplification was carried out for each coding exon. Following ExoSAPit 
purification, the products were sequenced and analysed using Sequencher. Several 
polymorphisms were identified (Table 2.2), which were confirmed by consulting 
SNP databases and screening other Fraser syndrome patients as well as Spanish 
control DNAs to ensure that they were polymorphisms and not disease causing 
mutations. None of the polymorphisms cause a change in splicing enhancers, as 
confirmed by analysis using ESEfinder, a web resource identifying changes in 
sequences that could result in the loss/ creation of an exonic splicing enhancer.
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Exon Synonymous/
Non-Synonymous
Base Change Amino acid dbSNP ID
3 Synonymous 2514C-»T 838 D -
5 Non-Synonymous 5630G->C 1877 R->T -
5 Non-Synonymous 5725C-*T 1909 R-*W -
9 Non-Synonymous 6403C-»T 2135 R->W -
15 Synonymous 7605A-»G 2535 T rs9532292
17 Non-Synonymous 8134T—>G 2712 Y-»D -
Table 2.2: Polymorphisms identified in FREM2 during mutation screening. SNP 
databases were consulted for any changes from the wt sequence, only one 
polymorphism had been previously reported (rs9532292), the rest were novel.
A variant, c5914G-»A (E1972K), was identified in exon 5 in two families of 
Spanish gypsy ancestry (Figure 2.1). This was initially checked by repeat PCR and 
subsequently the Human SNP databases were also checked. This variant had not 
been previously reported and introduces a BsrGI restriction enzyme site, resulting in 
cleavage of the 539bp PCR product into two fragments of 222 and 257bp (Figure 
2.2). Various controls were analysed for the variant by restriction digest with BsrGI; 
82 Caucasian individuals, 150 Spanish individuals and 30 Spanish gypsy individuals.
A total of 262 DNA samples were screened (524 chromosomes) and the variant was 
not detected. The rest of FREM2 was sequenced for potential mutations and none 
were found. Therefore we concluded that this was a disease causing mutation 
resulting in a change in charge (at a physiological level) from an acidic glutamic acid 
to a basic lysine. This residue is in the calx-p domain of FREM2 (Figure 2.3).
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T R C G R G G
R T 3  3  T 3  3
T R~ C R R G G
T R C fi R G G
fl T 3  T T 3  3
Figure 2.1: The FREM2 mutation, c5914G—»A (E1972K), identified in two families 
of Spanish gypsy ancestry. Chromatograms showing: wt allele (top), heterozygote 
parent (middle), affected individual (bottom).
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Figure 2.2: 2% agarose gel showing the results of BsrGI digestion of the FREM2 
exon 5. The PCR product following amplification of exon 5 was digested with 1 unit 
of BsrGI for 2 hours. The DNA of individuals with the wt allele does not contain a 
BsrGI restriction site and therefore is not cleaved, resulting in products of 539bp (A- 
C = control DNAs). The DNA of individuals homozygous for the mutant allele 
contains the restriction site and is cleaved, resulting in products of 222 and 257bp (F 
= affected 1, G = affected 2). The parents of affected 1 are heterozygous for the 
mutation and therefore produce bands for the 539bp fragment and the 222/ 257bp 
dimer (D, E). Parental DNA was unavailable for affected 2.
Signal
peptide
NG2-like
TM
E1972K
Figure 2.3: The protein structure of FREM2. The E1972K mutation lies in the 
second calx-p domain.
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Analysis of the region of FREM2 containing the mutation to identify any known 
exonic splicing enhancer motifs (SF2/ASF, SC35, SRp40, SRp55) did not yield any 
matches. The mutation was not found to introduce a new exonic splicing enhancer 
sites.
Mutation screening the third family with linkage to FREM2 has yet to reveal a 
mutation, however this family also has equivocal linkage to FRAS1 and therefore 
may not contain a FREM2 mutation at all.
2.2.3 Calcium binding assays
The E1972K mutation lies in the second calx-P domain of FREM2. Little is known 
about calx-p domains, however they share similarity with cadherin domains, which 
have Ca2+ binding properties, which will be discussed further later in the chapter. 
Therefore it is likely that calx-p domains also bind Ca2+ and the mutation may affect 
this binding as it reverses the charge of the amino acid involved.
To determine whether the E1972K mutation affects calcium binding, the boundaries 
of the calx-P domain, which contains the mutation was identified through 
bioinformatic analysis by Martin Taylor. The region was then amplified by PCR 
from human kidney cDNA using linkered primers to enable restriction enzyme 
digestion with EcoRI and BamHI to allow the product to be ligated into the pGEX- 
4TI vector. Further constructs containing the E1972K mutation were created by 
PCR. Two PCR reactions were carried out, introducing the mutation in either the 
forward or reverse primer. The two PCR products were then ‘sewn’ together using 
the linkered primers, resulting in a product containing the mutation and linkered with 
BamHI and EcoRI sites for cloning into pGEX-4TI (see Figure 8.6).
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Once the wt and E1972K calx-p domains had been correctly cloned into pGEX-4TI 
and sequence verified to ensure that they were in frame with the GST tag contained 
in the vector, the constructs were transfected into BL21 gold competent cells 
(Stratagene). Single colonies were cultured and expression of the GST-fused proteins 
was induced by addition of IPTG. Sample loading buffer was added and the samples 
were loaded onto polyacrylamide gels. The gels were then either stained with 
Coomassie blue or the cationic dye Stains-all, or used for Western blotting and 
Ruthenium red staining.
GST E1972K GST
WT E1972K
a) J S S .  --------------
Figure 2.4: Polyacrylamide gels stained with Stains-all (a) and Coomassie blue (b). 
The E1972K sample spilled over into the adjacent lane in the gel stained with 
Coomassie blue. The CalxP-GST fusion proteins are approximately 56kDa and the 
GST protein is 26kDa. Stains-all stains all proteins pink and calcium binding 
proteins blue/ purple. Neither of the Calxp-GST fusion proteins were stained purple.
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2.3 DISCUSSION
STRP studies of Fraser syndrome families in which a mutation in FRAS1 had not 
been identified resulted in three consistent with linkage to the FREM2 locus. 
Mutation screening of these families identified a missense mutation c5914G'A 
(E1972K) in two of the families, both of Spanish gypsy ancestry. This mutation is 
located in the second calx-6 domain of the FREM2 protein.
Both affected individuals harbouring the FREM2 mutation had complete 
cryptophthalmos, multiple skin syndactyly and ambiguous genitalia. As both families 
share gypsy ancestry and are originally from the same region in Spain, we 
hypothesised that they received the disease causing allele from a common ancestor. 
The haplotypes for both families (Table 2.1) suggested that this may be the case, 
though they only share the same haplotype over three markers. To investigate this 
further, the intronic sequences within the FREM2 gene were screened to identify any 
SNPs that the families shared. A SNP (rs9548503) was identified 64 bp into intron 
10, 62 kb 3’ of 5914G-A. The two affected individuals were homozygous with 
respect to different alleles. Therefore, it is likely that the c5914G-A mutation arose 
independently in the two families and does not represent an ancestral mutation as the 
mutation would have been inherited with the SNP.
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2.3.1 E1972K mutation analysis
Upon initial identification of the mutation, the Human SNP database was checked to 
determine whether this was a known polymorphism. It had not been previously 
reported in any SNP database. Next the degree of conservation of the residue was 
checked in different species, as well as in other proteins of the same family (Figure 
2.5). The amino acid is very well conserved in human, chimpanzee, chicken, toad, 
pufferfish and sea urchin and is conserved in all known calx-p domains.
Frem2_mur RFDKDEREKM CRILVIDDSL Y I  
FREM2_hum RFDKDEREKL CRIVIIDDSL IE 
ECM3 AFDKGEDLAY CRILIIDDSL Y E 
FRASl_hum IFGPGVTMST CDVMLIDDSE Y E 
frasl mur IFGPGVTVST CDVMVIDDSE Y E
EEETFQVL LSMPMGGRIG DKFPGANVTI 
EEETFHVL LSMPMGGRIG SEFPGAQVTI 
EDETFQVK LSNPMGGRIG NPS-AINVII 
EEEEFEIA LADASDNARI GRVATAKVLI 
EEEEFEIA LADASNNARI GRQAVAKVLI
Figure 2.5: Protein alignment of the Fras-Frem proteins and ECM3. The glutamic 
acid is very well conserved in all of these proteins.
As well as resulting in amino acid substitutions, missense mutations can also disrupt 
splicing signals resulting in splice variants. Exon splicing enhancers (ESEs) are 
important cis-acting elements required for the inclusion of exons. They are usually 
found in tissue-specific or developmentally regulated exons that have weak splice 
sites and require the ESEs for exon inclusion (Liu et al. 1998; Liu et al. 2000; 
Miriami et al. 2003). These ESEs serve as specific binding sites for the Ser/Arg-rich 
proteins (SR proteins). These proteins constitute a family of conserved splicing 
factors that participate in multiple steps of the splicing pathway (Liu et al. 1998). 
Nucleotide substitutions in ESEs can result in the failure of SR proteins to bind to the 
ESE, resulting in a failure of the splicing machinery to recognise the sequence as 
exonic and causing exon skipping. Pathogenic mutations in the MSH2 and MLH1 
genes, which are human mismatch repair genes that are related to human 
nonpolyposis colon cancer, are located in ESE sites at a much higher frequency than 
expected (Gorlov et al. 2003). The DNA sequence of the mutant form of FREM2 
was checked for the known ESE motifs SF2/ASF, SC35, SRp40 and SRp55 using 
ESEfinder (Cartegni et al. 2003), none of which were found.
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Figure 2.5a: Calxp is structurally related to the cadherin protein fold. An alignment of the representative calxp and cadherin domains showing a 
representative subset of Psi-BLAST (Altschul et al. 1997) matches using 60% conservation threshold and a default coloring scheme. Sequences 
are identified by either the Swisprot identifier or species abbreviation (Hs, Homo sapiens; Mm, Mus musculus\ Dm, Drosophila melanogaster, 
Lytechinus variegatus) followed by accession number or identified as Frem2. Amino acid ranges shown in the alignment are indicated after the 
forward slash. The E l972 residue is very well conserved across the domains of different proteins, and the position of the E1972K mutation is 
indicated by the box. Residue positions directly involved in Ca2+ coordination are indicated by alignment gap positions with and 
unassigned structure with (Jadeja et al. 2005 supplementary information).
2.3.2 A third E1972K mutation
The identification of a mutation in a second gene that results in Fraser syndrome 
confirms that the condition is genetically heterogeneous, as was originally suspected, 
and is the first missense mutation to have been identified in a Fraser syndrome 
patient or blebbed mutant. Further work carried out by Mieke van Haelst has 
identified the E1972K mutation in a third unrelated consanguineous family. This 
supports the view that the E1972 residue has an important role in the function of 
FREM2. However, all three affected patients sharing the mutation have had a varied 
phenotype. The Fraser syndrome patients with the E1972K mutation identified in this 
study had cryptophthalmos, syndactyly and ambiguous genitalia but affected 1 
additionally had an absent bladder, ureter and right kidney with a hypoplastic left 
kidney. Affected 1 died shortly after birth from respiratory failure whereas affected 2 
is still alive. This could be due to the extent of the blistering that occurred in utero 
but would not explain the differences in the renal and bladder phenotypes. Therefore 
there does not seem to be a genotype-phenotype correlation, however more 
mutations in FREM2 need to be identified before definitive genotype-phenotype 
correlation can be made. Further genotype-phenotype comparisons will be made in 
the overall discussion (Chapter 7).
2.3.3 The Calx-0 domain
The calx-0 domain was first described by Scharz and Benzer in 1997. The Calx gene 
of Drosophila melanogaster, was cloned and two novel domains, calx-a and calx-0 
were identified. The calx-0 domain contains two tandem high-affinity Ca2+ binding 
sites (Schwarz and Benzer 1997). Little else is known about the calx-0 domain, 
though normally calx-0 is found in proteins that span the cell membrane and 
involved in Na-Ca exchange. However, here in the Fras-Frem proteins it is found 
extracellularly. It is hypothesised that extracellular calx-0 binds calcium (Staub et al. 
2002).
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Previously, mutations in the calcium binding sites of extracellular matrix proteins 
have been identified as disease causing, e.g. mutations in the Ca2+-binding region of 
the fibrillin monomer can cause four related syndromes including Marfan syndrome. 
The Ca2+ ions may be important for the structure of the fibrillin monomers and their 
aggregation into the microfibrils that are found in many connective tissue. (Maurer et 
al. 1996). Calcium ions can induce conformational change within a protein by 
bridging domains. Mutations can therefore affect these conformational changes and 
subsequently the protein’s overall structure and function. The CSPG repeats in the 
NG2-like domain of FREM2 are related to cadherin domains (Staub et al. 2002). 
Cadherins mediate Ca2+-dependent cell-cell adhesion and the binding of Ca2+ to 
cadherins is known to induce major conformational changes such as rod formation, 
necessary for cell adhesion and migration. Calx-P domains are also known to bind 
Ca2+ with high affinity and undergo a major conformational shift upon binding.
2.4 FUNCTION OF THE E1972 RESIDUE
Tandemly arranged cadherin and calx-p domains intercalate multiple Ca2+ ions in a 
negatively charged pocket between consecutive domains. Protein structure analysis 
of FREM2 carried out by Martin Taylor suggests that FREM2 binds three Ca2+ ions 
between adjacent calx-P domains. Sequence to structure alignments show that E1972 
is located in the Ca2+ binding pocket at the interface of calx-P domains 2 and 3 and is 
directly involved in the coordination of at least one Ca2+ ion. The E1972K mutation 
reverses the charge of this residue from an acidic to a basic amino acid which is 
likely to reduce or abolish the intercalation of Ca2+ ions in this pocket and possibly 
abolish the binding of all three calcium ions. This is likely to have a substantial effect 
on the structure of FREM2 and may affect protein-protein interactions. To 
investigate this the calx-p domain containing the mutation was used in calcium 
binding assays. Stains-all and Ruthenium red were used to identify calcium binding 
proteins.
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2.4.1.1 Calcium binding assays
Unfortunately the Stains all did not stain the fusion proteins purple/ blue (Figure 
2.4), which would indicate the presence of a calcium binding protein. The ruthenium 
red also failed to stain the proteins. This is due to the presence of the detergent SDS 
in the protein gels used for both the Stains-all and Ruthenium red staining. SDS 
degrades proteins and therefore a non-denaturing gel should be run to maintain the 
conformation of the proteins and enable the binding of molecules such as Ca2+ ions to 
occur.
Stains-all has been shown to be sensitive to the conformation of the region to which 
it binds (Sharma et al. 1989). It is this ability, which enables Stains-all to distinguish 
between proteins that do and do not bind calcium ions. For Stains-all to stain the 
protein blue, the Stains-all binding region (anionic sites) should be present in the 
globular/ compact or helical conformation of the protein. Anionic sites located in a 
rod-like conformation will not result in Stains-all staining the protein blue. Also, as 
the protein was expressed in a prokaryotic cell (E. coli) the protein would lack any 
secondary modifications it may require. This could be overcome by expressing the 
entire protein in a mammalian cell line, which in itself would cause difficulties as the 
FREM2 protein is 3098aa.
The Ruthenium Red stains only calcium binding proteins. In the experiments carried 
out, no proteins were stained which is likely to be due to a denaturing gel being used. 
Levitsky et al. have shown that Ruthenium red staining is not as sensitive as 45Ca2+ 
binding experiments and does not discriminate between the ability of certain proteins 
to bind Ca2+ (Levitsky et al. 1994).
Similar experiments carried out to determine the effect of mutating the Glutamic acid 
residue at position 454 of the CBD1 (Calcium Binding Domain 1) of the sodium 
calcium exchanger NCX, showed that the mutation had a substantial effect on the 
conformation of the domain in the presence/ absence of Ca2+ as determined by gel 
mobility shifts on native polyacrylamide gels. The NCX protein contains two CBDs, 
in the absence of Ca2+ one of these, CBD1 unfolds and the other does not. This was
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found to be due to the presence of basic lysine residues in CBD2 which reduce the 
electrostatic repulsion between the acidic glutamate and aspartate residues which 
constitute its Ca2+ binding sites (Hilge et al. 2006). Therefore, it is likely that the 
E1972K mutation in FREM2 results in a change in protein conformation as was the 
case for the NCX protein. Similar experiments could be carried out to determine if 
this is the case. Changes in protein conformation change the mobility of the protein 
through polyacrylamide gels, therefore wt and mutant samples could be run on a high 
percentage polyacrylamide gel to detect possible changes in protein mobility and 
therefore conformation.
2.5 SUMMARY
Three Fraser syndrome families were found to be consistent with linkage to the 
FREM2 locus. Two of the three families have Spanish gypsy ancestry and a mutation 
was identified, c5914G->A (E1972K) in these two families. Screening control DNAs 
from Spain, including some of gypsy origin confirmed that the mutation is disease 
causing. A SNP for which the two families carrying the mutation differ was 
identified within FREM2 indicating that they do not share a common ancester from 
whom they inherited the mutation. This mutation has also been identified in a third 
unrelated family. The E l972 residue is located in the second of five Calx-|3 domains, 
which are involved in calcium binding and the residue itself may play an important 
role in the binding of calcium. As the mutation reverses the charge of the amino acid 
from a negative glutamic acid to a positive lysine it is predicted to affect calcium 
binding. Calcium binding assays were carried out to ascertain if this was the case, 
though these have so far been inconclusive. The E1972K mutation is the first 
missense mutation to be identified in Fraser syndrome and confirms the genetic 
heterogeneity of the condition.
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CHAPTER 3. IDENTIFICATION OF MURINE FREM2/
MYELENCEPHALIC BLEBS
3.1 INTRODUCTION
Two existing strains of the my mutant, myHule and myUcl were screened for mutations 
in the murine orthologue of FREM2. A further strain, myKst was identified that had 
been created by the insertion of a genetrap vector into the Frem2 locus. This supports 
the theory that mutations in the murine orthologues of Fraser syndrome genes result 
underly the phenotype of the blebbed mutants.
3.1.1 “The Little and Bagg strain”: myelencephalic blebs
The original my mutation (m y ^) arose in mice irradiated with X-rays (Little and 
Bagg 1923). These mice were found to have eye, jaw and foot anomalies as well as 
clear lesions filled with fluid, all of which were reported to be inherited. The foot 
anomalies affected the hindlimbs and were associated with haemmorrhagic lesions. 
These were of many grades and varied from slight shortening of the digits to a 
twisted, deformed hindlimb (Figure 3.1). The eye anomalies (Figure 3.2) were 
reported also to be of many grades and ranged from normal eyes to severely 
shrunken and sunken eyes, occasionally with opaque lenses (Little and Bagg 1923).
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Figure 3.1: Diagrams of 
the limb defects in 
affected animals, as 
reported in the original 
my paper, a) A limb with 
a slight abnormality 
associated with a 
haemorrhagic lesion, b- 
d) Three limbs with 
markedly deformed
digits due to haemorrhagic lesions, e) An abnormality due to the faulty position of
the digits, f)  An abnormally retracted and deformed left hind limb, g) Marked
twisting and deformity of a hind limb. The age of mice not given (Little and Bagg 
1923).
These mutants were originally referred to as the “Little and Bagg strain” and sparked 
much interest at the time, with many papers published describing the various defects 
they presented with. In 1931 Bonnevie interpreted the anomalies as due to the 
overproduction of cerebrospinal fluid leaving the myelencephalon in the form of 
blebs. These were reported to be moved by the elastic counter pressure of the 
epidermis in the direction of least resistance along the curvature of the body, resting 
at places of equilibrium -  at the tips of the snout and the extremities of the limbs and 
tail. This interpretation resulted in Little and McPheters 1932 coining the expression 
“myelencephalic blebs”, with the symbol my, which later became the accepted name 
of the strain, despite opposition to Bonnevie’s views (Gruneberg 1952). In 1933, 
George Plagens described the eye and limb defect as well as a “saddle” defect
consisting of the appearance of short hair on the sides and flanks. Bleb formation
was discussed and recognised as a separation of the surperficial ectoderm from the 
underlying mesenchyme, filled with an “amber-coloured fluid, which resembles 
lymph”. Bleb formation was recognized as beginning at El 1.5 and the eye, limb and 
saddle defects were believed to be a consequence of the thrombus formation and not 
the blebbing itself as was earlier suspected (Plagens 1933).
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Figure 3.2: Diagrams from the
original paper describing the my 
phenotype (age of mice not given), a) 
Normal-eyed albino, the skin over the 
eye is unbroken and smooth with no 
pigmentation visible. The eye is 
irregular in shape but of normal size. 
b) Normal-eyed brown, has similar 
appearance to (a) but the ring of iris 
pigment is slightly visible under the 
unbroken skin which covers the whole 
eyeball, c) Affected animal with
unbroken skin over the eye, just superior to the upper part of the eyeball there is a 
small lesion, dried and scabbed over with a crusty exudate. Note the peculiar 
shortened of the foreface, d) Mutant animal with a similar abnormality to (c) with a 
larger lesion. The eye is more generally affected and has become shrivelled and 
dried. In the centre of the scabbed area is a crystalline structure, opaque and almost 
spherical, the lens, e) A mutant with an abnormality of a larger area than (d) with a 
large, irregular scabbed area in which the lens is situated, f)  An example of an 
affected mouse with a more extensively damaged eye. The whole eye is dried and 
laid bare by a lesion, which removes the skin over the entire eyeball. The iris 
pigment seems dried and condensed. The lens is present, lying on the surface 
imbedded in the dried scabbed area surrounding it (Little and Bagg 1923).
In 1952 Gruneberg described the eye defects as a failure to cover the eye completely, 
due to an incomplete fusion of the eyelids or defective/ absent lids. The most 
common foot anomaly was described as syndactylism, with occasional 
hypodactylism and polydactylism, and the most common kidney defect was the 
absence of one of the kidneys. The eye defects were believed to preceed the foot 
anomalies. Whilst at this point it was accepted that the eye and limb abnormalities 
were due to the presence of the blebs, it was noted that the kidney abnormalities 
could not be attributable to blebbing (Gruneberg 1952).
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In 1956 the genetics of the strain were studied and found to show a recessive 
Mendelian inheritance. All of the defects were due to a single gene, my, with variable 
penetrance and expressivity and with various parts being dependant on modifying 
genes. The paper concluded that there were not just developmental abnormalities due 
to ectodermal blebs in embryos, but that there was a wide syndrome including early 
morphological upsets of the neural tube, urogenital system and hindlimbs (Carter 
1956).
More recently, in 1992 Center and Polizotto decided to investigate certain basement 
membrane (BM) and extracellular matrix (ECM) constituents in the my mice as the 
cornea and lens were markedly affected. Basement membranes form the in vivo 
substratum for the epithelial and endothelial cells from which the cornea and lens are 
formed, therefore it was deemed appropriate to investigate anomalies in BM and 
ECM components such as acidic glycosaminoglycan and laminin 1. Heparin-like 
glycosaminoglycans (HLGAGs) are the most acidic naturally occurring biopolymers. 
They are complex polysaccharides found in the ECM and play a key role in 
regulating the biological activity of several proteins in the coagulation cascade and 
angiogenesis. Laminin 1 is normally found in the lamina densa of the basement 
membrane zone. A decrease in and irregular deposition of acidic glycosaminoglycan 
and an increase in laminin 1 in BM structures of the my eye were found (Center and 
Polizotto 1992). These experiments were repeated in renal corpuscles and it was 
found that both acidic glycosaminoglycans and laminin 1 deposition was increased in 
the parietal layer of the Bowman’s capsule (Center and Emery 1997). This suggested 
disruption of normal histochemistry, which was interpreted as an indication of 
changes in permeability between cells which resulted in blebbing.
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3.1.2 myUcl: A second myelencephalic blebs allele
A second allele, myUcl, was identified during the creation of an unrelated transgenic 
strain, but then subsequently transferred out, as initial the transgene could be 
detected and later not. (S. Darling, unpublished data). It is possible that during the 
transgenesis procedure a fragment of the transgene inserted randomly in or around 
the my gene, disrupting it, and then transferred out again.
The myud strain has a phenotype similar to that of the original myHule strain (Little 
and Bagg strain), i.e. it shows epithelial blebbing, cutaneous syndactyly 
(occasionally accompanied by bony syndactyly) of the fore- and hindlimbs (Figure 
3.3), renal agenesis and cryptophthalmos. On the NMRI background, homozygotes 
have a semi-lethal phenotype, with approximately half the expected number of 
homozygotes surviving and some homozygotes being fertile.
Figure 3.3: Alizarin red staining of limbs from myUcl/myUcl mice showing an 
example of severe syndactyly secondary to bony fusion (a) and polydactyly (b).
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Figure 3.4: Linkage analysis localised the myUcl locus between the markers 
D3MU184 and D3Mit66\ distances between marker pairs are given in cM and are 
derived from the backcross. Figure not to scale.
In order to finely map the position of the region on chromosome 3 responsible for the 
myUcl phenotype, an initial backcross was carried out yielding 146 progeny. These 
were bred further to yield 1,030 mice. In this region, bordered by D3Mitl84 
proximally and D3Mit275 distally, two recombinants were detected with D3Mit66 
(in the gene Trpc4), placing the my gene proximal to D3Mit66 (Figure 3.4). TRPC4 
maps to human chromosome 13ql3.3, corresponding to the region to which some 
Fraser patients show linkage. Analysis of the mouse genomic region flanked by 
D3Mitl84 and D3Mit66 led to the identification of a gene encoding a Frasl-like 
protein 500 kb proximal to Trpc4 and 400 kb distal to D3Mitl84.
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3.2 RESULTS
The mouse blebbed mutants provide a model for studying Fraser syndrome. As 
Frasl is mutated in the bl mouse, the my mouse was screened for possible mutations 
in Frem2 as the gene responsible for the my phenotype had been localised to the 
same region as the murine orthologue of FREM2. To obtain compound mutants, bl 
and myVcl mice were bred together and the phenotypes of the resulting offspring were 
studied.
DNA from myUcl and myHule was screened for mutations in Frem2 using intronic and 
exonic primers. Following RNA extraction from myUcl and myKst embryos, RT-PCR 
and real-time PCR were carried out to identify any changes in the level of expression 
and any alternative splicing. Frasl (bl/bt) mutants and myUcl mutants were bred 
together to determine whether compound homozygotes were viable and if not, to 
determine the severity of the phenotype. Full details of the methods used are 
contained in Chapter 8.
3.2.1 Frem2 Gene structure determination
The my gene is located on murine chromosome 3, between the polymorphic markers 
D3Mitl84 and D3Mitl36. Three transcripts were identified in this region that 
together encoded a protein with homology to ECM3. These transcripts were based on 
the original Genscan gene predictions;
CAAAO1057941.1.1.15961.1580.13228 
CAAAO1143011.1.1.22405.6998.22185 
AC121885.3.1.155690.14971.109814.
These were combined, resulting in a gene of 28 exons, which was subsequently 
known as Frem2. The intron/ exon boundaries were established and intronic primers 
were designed to amplify all of the coding exons. Exon 4 is 5020bp in length, 
therefore 8 sets of overlapping amplimers were used to amplify it.
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Figure 3.5: Output from the UCSC genome browser showing the location of Frem2 
on chromosome 3 on the mouse August 2005 assembly.
3.2.2 Mutation screening
The myucl strain was initially used for mutation screening. The myucl strain originally 
arose on a CD1 background and was later crossed onto an NMRI background, 
therefore DNA from both strains was used as controls. DNA extraction from tail tips 
was carried out to obtain genomic DNA, which was subsequently used for PCR 
amplification and direct sequencing. Some exons failed to be amplified by normal 
PCR. Further primers were designed for these exons, outside the original primers. 
These new primers were then used for initial amplification. The products were then 
purified by ExoSAPit and then re-PCRed using the original primers, i.e. nested PCR. 
Screening the entire gene as well as the 5’ and 3’ UTRs revealed no mutations. DNA 
from the myHule strain, thought to be the original Little and Bagg strain, is available 
through the Jackson Laboratories. Genomic DNA from this strain was obtained and 
used for mutation screening. Again, no mutations were identified.
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At this point, it was decided to revert back to the myucl strain as animals were 
available. The expression level of Frem2 in my mice was checked by carrying out an 
RT-PCR experiment (using primers located in exons 4 and 5, see Table 8.7). Total 
RNA was extracted from E14.5 homozygous myicl mice and wt CD1 mice. 
Following first strand synthesis, it was determined whether or not there was a 
quantitative change in the expression of Frem2 by using a range of cycle numbers for 
amplification. Intensities of the bands obtained for wild type and mutant reactions 
were compared, along with Gapdh controls. As Figure 3.6 shows, there is not a 
significant change between the level of expression of Frem2 from the wt and myLcI 
strains.
1 2 3 4 1 2 3 4 1 2 3 4 1 2 3 4  1 2 3 4 1 2 3 4 1 2 2 4
Figure 3.6: Photograph of a 2% agarose gel showing the products of RT-PCR for 
myucl. Total RNA was extracted from E14.5 embryos. Following first strand 
synthesis, PCR was carried out in a total volume of 50/d. 5/d was removed following 
21, 23, 25, 27, 29, 31 and 35 cycles to determine whether there was any difference in 
gene expression for Gapdh and Frem2 between wt CD1 embryos and myUcllmyicl 
embryos. 7) Gapdh wt, 2) Frem2 wt, 3) Gapdh myUcl/myicl, 4) Frem2 myUcl/myUcl. No 
difference was detected.
In order to confirm that the exon-intron structure predicted from the gene databases 
was correct and that there were no splice variants in the myUcl mutant strain it was 
decided to sequence the cDNA of the Frem2 gene. Primers were designed from the 
cDNA sequence of Frem2 to amplify overlapping 500-600bp segments of the gene. 
RT-PCR was carried out to amplify the cDNA sequence. Any deviation from the 
expected product size would indicate a different splicing variant. However, all of the 
products obtained were of the correct size.
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The primers MY 13 and MY 14 failed to produce a product. The genome databases 
were then searched to identify whether the exon amplified by these primers was 
conserved in any other members of this family of proteins from other species. It was 
found that it was not and that this exon had removed from the Ensembl database’s 
gene prediction. This led us to believe that this was not a bona fide exon. This ‘exon’ 
was then disregarded from further analysis.
3.2.3 Frem2 Genetrap
Whilst carrying out database interrogation to check the gene structure of Frem2 a 
genetrap mutant from BayGenomics was identified containing a P-geo cassette in 
intron 4. This genetrap was created as part of the Knockout mouse project (Austin et 
al. 2004), which aims to create a genetrap mutant for each gene in the murine 
genome. Conventional gene trapping vectors contain a splice acceptor site linked to a 
lacZ or /3-geo (/3-galactosidase-neomycin phosphotransferase fusion gene) reporter. 
These vectors integrate into the genome randomly, resulting in LacZ fusion genes 
containing the N-terminus of the endogenous gene. The genetrap vector also contains 
a stop codon and polyadenylation signal usually resulting in a null mutant. The 
endogenous gene into which the genetrap has inserted is identified by carrying out 5’ 
RACE cloning. The insertion of genetraps into genes is largely random, though 
hotspots have been identified, especially in large genes, and some genes such as 
those encoding cell surface and transmembrane proteins are more difficult to trap. In 
order to target genetrap vectors to capture genes encoding N-terminal signal 
sequences for cell surface and transmembrane proteins Skarnes et al. 1995 modified 
the gene trap vector to detect insertions in such genes.
71
The modified vector, pGT1.8geo, relies on capturing the N-terminal secretory signal 
of the endogenous gene to generate an active P-galactosidase fusion protein. Initially 
it was found that the fusion proteins generated by this vector accumulated in the 
endoplasmic reticulum and lacked P-gal activity. This was solved by placing the 
transmembrane domain of CD4 upstream of the p-geo enabling the insertion of the 
vector into both secreted and transmembrane proteins. This vector, the secretory trap 
pGT1.8TM, was modified further to include an internal ribosome entry site (IRES) 
5’ of a second reporter gene, human placental alkaline phosphatase (PLAP) to enable 
the labelling of the cell bodies (P-geo) and the axons (PLAP) of neurons in order to 
deduce the function of genes involved in brain wiring (Leighton et al. 2001). The 
modified vector was named pGTlTMpfs and was used in a study to analyse the 
phenotype of mice obtained using the secretory-trap method. The Kst252 cell line 
was first identified in this screen (Mitchell et al. 2001), however the cell line was not 
investigated further.
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Figure 3.7: The pGTlTMpfs vector, which was used to create the Frem2 genetrap 
mutant myKst, modified from the secretory trap vector pGT1.8TM. It contains the N- 
terminal cleavable signal sequence and transmembrane domain of the CD4 type I 
membrane protein, the mouse Engrailed2 splice acceptor and simian virus 40 
polyadenylation signal, a p-geo reporter fusion flanked by frt sites (not shown) and a 
CMV IRES- human PLAP fusion. The genetrap inserts randomly into an intron of a 
gene containing a signal sequence. Following processing the P-geo and PLAP are 
expressed in cells that would express the endogenous gene into which the genetrap 
has inserted. The PLAP was included as it is expressed in the axons of genes 
potentially involved in brain wiring (Leighton et al. 2001).
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Figure 3.8: Schematic of the gene (Frem2) trapped in cell line Kst252 during a study 
carried out to study the function of genes trapped by the secretory trap method. IR 
denotes internal repeat. Modified from Mitchell et a l 2001.
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The relevant ES cell line (Kst252) was ordered and injected into blastocysts to obtain 
germline transmission of normal heterozygotes. To ensure that a mutation in Frem2 
did result in the my phenotype complementation analysis was carried out. 
Heterozygous genetrap mice (named myKst) were crossed with heterozygous myUcl 
mice, with the resultant compound heterozgotes showing a failure of 
complementation of the mutation, indicating allelism. The compound heterozygote 
mice (myKst/myUcl) also showed evidence of blebbing as shown in Figure 3.9. RT- 
PCR was carried out using primers spanning the genetrap insertion to determine if 
the mutant was null for Frem2. As can be seen in Figure 3.10, the PCR was 
successful, indicating that the mutation is not completely null.
Figure 3.9: Photographs of E14.5 Frem2 compound heterozygote (myKst/myUcl) 
showing blebbing. The embryo shown in a) has haemorrhagic blebs over its left eye, 
forelimb and hindlimb. The embryo shown in b) has blebs at various different stages, 
including a large haemorrhagic bleb over its left eye («). It also has serous blebs on 
the snout (/), hindbrain (iii) and neck (tv) and resolving heamorrhagic blebs over the 
hindlimbs (v and vi).
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Figure 3.10: 2% agarose gel showing the results of RT-PCRs carried out using RNA 
extracted from E l4.5 embryos to determine whether or not the myKst homozygous 
mutants are null. The exonic primers MY14 were used which span the region of the 
genetrap insertion. The presence of product shows that the myKst mutants are not null. 
Primers for Gapdh were used as an internal control and samples from myicl 
homozygous mutants were used as a positive control.
3.2.4 Real-time PCR
As the RT-PCRs carried out showed no detectable difference in the level of Frem2 
expression between myid mutants and wt CD1 mice, and that there was expression of 
Frem2 across the genetrap insertion site in the myKst mutants, it was decided to carry 
out real-time PCR, which is a more sensitive method of detecting changes in 
expression levels. cDNA samples from E14.5 CD1, my1*1 and myUcl of Frem2 were 
used to determine whether there was a difference in the level of expression between 
wt CD1 and myicl and m y^  embryos. Triplicates of each sample from the same 
mastermix of reactants were used for both Frem2 and Gapdh exonic primers. The 
raw fluorescence data obtained for each experimental group (CD1, myUd and my1*1) 
were analysed using the DART-PCR programme.
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This programme allows an automated calculation of amplification kinetics and 
performs the subsequent calculations for relative quantification and calculating assay 
variability. Amplification efficiencies are also tested to detect outliers and 
differences between the experimental groups (amplification equivalence).
DART-PCR converts raw data into expression values (R0), based on the theory that 
fluorescence is proportional to DNA concentration. The data was the normalised by 
dividing the target gene (Frem2) R0 by the internal gene control {Gapdh) R0 to give a 
normalised expression value. The experiment was repeated five times in order to 
obtain an average of the normalised values, which was then used to calculate the fold 
difference in expression levels of Frem2 between CD1, myUcl and m y^  mice at E14.5.
Sample Average 
normalised value
Fold
difference
CD1 E14.5 3.04E-03 1.00
myUcl E14.5 2.82E-03 0.93
CD1 E14.5 3.04E-03 1.00
myP E14.5 4.10E-04 0.13
myUcl E14.5 2.82E-03 1.00
m y E14.5 4.10E-04 0.15
Table 3.1: Table to show the relative fold differences in the level of expression of 
Frem2 between CD1, myUcl and m y mice at E14.5 using real-time PCR to detect 
changes at a region downstream of the genetrap insertion (intron 4). There is very 
little difference in the level of expression of Frem2 between the CD1 and myucl but 
the level of expression of Frem2 in the m.ykst mice is greatly reduced to 13% of 
normal levels (arrows).
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3.2.5 Compound Frasl/  Frem2 double mutants
The bl mice were on a mixed, unknown background, on which homozygotes were 
not viable. Therefore, in order to obtain double compound homozygotes for bl and 
myUcl initially bl/+ were used and crossed with myUcl/+ mice. The resulting double 
compound heterozygotes (bl+/myUcl+) were crossed together and the offspring 
produced were used for phenotypic analysis. In total 144 mice from 19 litters were 
produced from 6 breeding pairs. It became apparent that on the new mixed 
background (the unknown bl background mixed with the NMRI background of the 
myUcl mice) not only were the bl homozygotes were viable, but compound double 
mutants (blblV myUclmyUcl) were also viable. The phenotype of these double mutants 
was not more severe than the either of the single homozygote mutants, except that 
occasionally some double mutants presented with blebs on birth, which are normally 
resolved during gestation (Figure 3.11a, b) and were significantly smaller than their 
littermates (Figure 3.1 \e).
c)
Figure 3.11: Two day old bl+/myUclmyUcl pups (a -d) showing postnatal blebbing, 
arrowheads (a &b). Haematoxylin and eosin stained wax sections show fusion of the 
cornea to the eyelid, i. e. cryptophthalmos (arrowheads), and folding of the rpe; 
retinal pigment epithelium (c) and haemorrhagic postnatal blebbing of the limb (d). 
Adult mice illustrating the difference in size between double homozygotes and their 
littermates (e).
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blbl/ blbl/ blbl/ bl+/ bl+/ « + / + + / +  + / + + /
_j_ 4 . my+ myrny + + my+ myrny + + my+ rnymy
Actual N um ber 5 1 14 21 'JC 28 10 16 8
Expected N um ber 11 6 22 6
11 11
0 0 0 30 30 8 16
M endel ian Ratio
i 4 1 4 4 4 1 4 A
0 0 0 4 4 4 1 4 A
T ab le  3.2: Table showing the genotypes o f m ice obtained by crossing com pound 
heterozygotes (bl+/mylKl+) together. Tw o sets o f expected num bers and M endelian 
ratios were predicted as blbl m ice are not viable, therefore one set gives the ratio and 
num bers of mice expected given that blbl m ice would also be em bryonic lethal on 
the N M R I background o f the m ybd m ice (green) and the other set gives the ratios and 
num bers o f mice expected if they are viable (red). The actual num bers fall in 
betw een the twro sets o f expected num bers.
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3.3 DISCUSSION
Two strains of the my mouse were screened for possible mutations in Frem2 due to 
the close proximity of the gene responsible for the my and the murine orthologue of 
FREM2. No mutation was identified in the myUcl and myHule strains, however, a 
genetrap mutant for Frem2 was identified that is allelic with myUcl and has a blebbing 
phenotype.
3.3.1 Mutation screening
Mutation screening of the strains myUcl and myHule failed to identify a mutation. It is 
difficult to suggest why this would be the case for two strains. Unless there is a 
splice variant that we are unaware of, we have screened all of the exons and the 
splice sites for the gene though the Ensembl and UCSC databases are continually 
being updated and are checked regularly for any updates to the region of the genome 
to which Frem2 maps. The method of screening being undertaken is not failsafe and 
though we are confident that a mutation has not been missed, we cannot be sure. 
However, Timmer et al. also carried out a mutation screen of myHule for Frem2 and 
failed to identify any mutations. They were able to detect a nonsense mutation, 
c5640C —>A (pY1880X) in an A-ethyl-TV-nitrosourea induced strain, myFU, which 
results in a truncated protein, lacking the final four of the five calx-P domains. The 
myF11 strain seems to be the most severely affected of the strains so far reported with 
heart defects as well as cryptophthalmos, syndactyly and renal defects (Timmer et al. 
2005). This is further validation of a mutation in Frem2 being responsible for the my 
phenotype.
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Sequencing was carried out of the exons, 5’ UTR and 3’ UTR, but only a very small 
portion of each intron, encompassing the splice sites, was screened. This was mainly 
due to some of the introns being very large, for instance the intron into which the 
genetrap was inserted was over 40 kb in length. Intronic mutations can be 
pathogenic, for instance, DNA sequencing of a patient with clinically defined 
neurofibromatosis type 1 (NF1) identified only a single polymorphism in intron 30 
due to an A to G transition 279 nucleotides from the 3’ splice site. This change was 
shown to produce a cryptic exon with a 3’ splice site introduced by the change and 
the activation of a 5’ splice site (Raponi et al. 2006). Intronic changes affecting 
splice sites can cause a change in splicing and although no such changes were 
identified by RT-PCR the possibility of alternatively spliced forms of Frem2 existing 
in the myUcl mutant cannot be completely ruled out. PCR will preferentially amplify 
the smallest fragment, therefore if a small level of abnormal transcript is present it 
may not be detected. Northern blot analysis would be the best method to detect such 
splice variants as a Frem2 probe would hybridise to all transcripts, enabling 
identification of shorter/ longer transcripts.
The cause of the mutation in myUcl and myHule may be due to a mutation/ 
rearrangement many bases up/ downstream of Frem2. These “position effect” 
mutations are so-called because of their location, which may be several hundred 
kilobases from the affected gene, but they alter gene expression through long-range 
effects on chromatin structure or by disrupting distal regulatory elements (Bedell et 
al. 1996). Such mutations have been found to be responsible for human disorders 
such as Reiger syndrome. This is an autosomal dominant disorder resulting in 
malformations of the anterior segment of the eye, dental hypoplasia and failure of the 
periumbilical skin to involute. As well as deletions and mutations in the responsible 
gene, PITX2, patients with translocation breaks mapping between 15 and 90kb 
upstream of the gene have been identified (Kleinjan and van Heyningen 1998).
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Premature termination codons (PTCs) result in nonsense mediated decay (NMD), a 
surveillance mechanism that selectively degrades mRNAs that prematurely terminate 
translation due to a frameshift or nonsense mutation. In mammals, NMD occurs after 
PTCs are recognised by the deposition of a complex of proteins involved in splicing 
and mRNA transport 20-24 bases upstream of exon-exon junctions. This complex 
recruits Upf3/3X, a nuclear protein which is exported with the mRNA to the 
cytoplasm, where it recruits Upf2. If termination occurs more than 50-55 bases 
upstream of the most 3’ exon during the first (pioneer) round of translation the 
termination complex interacts with junction bound Upfs to elicit NMD (Mendell and 
Dietz 2001; Maquat 2002; Weischenfeldt et al. 2005). As there is some expression of 
the Frem2 transcript NMD is not taking place.
It is unlikely that this is the cause of the myUcl mutation as the level of expression of 
Frem.2 is not greatly changed as shown by RT-PCR (Figure 3.6) and real-time PCR 
(Table 3.1), therefore it was concluded that the defect was not at the level of the 
promoter. Also, as the RT-PCR was carried out with RNA extracted from E14.5 
embryos, there could be a stage specific difference, which was therefore not 
detected. For instance, there could be a decrease in Frem2 expression at E l 1.5, the 
stage at which the renal defects begin and bleb formation begins. There could be a 
tissue specific difference that was not detected as the RNA was extracted from whole 
embryos, therefore small changes caused by loss of Frem2 expressing cells may have 
been masked.
A hypomorphic mutation could also be responsible for a small decrease in the level 
of expression of the gene. Such mutations involve an altered gene product which 
possesses a reduced level of activity, or in which the wild-type gene product is 
expressed at a reduced level. A hypomorphic FgflO mutant was created by the 
insertion of a transgenic cassette upstream of the FgflO gene. These mutants had 
decreased expression of FgflO, smaller eyelids and decreased branching 
morphogenesis of the lung, similar to other FgflO mutants (Mailleux et al. 2005). 
The Erbb2 receptor tyrosine kinase is a member of the epidermal growth factor 
receptor (EGFR) family. A transgenic mutant of Erbb2 was created that was viable 
and phenotypically normal, but exhibited subtle defects. Examination of the levels of 
Erbb2 expression revealed that the mutant expressed only 10% of the expected Erbb2
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protein and showed a ten-fold decrease in the number of muscle spindles (Chan et al. 
2004). Therefore transgenesis has been reported to result in hypomorphic mutants, 
which may be the case for the myUcl mice.
Further analysis carried out to detect more subtle changes in the level of Frem2 
expression by real-time PCR also failed to detect major differences in expression 
level. Methods other than sequencing will have to be employed to elucidate what is 
responsible for the myUcl phenotype, for example, it may be worthwhile carrying out 
FISH analysis to detect any rearrangements. The myUct strain was originally created 
through the introduction of a transgene, which subsequently may have translocated 
out through a chromosomal rearrangement which could have affected cis-acting 
transcriptional elements, such as transcriptional insulators and enhancers. Cis-acting 
elements are DNA sequences with no coding function that regulate genes that are in 
physical contact with them. Enhancers contain sequences that stimulate initiation of 
transcription by binding transcription factors and can be located several kilobases 
upstream or downstream of the promoter. Insulators also act in a bi-directional 
manner to protect a gene from the activation activity of enhancers or the inactivating 
effect of heterochromatin. Disruptions to either of these would have an effect on the 
transcription of a gene such as Frem2, resulting in changes in the levels of 
transcripts.
Alternatively the transgene could have caused a chromosomal abnormality such as 
an inversion, deletion or rearrangement. These would not be detected by PCR as the 
relatively small regions amplified would be intact whilst the gene as a whole may be 
affected. Changes in chromosomal size can be identified by carrying out pulsed field 
gel electrophoresis (PDGE), which fractionates large DNA molecules such as 
chromosomes according to their size by using several oscillating fields oriented in 
several different directions. This enables the DNA molecules to snake through the 
gel to different positions according to their size, therefore any changes in the size of 
the chromosome would be detected.
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3.3.2 Frem2 Genetrap
RT-PCR (Figure 3.10) shows that there is some expression across the insertion point 
of the genetrap cassette, i.e the mutation is not null. The genetrap should cause 
splicing to occur resulting in the /3-geo gene being fused to the preceeding Frem2 
exon (exon 4). The genetrap contains a stop codon and polyadenylation signal which 
should result in a premature termination of Frem2, with no expression of the 
following exons (exon 5 onwards). The expression across the insertion point would 
suggest that there is some splicing out of the genetrap cassette occurring as the 
product produced is the same size as the wildtype band, and not significantly larger 
as would otherwise be expected. Real-time PCR showed that expression of Frem2 
downstream of the genetrap insertion point in the myKst mice is greatly reduced, 
approximately 13% of normal levels.
Although the expression level of Frem2 is lower in the myKst strain than the myUcl 
strain, the phenotype is not much more severe. However, the myKst mice are currently 
on a mixed background of 129P2- C57BL/6J and will need to be bred onto a pure 
background, preferably NMRI, in order to compare the strains fairly as the 
background of the strain can affect severity. With both strains there is a spectrum of 
phenotypes ranging from mild syndactyly and cryptophthalmos to quite severe cases 
in which the limbs appear folded back in towards the body.
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3.3.3 Compound Frasl! Frem2 double mutants
Crossing 6 breeding pairs of bl+/myUcl+ mice together resulted in the production of 
19 litters, with a total of 144 mice. The majority (24%) of these were bl+/myUcl+, 
however, the fact that more double homozygote mice were produced than wt mice 
suggests that more breeding needs to be carried out as these two categories would be 
expected to be roughly equal. As blbl mice on their mixed background are embryonic 
lethal, no bl homozygotes were expected. Previously, it has been shown that 
changing the background of the bl strain affects the phenotype, making it more 
severe. Therefore putting the bl mutation onto the NMRI background of the myUcl 
mice could have resulted in a milder, viable phenotype.
blblI 
+ +
blbl/
my+
blbl/
mymy
bl+/ 
+ +
bl+/
my+
bl+/
mymy
+ +/ 
+ +
+ +/ 
my+
+ +/ 
mymy
Number 
of mice 5
7 14 21 35 28 10 16 8
Table 3.3: The genotypes of the 144 mice produced from crossing bl+/myUcl+ 
together and the number of mice produced with each genotype.
Therefore, the breeding of double mutants should be repeated once both strains are 
on the same background, thereby reducing any effect of background and/ or 
modifying genes on the phenotype. The blbl mutants did not seem to be more 
severely affected than the myrny mutants and the genotypes of the mutants could not 
be distinguished on the basis of their phenotypes. The only novel phenotype 
identified in these compound mutants was the difference in size between some of the 
compound double mutants (blbl/mymy) and their littermates. In some cases these 
mice were about half the size of their littermates. Initially it was thought that these 
differences in size were due to renal anomalies, but dissections carried out on adult 
mice showed that there was no renal agenesis in the mice studied, though some mice 
did develop renal cysts which will be discussed in Chapter 4, Frem2 expression and 
phenotype analysis.
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3.4 SUMMARY
Frem2 has been shown to be the gene responsible for the my phenotype. Although no 
mutations were identified in the myUcl and myHule strains and real-time PCR analysis 
showed myUcl embryos have 93% of Frem2 expression compared to wt embryos, a 
nonsense Frem2 mutation, c5640C -*A  (pY1880X), has been identified in an N- 
ethyl-A-nitrosourea induced strain, myF11 (Timmer et al. 2005). A Frem2 genetrap 
mutant (myKst) was also identified with a phenotype very similar to that of the other 
my mutants and is allelic with myUcl. This mutant is not a complete null as there is 
some expression of Frem2 downstream of the genetrap insertion. Real-time PCR 
showed that myKst embryos have only 13% expression of Frem2. In addition, double 
Frasll Frem2 mutants were created and were found to be viable, with no increase in 
the severity of the phenotype.
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CHAPTER 4. MURINE FREM2 EXPRESSION AND
PHENOTYPE ANALYSIS
4.1 INTRODUCTION
The P-geo cassette within the Frem2 genetrap enables expression of Frem2 to be 
studied easily. X-gal staining was carried out to obtain the embryonic expression 
pattern of Frem2. Phenotypic analysis of Frem2 mutants was also carried out to 
determine the location of the blebs and to detect any other abnormalities. The 
expression analysis indicated expression of Frem2 heart and the inner ear, and as 
abnormalities in both these organs has been reported in Fraser syndrome patients 
phenotypic studies of the ear and heart were carried out.
4.1.1 Transgenics and reporter genes
The use of transgenesis not only allows the generation of mutants but also enables 
the expression of the targeted gene to be studied. These transgenes are often of 
prokaryotic origin and encode products that are not normally associated with 
eukaryotic cells and tissues. Reporter genes have been used to analyse gene 
expression and to study development. The most commonly used in situ reporter gene 
is lacZ, which encodes a bacterial beta-galactosidase, a sensitive histochemical 
marker (Cui et al. 1994).
E. coli (3-galactosidase is a tetramer of four identical 1023-amino acid chains. Each 
chain consists of five domains, the third of which is an eight-stranded a / p barrel that 
comprises most of the active site, p-galactosidase hydrolyses lactose and other p- 
galactosides into monosaccharides. The enzyme is the product of the lacZ operon 
and P-galactosidase has two catalytic activities; it hydrolyses the disaccharide lactose 
to galactose plus glucose and it converts lactose to another disaccharide, allolactose, 
which is the natural inducer for the lac operon.
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Different substrates can be used, including those with useful chromogenic properties 
such as 5-bromo-4-chloro-3-indoyl-P-d-galactopyranoside, X-gal (Matthews 2005). 
After beta-galactosidic cleavage X-Gal gives rise to a blue precipitate. These 
properties of P-galactosidase and X-gal make them ideal for use in expression 
analysis. Genetrap insertions, such as that in myKst contain a P-geo fusion under the 
control of the endogenous trapped gene, in this case Frem2. Therefore, wherever 
Frem2 is expressed, p-galactosidase is expressed and can be visualised by using X- 
gal as a chromogenic substrate. This was used to obtain the expression pattern of 
Frem2.
S ™ " '  TsTT tm  _ - 75*
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Figure 4.1: The secretory-trap vector pGT1.8TM uses protein sorting and the fact 
that p-galactosidase activity is abolished in the endoplasmic reticulum (ER) to trap 
genes which encode secreted and transmembrane proteins and are expressed in 
embryonic stem (ES) cells. The pGT1.8TM vector contains a transmembrane (TM) 
domain downstream of a splice acceptor (SA) site, followed by the P-geo reporter 
with its own polyadenylation (pA) site. The TM domain of the vector sequesters 
gene-trap fusion proteins that do not have a signal sequence in the ER lumen, 
abolishing P-gal activity. When a fusion protein contains a secretory signal (SS) 
sequence, it is translocated into the cytosol where p-gal activity can be assayed 
(Stanford et al. 2001).
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4.1.2 Fraser syndrome and ear development
Ear abnormalities occur in 75% of Fraser syndrome patients (Mieke van Haelst, 
personal communication), the majority of which are external anomalies which may 
be attributable to blebbing in utero, i.e. low set ears, stenosis or atresia of the 
external auditory ear canal and microtia (absence of the pinna). However some 
patients also suffer auditory defects independent of ear canal atresia, including one of 
the Fraser syndrome patients with a mutation in FREM2. The cause of these auditory 
defects is unknown and has not been investigated, therefore the Frem.2 mutants were 
used to study these defects.
The mammalian ear consists of three components: the outer, middle and inner ears. 
The outer ear consists of the pinna and ear canal, which serve to direct sound waves 
to the tympanic membrane. The tympanic membrane, ossicles (malleus, incus and 
stapes), and the opening of the auditory tube form the middle ear, which is filled with 
air. Vibrations of the tympanic membrane are transmitted via the ossicles through the 
oval window of the vestibule via the foot-plate of the stapes, which causes the 
vibrations to enter the fluid-filled inner ear. The inner ear is composed of the 
cochlea, the auditory organ; the vestibule, the central compartment housing the 
saccule and utricle, which contain sensors for gravity and linear acceleration; and 
three semi-circular canals for detecting angular acceleration (Morsli et al. 1998).
The cochlea is a coiled structure enclosing three fluid-filled chambers and is encased 
in temporal bone with two membranous surfaces exposed at its base, the oval and 
round windows. Two of the three chambers, the scala vestibuli and scala tympani, 
are contiguous at the apex due to a small opening called the helicotrema, and are 
filled with perilymph. Pressure waves enter the cochlea through the oval window and 
move along the coils of the cochlea in the scala vestibuli to the apex. They are then 
transmitted through the roof (Reissner’s membrane) of the scala media and out 
through the floor (basilar membrane) of the scala media, back down the coils of the 
cochlea in the scala tympani and are dissipated out of the round window, which 
serves as a release valve (Torres and Giraldez 1998).
The organ of corti is located on the basilar membrane of the scala media. Pressure 
waves travelling through the scala media produce a shearing force on the hair cells of 
the organ of corti. These hair cells are imbedded in the gelatinous tectorial 
membrane, which is resistant to movement. The shear forces acting on the hair cells 
cause them to bend, opening ionic channels depolarising the hair cells due to K+ 
influx. The hair cells synapse on processes of neurons of the spiral ganglia, initiating 
signal transmission into the central nervous system. The cochlea is tonotopically 
mapped so that the hair cells at different locations along the cochlea are more 
sensitive to a particular frequency, i.e. hair cell sensitivity progresses from high 
frequencies at the base to low frequencies at the apex. This is achieved by having 
abundant hair cells with shorter cell bodies at the base, compared to at the apex. 
Also, at the apex, the width of the basilar membrane and the mass of the tectorial 
membrane increase (Cantos et al. 2000).
The formation of the vertebrate ear is induced by signals from the endoderm, 
mesoderm and the neuroectoderm in the area surrounding the ear region. Otic 
induction requires interactions with a variety of tissues over a period of time and is 
therefore a gradual process. The inner ear derives from the otic placode, a thickened 
area of ectoderm close to the hindbrain. The otic placode invaginates to form the otic 
cup and then the otic vesicle/ otocyst, an ellipsoid structure lined by pseudo-stratified 
epithelium which then proceeds to differentiate to form the many different cell types 
of the ear.
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Figure 4.2: The structure of the mammalian ear, consists of three components, the 
outer, middle and inner ears. Incoming sound waves vibrate the ossicles in the 
middle ear. This transmits the sound to the inner ear (a). The cochlea is a fluid-filled 
continuous coiled duct separated into three fluid-filled chambers, the scala vestibuli, 
scala media and scala tymapni (b). The sensory part of the cochlea, the organ of corti 
is found in the scala media and sits on the basilar membrane (c). The organ of corti, 
has two types of mechanosensitive cells, the inner and outer hair cells for converting 
mechanical vibrations into electrical impulses (d). Sound vibrations reach the 
tympanic membrane and are transmitted via the ossicles through the oval window. 
Vibrations then travel up the scala vestibuli, through the scala media and organ of 
corti, and down the scala tympani. The round window acts as a pressure valve, 
releasing the sound vibrations (e, f)  from Frolenkov et a l 2004.
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At El 1 in the mouse, the cochlea develops as a hollow tube from the ventral portion 
and the endolymphatic duct develops as a tube from the medial portion of the otocyst 
and grows dorsally. By El 1.5 the cochlea completes its first turn and an 
outpocketing (vertical canal plate) begins to bulge out from the otocyst, from which 
the superior and posterior semicircular canals develop. The horizontal canal plate 
from which the lateral semicircular canal develops appears as a bulge in the lateral 
part of the otocyst at E l2. At this stage the utricle begins to form in the anterior part 
of the inner ear, ventral to the vertical canal plate. By E l3 the primordium for the 
endolymphatic sac has formed in the endolymphatic duct, the semicircular canals 
have all formed and the utricle has adopted a more horizontal orientation. The 
saccular anlage begins to form as an expansion of the proximal part of the cochlea, 
ventral to the utricle. By E15, most structures have gained their mature shape, the 
utricosaccular and cochleosaccular ducts have formed. The cochlea continues to 
enlarge and completes its full one and three quarter turns by E17 (Martin and 
Swanson 1993; Fritzsch and Beisel 1998; Morsli et al. 1998; Torres and Giraldez 
1998; Fekete 1999; Cantos et al. 2000; Riley and Phillips 2003).
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Figure 4.3: Lateral view of paint-filled mouse inner ears. Unlabelled arrows 
illustrate the growth of the proximal part of the cochlea from E12 to E17. cc, 
common crus; co, cochlea; csd, cochleosaccular duct; ed, endolymphatic duct; es, 
endolymphatic sac; hp, horizontal canal plate; Isc, lateral semicircular canal; psc, 
posterior semicircular canal; s, saccule; ssc, superior semicircular canal; u, utricle; 
usd, utricosaccular duct; vpl, vertical canal plate. Scale bar, 100pm. Modified from 
Morsli et al. 1998.
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4.1.3 Fraser syndrome and heart development
Approximately 10% of Fraser syndrome patients suffer cardiac abnormalities which 
include patent ductus arteriosis (the failure of the ductus arteriosus blood vessel 
connecting the pulmonary artery and the aorta to close), atrial septum defects and 
cardiomegaly (abnormal heart enlargement). FRAS1 is expressed in the foetal heart 
(McGregor et al. 2003), although the precise location of the expression has not been 
determined. Therefore Frasl could have a role in heart development.
The heart arises from paired heart-forming fields in the lateral mesoderm. The heart 
fields are situated on opposite sites of the embryonic midline and contain endocardial 
and myocardial precursors. As the embryo develops, the heart fields fuse to form the 
primary heart tube. Cardiomyocytes differentiate form the heart fields to form the 
cardiac crescent. The cardiac epithelium in the anterior portion of the crescent forms 
a myocardial trough, surrounding a tube of endocardial cells. These two cell layers 
are separated by an extracellular matrix known as the cardiac jelly. Left-right signals 
then cause the rightward looping of the heart tube. During cardiac looping, the 
cardiac jelly disappears from the future chambers of the heart and the cardiac jelly 
overlying the future atrioventricular junction and outflow tract accumulates, resulting 
in the formation of cardiac cushions. The formation of these cushions is marked by 
epithelial to mesenchymal transition, in which a subset of endocardial cells 
delaminate and invade the cardiac jelly where they proliferate and differentiate into 
mesenchymal cells (Kelly and Buckingham 2002; Wessels and Sedmera 2003; 
Armstrong and Bischoff 2004).
Cardiac looping occurs after the ventricular component and atrioventricular canal 
have formed. The linear heart tube grows at both poles and bends towards the ventral 
side and turns towards the right. This results in the original left lateral wall becoming 
the ventral ventricular wall, the dorsal side becoming the inner curvature and the 
ventral side becomes the outer curvature. The original ventral side expands and 
bends towards the right. This process results in the formation of the cardiac chambers 
(Lamers and Moorman 2002).
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Septation of the atrial and ventricular chambers occurs following chamber formation. 
The atrial septum is formed by the development of the primary atrial septum as a 
crescent-shaped muscular septum which expands from the dorsal wall of the atrium 
towards the atrioventricular canal. The atrial spine (spina vestibuli) penetrates the 
atrium as a prong of mesenchyme above the inferior atroventricular cushion. The 
cranial spur of the atrial spine is a mesenchymal cap which follows the developing 
primary atrial septum as it develops. The primary atrial septum, mesenchymal cap 
and atrial spine merge and fuse with the superior endocardial cushion, which then 
fuse with the inferior endocardial cushion to separate the left and right atria. This is 
followed by myocardialisation to create a muscular septum (Lamers and Moorman 
2002; Moorman and Christoffels 2003; Wessels and Sedmera 2003).
4.2 RESULTS
Wildtype, myKs‘/+ and myKst/myKst embryos from stages E8.5- E l6 were used for 
either whole mount or cryosections were taken for P-galactosidase staining. Staining 
of some organs required that particular organ to be dissected and stained separately. 
In situ hybridization was also carried out for Frasl expression analysis. Optical 
projection tomography (OPT) was carried out to analyse 3D morphology and 
staining. Full details are contained in Chapter 8.
Frem2 expression was analysed using the myKst mutants which contain a P-geo 
construct, enabling X-gal staining for lacZ expression to be studied. Heterozygote 
embryos were obtained by crossing myKst/+ males with CD1 females. Wildtype 
littermates were used as controls to ensure no background staining was observed. 
Wholemount staining was carried out on embryos between E8.5 and E14.5.
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4.2.1 X-gal analysis of Frem2 expression
Heterozygous myKst embryos were harvested at the appropriate stage, fixed briefly 
and stained with X-gal solution for a few hours -  overnight. Strong expression of 
Frem2 was detected at the stages used (E8.5- E14.5) for wholemount staining in 
many tissues, including the developing kidney, ear and brain.
nd‘ b)
t
nd
ba
f
op
c)
\
d)
Figure 4.4: Wholemount X-gal staining of E8 (a) and E8.5 (b-d) myKst/+ embryos. 
Staining is visible in the nephric ducts (nd), first and second branchial arches (ba) 
and otic pit (op) as well as the midbrain/ hindbrain boundary.
Figure 4.5: Wholemount 
X-gal staining of E9.5 
myKst/+ embryos showing 
staining in the nephric 
ducts (nd), first and second 
branchial arches (ba), otic 
vesicle (ov), midbrain/ 
hindbrain boundary (mh) 
and along the anterior 
midline (am) along the 
forebrain and midbrain.
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Figure 4.6: Wholemount X-gal staining of E10.5 myKst/+ embryos. Frem2 
expression can be seen in the optic cup, somites (s), the optic vesicle (op) and the 1st, 
2nd and 3rd branchial arches (a). Expression at the midbrain/ hindbrain boundary (mh) 
has become more restricted and can also be seen at the anterior midline (am) the otic 
vesicle (ov) and apical ectodermal ridge (e). There is also some neuronal expression, 
possibly in the trigeminal ganglion and fourth and fifth ventricles (d). Sectioning will 
be required to identify some of the internal staining.
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Figure 4.7: Wholemount X-gal staining of El 1.5 myKst/+ embryos. Compared to the 
staining at E10.5, there is stronger expression in the somites (s), and there is 
additional expression in the Meckel’s cartilage (me), which proceeds to form the 
mandible. Expression remains in the apical ectodermal ridge (aer), otic vesicle (ov) 
and the optic vesicle (op) and there is additional expression above the otic vesicles, 
in the hindbrain region (c) and in the endolymphatic sac (es).
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Figure 4.8: Wholemount X-gal staining of E12.5 myKst/+ embryos. A similar 
expression pattern can be seen to that of the embryos at E l 1.5. Expression in the 
endolymphatic sac (es), optic vesicle, anterior midline (am), somites and apical 
ectodermal ridge remain. The expression in the midbrain/ hindbrain boundary (mh) 
has expanded laterally (c).
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Figure 4.9: Wholemount X-gal staining of E l3.5 myKst/+ embryos. Expression can 
be seen in the eyelid (el) and vibrissae (v). Expression in the ear includes the 
endolymaphatic sac (es) and endolymphatic duct (ed) as well as the external ear, the 
pinna (b). A sagittal cut along the ventral midline shows expression in the lung (1), 
kidney (k), pancreas (p) and gut.
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Figure 4.10: Wholemount X-gal staining of E l4.5 myKst/+ embryos. The most 
distinctive expression is in the pelage follicles (pf), there is also expression in the 
vibrissae (v). Expression is also shown along the ventral midline (dm), eyelids (el) 
and between the digits of the forelimbs (arrow).
In order to determine where Frem2 was expressed internally, the embryos were 
embedded in wax and either transverse or sagittal sections were taken. For larger 
embryos (E14.5 and older) whole mount staining does not stain the centre of the 
embryo as there are problems with penetration. Therefore, larger embryos were 
cryosectioned and the sections were subsequently stained with X-gal. Analysis of the 
expression pattern may enable the function of Frem2 during development to be 
inferred. OPT analysis was also carried out by Rob Watson at the MRC-Human 
Genetics Unit in Edinburgh on E l0.5 embryos stained with X-gal, enabling a 3D 
picture of the expression pattern to be created and sections through various planes to 
be taken. OPT movies can be seen in Appendix D (CD attached to back cover).
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Figure 4.11: OPT scans of E10.5 of myKst/+ embryos lightly stained with X-gal, 
showing Frem2 whole mount expression. The X-gal staining was pseudo-coloured 
with colours reflect the density of staining, red indicating strongest staining (highest 
expression) and blue indicating weakest staining (c).
Figure 4.12: Stills 
taken from OPT 
movies that show 
Frem2 expression 
(bright white areas) 
in E10.5
embryos taken from 
different planes of 
orientation.
Expression can be 
seen in the branchial 
arches (ba), otic 
vesicle (ov), Rathke’s 
pouch (rp) and the 
trigeminal 
ganglion (tg).
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Figure 4.13: X-gal staining to show Frem2 neural expression, a) A sagittal section 
through an E10.5 myKst/+ embryo showing staining in the Meckel’s cartilage (me), b) 
A transverse section through an E l0.5 myKst/+ embryo head. Staining can be seen in 
the lens, Rathke’s pouch (rp) and trigeminal ganglion (tg). c) A transverse section 
through the head of an E l2.5 myKst/myKst embryo with expression in the trigeminal 
ganglion. Counterstaining of all sections is with nuclear fast red.
Figure 4.14: X-gal staining of sense organs of myKst/+ embryos. Sagittal sections 
showing staining in the lens of an E10.5 embryo (a) and the cornea (c) of an E14.5 
embryo (b). Transverse sections showing Frem2 expression in the tongue (t) and 
vibrissae (v) of an E l5.5 embryo (c) and the nasal epithelium (ne) of an E14.5 
embryo (d). A transverse section of an E14.5 embryo showing expression in the 
cochlea (e).f) A sagittal section of an E14.5 embryo showing expression in the pinna 
(p) and ear canal (ec). {b & c) counterstained with eosin, other sections 
counterstained with nuclear fast red.
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Figure 4.15: Sections showing Frem2 expression in the chest, a) A sagittal 
cryosection of an E14.5 myKst/+ embryo showing staining in the atrial wall (aw) and 
alveoli (alv). b) A sagittal section of an El 1.5 myKst/+ embryo showing staining in 
the inter-vertebral discs (ivd). c) A transverse section of an E l5.5 myKst/myKst embryo 
showing expression in the alveoli. All sections were counterstained with nuclear fast 
red.
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Figure 4.16: Coronal section showing X-gal staining of the ectoderm and 
mesodermal core (me) of the 1st and 2nd branchial arches of an E10.5 myKst/+ embryo 
(a). Transverse sectioning shows that the somatic expression is restricted to the 
myotome (m) due to the lateral patterning of the staining in this E l2.5 myKst/myKst 
embryo (b). Sections are counterstained with nuclear fast red.
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Figure 4.17: Sagittal (a) and transverse (b) sections of an E14.5 myKst/+ embryo 
showing staining in the pelage follicles. Counterstaining was carried out with nuclear 
fast red (a) and eosin (b).
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E8.5 E9.5 E10.5 E11.5 E12.5 E13.5 E14.5
• Nephric duct • Mesonephric • Mesonephric duct/ • Metanephric • Metanephric • Metanephric • Metanephric
• Midbrain/ duct Urogenital ridge blastema, blastema, blastema, blastema,
hindbrain • Midbrain/ • Midbrain/ mesonephric duct/ mesonephric duct/ mesonephric duct/ mesonephric
boundary hindbrain hindbrain boundary tubules, ureteric bud tubules, ureteric bud tubules, ureteric duct/ tubules,
• Otic pit boundary • Otic vessicle • Midbrain/ hindbrain • Cochlea, bud ureteric bud
• Is'/ 2nd branchial • Otic placode/ pit • Future tympanic boundary endolymphatic duct, • Cochlea, • Cochlea,
arch • Future tympanic membrane • Cochlea, semicircular canals endolymphatic endolymphatic
membrane • 1st/ 2nd/ 3rd arch endolymphatic duct • 1st/2nd/3 rd arch duct, semicircular duct,
• 1st/ 2nd branchial ectoderm & • 1st/ 2nd/ 3rd arch ectoderm & canals semicircular
arch ectoderm & mesodermal core ectoderm & mesodermal core • Lens canals
mesodermal core • Rathke’s pouch mesodermal core • Peritoneal cavity • Choroid plexus • Lens
• Rathke’s pouch • Trigeminal • Peritoneal cavity • Midgut/ hindgut • Muscle • Cornea
• Peritoneal cavity ganglion • Midgut/ hindgut • Lens • Bronchus • Choroid plexus
• Midgut • Lamina terminalis • Lens pit • Nasal pit lining • Alveoli • Muscle
• Notochord • Peritoneal cavity • Nasal pit lining • Thyroid primordium •AER • Bronchus
• Midgut/ hindgut • Thyroid • Trachea • Hindbrain • Alveoli
• Notochord primordium •AER • Thymus •AER
• Lens pit • Trachea • Bronchus • Gut • Thymus
• Nasal pit lining •AER • Cloaca • Nasal pit lining • Atria
• Thyroid • Bronchus • Dorsal midline •Trachea • Gut
primordium • Cloaca • 4th ventricle • Nasal pit lining
•Trachea • Dorsal midline • Telencephalic vesicle •Trachea
•AER • 4th ventricle • Gall bladder • Hair follicle
• Bronchus • Telencephalic • Meckel’s cartilage • Atrial walls
• Cloaca vesicle • Myotome
• Dorsal midline • Gall bladder • Choroid plexus
• 4th ventricle • Meckel’s cartilage
• Myotome
Table 4.1: Expression pattern of Frem2. The table shows the major locations of Frem2 expression.
4.2.2 Frem2 phenotype analysis
Although the my strain is the best characterised of the blebbed strains, it had not been 
studied at an embryonic level. The position and severity of the blebs and the 
resulting phenotype was studied in embryos at El 1.5 -  E16.5, the stages between 
which blebbing occurs. The blebs seem to occur along areas particularly exposed to 
friction in utero, such as the head, along the back, the limbs and the rump.
The majority of the my mice present with phenotypes attributable to these blebs, such 
as cryptophthalmos and syndactyly. On dissection, some homozygotes were found to 
have exencephaly. These were almost certainly not going to survive, and in some 
instances the embryos were found dead or in varying degrees of resorption.
The myKst strain is semi-lethal, with approximately half the expected number of 
homozygotes surviving to liveborn. The homozygote embryos display a spectrum of 
phenotypes ranging from reasonably mild in the case of syndactyly to severe in the 
case of exencephaly and renal agenesis. Some embryos were discovered in the 
process of being resorbed. The stages at which these were found varied from as early 
as E12 to quite near the end of gestation. Both the liveborn and embryonic phenotype 
seem to be highly variable and result in the death of embryos and mice at different 
stages.
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Figure 4.18: myKst/myKst embryos showing haemorrhagic blebbing at E15.5 (a- d) or 
E l3.5 (e, f). White arrows indicate haemorrhagic blebs, black arrows indicate serous 
blebs, a) A large haemorrhagic bleb can be seen over the snout. A large serous bleb 
can be seen over the right eye and a small bleb can be seen at the top of the head, b) 
This embryo shows several blebs over its face, including haemorrhagic blebs over its 
eyes and snout. It also has a haemorrhagic bleb over its right hindlimb and a serous 
bleb over its right forelimb. There appears to be a bleb (*) on its back which seems to 
have prevented normal neural tube closure, c) This embryo has haemorrhagic blebs 
over both eyes, on its forehead and snout. It also has haemorrhagic blebs over both 
hindlimbs. d) Blebs can also occur on the rump, as seen in this example. There are 
two haemorrhagic blebs over this region, as well as some thrombosis (*) at the base 
of the bleb, e) Particularly severe blebbing over the snout, as seen here, is unlikely to 
be compatible with life as severe bleeding can cause death, f)  A schematic showing 
the usual locations of blebs in the Frem2 mutant mice. Blebbing can occur along the 
length of the limb, as well as on the face and head, and along the spine; locations 
expected to experience friction in utero.
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Figure 4.19: Figures of embryos suffering from exencephaly. An El 1.5 myKst/myKst 
embryo stained with X-gal (a, b) and an E l5.5 myKst/myKst embryo with a 
haemorrhagic bleb over its right hindlimb.
108
Figure 4.20: Homozygote myKst/myKst embryos which were found to be dead upon 
dissection. All embryos seem to have been between E13 and E14.5 when they died 
and were discovered at various stages of resorption when dissected, making the 
cause of death difficult to ascertain. These embryos appear quite dysmorphic with 
low set ears (a, c ,f)  and a short lower jaw (c, d, e).
4.2.3 Searching for Fraser syndrome phenotypes in Frem2 mice
As well as the blebbing phenotype, the Frem2 mutants exhibit some of the other 
phenotypes of Fraser syndrome. Some of the other characteristics used to diagnose 
Fraser syndrome include malformations of the ear, nose, larynx and heart, genital 
abnormalities and renal agenesis. No malformations of the nose were identified in 
the Frem2 mice and all homozygotes are able to breed, although their breeding 
capacity decreases after 6- 8 months. Malformations of the larynx were observed in 
some mutant mice, in the form of a “clicking” sound, however this was not analysed 
further. Malformations of the kidney, heart and ear were studied in more detail in the 
Frem2 mice as X-gal studies showed expression of Frem2 in these regions.
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4.2.3.1 Frem2 renal expression
Frem2 is expressed in the mesonephros and metanephros and this expression remains 
into adulthood. Renal agenesis is reported for the my strain and cysts have been 
discovered in adult mutant mice, the location of which was studied.
Figure 4.21: Transverse sections (a- d , f  g) showing X-gal staining. Staining can be 
seen in El 1.5 5 myKst/+ embryos in the mesonephric tubules (a) and metanephric 
ducts (b). In E14.5 myKst/+ embryos staining is also visible in the glomeruli (c) and 
urethra (d). Expression of Frem2 can be seen in cells of the medulla and cortex of a 
p7 myKst/myKst kidney (e). Staining can be seen in most epithelial structures, such as 
the stomach epithelium (se) of a cryosectioned E l5.5 myKst/myKst embryo (f). Frem2 
is also expressed in the gut in E l0.5 myKst/+ embryos (g). All sections are 
counterstained with nuclear fast red, except (d). g, glomeruli; u, urethra.
Cysts were detected upon sectioning some adult myUcl/myUd kidneys, therefore in 
order to determine which cell types were expressing Frem2 and to establish if this 
was consistent with cyst localisation, staining was carried out with known renal 
markers.
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Figure 0.1: a) Frem2 expression in the adult myKst/+ kidney as indicated by X-gal 
staining, counterstained with eosin. b) Frem2 is expressed in the arterioles as 
indicated by colocalisation with a-smooth muscle actin (SMA). c) Section of an 
adult myKst/+ kidney, showing X-gal expression in the proximal convoluted tubules 
(pet) and collecting ducts (cd) but not the ascending loop of Henle, stained brown 
with Tamm-Horsfall protein, a marker for the ascending loop of Henle. d) 
Expression in collecting ducts (cd) was confirmed by X-gal expression in a section 
of adult renal cortex and e) the same section labelled with Dolichos biflorus lectin, a 
collecting duct marker, and counterstained with Hoechst stain. /)  Homozygous myUcl 
mice develop renal cortical cysts as adults, as indicated here in a section of an adult 
myUcl /myUcl haemotoxylin-eosin stained kidney.
■ -cd
Immunostaining of cysts is partially consistent with Frem2 expression. Some cysts 
were present in the collecting duct, whereas others existed in the thick ascending 
limb of the loop of Henle. Cysts were negative for proximal tubule markers.
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4.23.2 Frem2 and Frasl expression in the heart
Cardiac abnormalities such as cardiomegaly and atrial septal defects are occasionally 
present in Fraser syndrome. As Figure 4.15 shows, there is some expression of 
Frem2 in the heart at E14.5, therefore to determine exactly where in the heart Frem2 
is expressed and at which stages, hearts were dissected from myKst/+ and myKst/myKst 
embryos and stained with X-gal. Expression in the heart is first seen at E14.5 in the 
atrial walls. Strongest expression is seen at E15.5, after which expression diminishes, 
though some expression of Frem2 in the heart remains throughout adulthood. The 
expression of FRAS1 and Frem2 in the heart and the existence of cardiac 
abnormalities in Fraser syndrome patients suggests a potential role for the Fras-Frem 
proteins in cardiac development.
Figure 4.23: Whole mount X-gal staining of hearts. Expression is strongest at E l5.5, 
as seen in these E l5.5 myKst/+ hearts (a, b). There is a tight band of expression 
surrounding the base of the major vessels (a) and strong expression in the atria. 
Expression decreases after this stage, as seen in this E l7.5 myKst/+ heart (c). Frem2 
is also expressed at lower levels in the adult myKst/+ heart (d-f) where expression is 
reduced to the edges of the atria. However there is also some expression in the 
smaller cardiac vessels (cv) and at the heart apex (ha).
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Figure 4.24: Wax sections of E l5.5 myKst/+ hearts stained with X-gal to show 
Frem2 expression. Expression can be seen in the atrial walls (a, c, d) as well as the 
atrio-ventricular valves (avv), atrial septum (as) and the cuff of the pulmonary 
infiindibulum (cpi). Counterstaining was carried out with eosin.
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Figure 4.25: Wax sections of E l7.5 myKst/myKst hearts stained with X-gal to show 
Frem2 expression. Expression is lower than at E l5.5, and whilst some staining in the 
atrial walls remains, expression around the cuff of the pulmonary infundibulum is 
greatly reduced (arrow). Sections are counterstained with eosin.
In order to detect any cardiac anomalies, E l5.5 myKst/myKst embryos were sent to 
Prof. Bhattacharya in Oxford to carry out MRI analysis. Embryos of this stage were 
selected as it was though that they were sufficiently developed for any abnormality 
to be detectable and also, as the presence of blood can disturb MRI analysis, by this 
stage any haemorrhagic blebs have or are in the process of resolving. Unfortunately 
no defects were identified in the embryos sent for analysis.
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As cardiac anomalies affect 10% of Fraser syndrome cases (M. van Haelst, personal 
communication), including a patient with a FRAS1 mutation, it was decided to look 
at Frasl expression in the heart. As the bl (Frasl) mutant mice do not have a lacZ 
cassette, in situ hybridisations were carried out to assess Frasl cardiac expression.
Figure 4.26: Frasl in situ hybridisations carried out on E l3.5 (a), E14.5 (b -  d) and 
E15.5 (e, f)  wt hearts. Frasl expression seems to peak at E14.5 with expression 
strongest in the atria. Frem2 expression occurs at the cuff of the primary 
infundibulum, however Frasl expression occurs in a distinct pocket lying more 
caudally (c). Apparent staining in the ventricles is probably a result of “trapping”.
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In order to determine whether there was any “trapping” and to determine exactly 
where Frasl is expressed in the heart, the embryos were embedded in wax and 
sectioned. Hybridisation with the sense probe showed no staining.
Figure 4.27: Sections from wt hearts used for Frasl in situ hybridisations. There 
seems to be some Frasl expression in the endothelium lining (e) and trabeculae (t) of 
wt E14.5 hearts (a, b). Some expression can also be seen in the cardiac vessels (cv) 
at E15.5 (c).
The X-gal staining for Frem2 expression and the Frasl in situ hybridisations show 
that both genes are expressed in the heart, though in slightly differing locations. 
Frem2 is expressed in the atrial walls, the atrio-ventricular valves, atrial-septum, 
heart apex and the cuff of the primary infundibulum. Frasl is expressed in the atrial 
walls, the ventricular epithelium and cardiac vessels. Whereas Frem2 expression in 
the heart begins at E14.5, peaking at E l5.5 and gradually decreasing to lower levels 
in the adult heart, Frasl expression seems to peak at E14.5 and decrease thereafter.
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4.2.3.3 Frem2 and auditory function
As there seemed to be expression of Frem.2 in the cochlea, it was decided that the 
myKst mice should be tested for hearing abnormalities. The startle response test was 
carried out, in which a “click-box” emitting a high frequency signal is used to 
determine whether or not mice respond to the auditory stimulus. The response was 
graded, with 1 corresponding to a startle response, 0.5 corresponding to a small 
startle or ear twitching and 0 corresponding to no response. Most homozygote mice 
tested had no response to the test, and all heterozygote and wt control mice had some 
level of response (0.5 or 1).
AGE GENOTYPE LEVEL OF RESPONSE
0 0.5 1
4.5 weeks
++ 2
myKs7+ 2
myKs7myKst 1 1
5 weeks
++ 1
bl+/myUcl+ 2
myUc7+ 1
7.5 weeks
bl+/myUclmyUcl 2 1
blbl/myUclmyUcl 2
8 weeks
++ 2
bl/+ 1 1
myUc7+ 1
bl+/myUcl+ 1
bl+/myUclmyUcl 1
8.5 weeks bl+/m yUclmyUcl 7
Table 4.2: Table to show the number of mice with each level of response to the 
startle response test. Compound mutants were also tested to determine whether bl 
mice had a response, as single bl mutants are not viable. All wt and heterozygous 
mice tested showed a response. Most homozygotes showed no response, though 2 
mice did show some response.
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Oto-acoustic emissions were also tested to confirm these results. This involved 
securely placing a probe into the ear of an anaesthetised mouse. The probe emits 
sounds of varying frequencies into the ear, and the sound reflected back is measured, 
therefore any defects resulting in the sound not being reflected can be detected. Such 
defects could include blockages and abnormalities in the cochlea. Oto-acoustic 
emissions (OAEs) were tested in two homozygote and two heterozygote and two wt 
mice. Only two mice of each phenotype could be tested due to the time restraint on 
the availability of the OAE equipment. Both wt mice had normal readings at the 
frequencies tested in both ears, however the homozygote mice had no reading at all 
in both their ears. Cryptophthalmos was unilateral in both mice and the extent of 
cryptophthalmia had no bearing on the OAE result.
To ensure that there were not also vestibular defects, a “reaching response” test was 
carried out, involving the mouse reaching for a nearby surface when being held by its 
tail. All homozygotes had a normal response to this test and analysis of the bones of 
the inner ear of the mutants (Figure 4.37) was normal, therefore a vestibular defect 
was ruled out.
As many of the phenotypes associated with Fraser syndrome and the blebbed 
mutants can be attributed to the presence of the blisters, it was initially though that 
the hearing abnormalities could also be due to the blisters. To check if blistering had 
caused stenosis/ atresia of the ear canal, five Frem2 homozygotes (not including 
those that were tested for OAEs) were dissected along the ear canal to the cochlea. 
No constrictions were observed.
In order to determine the cause of the failure to respond to the tests, heads from 
embryos at various developmental stages were sectioned transversely and stained 
with X-gal to establish exactly where in the cochlea Freml is expressed and if this 
would yield some more information on the cause of the defect.
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Figure 4.28: Transverse sections through the heads of myKst/+ embryos to determine 
where Frem2 is expressed in the ear. Frem2 is expressed in the sub-domains of the 
otocysts of the cochlea (*), the pinna, ear canal and in the cochlear membranes (cm). 
All sections counterstained with nuclear fast red, except (c) which was 
counterstained with eosin.
To determine which membranes in the cochlea stain for Frem2, cochleas were also 
dissected and sectioned. It was found that the most successful method of embedding 
the cochleas was with OCT under pressure (vacuum) for cryosectioning. Upon 
sectioning, the cochleas were stained with X-gal.
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Figure 4.29: An adult myKst/+ cochlea stained with X-gal (a). The organ of corti of a 
wt mouse (b) from (Ikeda et al. 2000). A pl6 myKst/+ cochlea sectioned and stained 
with X-gal, showing expression in the Reissner’s membrane, Claudius cells and 
Interdental cells, counterstained with nuclear fast red (c). Expression of Frem2 can 
be seen in the Reissner’s membrane (RM). CN, cochlear nerve fibres; IHC, inner hair 
cells; OHC, outer hair cells; TM, tectorial membrane; IDC, Interdental cells; CC, 
Claudius cells.
To establish whether there was any damage in the Reissner’s membrane of Freml 
homozygotes it was decided to carry out optical projection tomography (OPT) 
analysis. This enables a 3D image to be created of the cochlea that can be 
manipulated to detect any structural abnormalities present.
Figure 4.30: Stills taken from OPT movies showing scans through wt and mutant 
cochleas. The Reissner’s membrane (RM) seems to be intact in the mutant cochlea, 
however there appears to be a structural abnormality at the apex of the mutant 
cochlea (*).
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To determine whether or not the hair cells were affected and if there was a defect in 
the Reissner’s membrane, scanning electron microscopy (SEM) and transmission 
electron microscopy (TEM) was carried out by Andy Forge at the UCL Centre for 
Auditory Research.
Figure 4.31: Scanning electron microgram of an adult my*s'/my*5' cochlea mid-turn. 
The apparent disorganisation of the stereocilia is a dissection artefect and otherwise 
is normal. Ihc, inner hair cells; ohc, outer hair cells.
Figure 4.32: Transmission electron micrograms showing the stria vascularis (a) and 
Reissner’s membrane (b) of a wt adult cochlea. The arrow indicates the ECM 
between the two cell layers which compose the Reissner’s membrane.
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Figure 4.33: TEMs showing 
the Reissner’s membrane (a & 
b), stria vascularis (b) and 
Organ of Corti (c) of an adult 
myKs7+ cochlea, which appears 
normal. The arrowhead (b) 
indicates the ECM between the 
two cell layers which compose 
the Reissner’s membrane. The 
outer hair cells (ohc) in the 
Organ of Corti are intact but 
appear disrupted due to the 
process of sectioning.
Figure 4.34: TEMs of an adult
myKs,/myKst cochlea. No defects 
were detected in the Reissner’s 
membrane (a), the ECM of the 
Reissner’s membrane (b), Stria 
vascularis (c), Organ of Corti 
(d) or outer hair cells, tm, 
tectorial membrane; ihc, inner 
hair cells; ohc, outer hair cells.
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4.3 DISCUSSION
4.3.1 Frem2 mutant analysis
Although the original my strain was created and first studied in the 1920s, following 
a period of enormous interest in the strain in the subsequent years, it had not been 
thoroughly studied using modern molecular biology techniques. As well as the 
common phenotypes shared with the other blebbed strains such as cryptophthalmos, 
syndactyly and renal agenesis, the my mice also have renal cysts and auditory 
problems making them very interesting. Many of these phenotypes can be attributed 
to the presence of the blebs disrupting the epidermal-mesenchymal interactions 
required for the development of the structures affected such as the eye and limb.
4.3.1.1 Bleb formation
The blebs first appear at E ll ,  become haemorrhagic around E13 and resolve around 
E15. Blebbing in the Frem2 mutants can occur in multiple sites, the precise location 
of which is highly variable. The mechanism behind blebbing will be discussed fully 
in Chapter 7, however it is thought that the initial blistering occurs due to epidermal 
fragility combined with mechanical friction in utero could result in blister formation. 
This is supported by the fact that the blisters all occur in regions likely to be in 
contact with the uterine wall, i.e. the limbs, head and face, back, rump and tail 
(Figure 4.18/).
The blistering could also be secondary to basement membrane turnover during 
growth. There are a few theories behind the cause of haemorrhaging. These include a 
defect in vascular stability due to Frem2 absence or a failure of adhesion in the cells 
lacking Frem2 together with normal angiogenesis causing leaking of blood into the 
blister cavity (Timmer et al. 2005).
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An earlier theory hypothesised that blebbing was caused by an increased 
permeability of capillaries, allowing the flow of plasma out of the vessels. The 
increase in size of the blebs was attributed to the volume of liquid and the pressure it 
was under in embryonic circulation increasing during development, causing more 
blood to pass through the peripheral vessels and thus increased diffusion of plasma 
(Plagens 1933).
Haemorrhaging of the blebs is often also accompanied by thrombosis (Figure 4ASd) 
at the base of the blister. Thrombosis usually occurs following injury to the 
endothelium of vessel walls, causing thrombocyte deposition and blood cell 
agglutination. The blebs resolve from E15 onwards, but it tends to be the thrombi 
which are the last to resolve and could be responsible for the more severe 
phenotypes.
It is unclear why some of the homozygotes die in utero but it is thought that those 
embryos with a more severe phenotype or with excessive haemorrhaging do not 
survive. Possible reasons for embryonic death include excessive haemorrhage or 
possibly heart defects. Embryos that are already dead on dissection have been found 
at stages between El 1 and E l6, suggesting that there may be more than one cause of 
death. It is likely that the more severely affected embryos die earlier.
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4.3.2 X-gal analysis of Frem2 expression
The presence of the fi-geo cassette in the myKst strain enabled a quick and easy 
method of analysing the expression pattern of Frem2. Frem2 expression is dynamic, 
both temporally and spatially. Although Frem2 is expressed in some organs such as 
the kidney throughout development and into adulthood, expression of Frem2 in 
organs such as the heart seems to be restricted to a specific time point. Frem2 seems 
to be required in the skin BMZ between E l l  and E15, and the lack of the gene 
product causes epidermal fragility and skin blistering during this period.
In situ anlaysis shows Frem2 is expressed in the same regions as were identified by 
X-gal analysis. These include the developing kidneys, lungs, midbrain hindbrain 
boundary, branchial arch ectoderm, myotome and endodermal derivatives such as the 
stomach, oesophagus and gut (Timmer et al. 2005).
However, the sensitivity of the X-gal method enables a more detailed pattern of 
expression to be compiled. In situ hybridisation relies on the quality of the probe 
used, which can vary greatly. Though both methods are susceptible to background 
staining (non-specific staining in the case of in situs and endogenous P-galactosidase 
activity for X-gal staining) there was no background X-gal staining in the myKst mice. 
The X-gal staining method enabled expression to be identified, such as in the 
cochlea, that may have been missed when carrying out in situ analysis. Frem2 is 
expressed in a wide variety of tissues and organs, highlighted by the expression in 
the branchial arches (Figure 4.16), where it is expressed in the ectoderm and 
mesodermal core. Frem2 is expressed in the epidermis, vibrissae, notochord, 
somites, ear and blood vessels. On the whole, expression of Frem2 occurs in all areas 
in which epithelial-mesenchymal interactions appear to play a part in development, 
such as the apical ectodermal ridge (AER), eye and kidney, which is consistent with 
the Frem2 phenotype. Other areas that show expression of Frem2 include the regions 
of neural expression, other than the exencephaly no neural defects have been 
reported in the blebbed mutants or Fraser syndrome.
125
Frem2 is expressed in most developing epithelial structures as is Freml. A mutation 
in the Freml gene is responsible for the head blebs phenotype. However, unlike 
Freml, Frem2 expression is restricted to the epithelia in a complementary manner to 
Freml, which is expressed in the dermis and mesenchyme (Smyth et al. 2004). This 
suggests that expression of both genes is required in a coordinated fashion to 
maintain epidermal adhesion.
4.3.2.1 Pattern ofFg/8 expression
The fibroblast growth factor (FGF) family encode cytokines which transduce a signal 
through a family of transmembrane receptor tyrosine kinases, the FGF receptors 
(FGFRs). They also bind with lower affinity to glycosaminoglycans and 
proteoglycans associated with the cell surface and extracellular matrix. The FGFs 
can modulate a wide range of developmental processes, they are mitogens for cells of 
all three germ layers and have been implicated in mesoderm induction, 
vascularisation and the development of muscle, teeth and limbs. Fgf8 is involved in 
neural development, in particular in the organization of the midbrain-hindbrain 
junction and in kidney development. Fgf8 is widely expressed in the embryonic 
tailbud, primitive streak, neural plate, midbrain/ hindbrain boundary, olfactory pits, 
AER, primitive glomeruli, somites, pharangeal region and the facial primordia 
(Crossley and Martin 1995; Garel et al. 2003). Therefore Fgf8 and Frem2 expression 
was compared, and as Figure 4.35 shows, there are striking similarities. This would 
suggest that Frem2 could interact with Fgf8, possibly through its NG2-like domain, 
which is known to bind FGF in NG2 itself.
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Figure 4.35: Comparison of the expression of Frem2 and Fgf8. Whole mount Fgf8 
in situ hybridization on a wt E9.5 embryo. Fgf8 is expressed in the midbrain- 
hindbrain boundary (white arrow) and in the rostral midline (black arrowheads). Fgf8 
is also expressed in the ov, otic vesicle; ba, branchial arches and; nd, nephric duct (a) 
from (Garel et al. 2003). X-gal staining of a myKst/+ E9.5 embryo shows Frem2 is 
also expressed in the otic vesicle, branchial arches and nephric duct (b).
4.3.3 Frem2 phenotype analysis
4.3.3.1 Frem2 renal expression and phenotype
Freml is expressed in the mesonephric tubules and in the metanephric epithelia at 
El 1.5 with strongest expression at the tips of the developing ureteric buds, which is 
similar to Frasl renal expression at similar stages (McGregor et al. 2003), and 
complementary to that of Freml, which is expressed in the stroma (Smyth et al. 
2004). At later stages expression also occurs in the epithelia fated to form nephrons, 
which are induced by the ureter tips to differentiate from the mesenchymal 
condensations that surround them, the proximal convoluted tubules and collecting 
ducts. This expression is maintained into adulthood.
As well as renal agenesis, adult my mice can develop renal cysts in the collecting 
ducts and the ascending loop of Henle, which is consistent with Frem2 gene 
expression of those cyst origins. Very little is known about the role of Frem2 in the 
kidney, however the role of Frasl has been studied in more detail.
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Frasl is expressed in the mesonephric duct and immunolocalises to the basal 
surfaces of the ureteric bud. The mouse Frasl model is the bl strain in which the 
mice have a nonsense mutation in Frasl. The bl/bl mice are non-viable and die 
around E14-15. Mid-gestation bl homozygotes have blind ending ureters and E l3 
homozygotes have very small remnants of the kidney.
The two main steps in ureteric bud formation involve reciprocal interactions between 
the metanephric mesenchyme and the forming ureteric bud. As the ureteric bud 
invades the mesenchyme it induces it to condense. The condensed mesenchyme then 
induces the ureteric bud to branch. In the bl/bl mice, the early stages of kidney 
development occur, i.e. the intermediate mesoderm is present and the ureteric bud 
branches from the correct site of the mesonephric duct at E10.5. At E ll ,  the renal 
mesenchyme should aggregate around the ureteric bud which should then branch into 
the renal mesenchyme. However, in bl/bl El 1.0 embryos, the ureteric bud reaches 
the renal mesenchyme but does not enter it. This results in apoptosis of both the 
ureteric bud and renal mesenchyme.
The homozygote mice express normal levels of Pax2 in the ureteric bud and renal 
mesenchyme. The Pax2- upregulated TGFP-related growth factor GDNF, which is 
required for ureteric bud integrity and migration, is also expressed normally in the 
renal mesenchyme of mutants. In wt mice, GDNF is upregulated in the renal 
mesenchyme at E ll ,  but cannot be detected in mutant mice. In addition, the normal 
up-regulation of a8 integrin and BCL2, which are cell adhesion and survival 
molecules, does not occur in bl/bl embryos. Frasl is not required for ureteric bud 
outgrowth but is required for further development when the ureteric bud penetrates 
the renal mesenchyme, suggesting that Frasl directly mediates the reciprocal 
signalling between the ureteric bud and renal mesenchyme (J. Pitera, personal 
communication). The lack of these reciprocal interactions could result in the absence 
of cell survival signals and result in apoptosis and renal agenesis. In order to 
determine whether the increased apoptosis is the cause for renal agenesis, caspase 
inhibitors, which minimise apoptosis, could be administered to pregnant females to 
investigate whether their offspring develop renal agenesis.
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4.33.2 Frem2 and Frasl expression in the heart and heart phenotype
X-gal staining for Frem2 and in situ hybridisation for Frasl expression in the heart 
showed that Frem2 is expressed in the atrial wall, cuff of the pulmonary 
infundibulum, base of the aorta and vena cava, the apex of the heart, atrioventricular 
valves and the atrial septum. Expression first occurs at E l4.5 and lasts into 
adulthood. Frasl is expressed in the endothelium lining of the ventricles, trabeculae, 
atrial walls and the cardiac vessels. These regions, particularly for Frem2, localise 
with the regions with phenotypes in Fraser syndrome and some mouse models. 
Timmer et al. describe myFU mutants with malformations of the septa and valves, 
including complete absence of the atrial septum (Figure 4.36), which has not been 
seen in any of the my mutants available to us.
Figure 4.36: Section of an E15.5 myF1! homozygote heart, showing an apparent 
failure of atrial septation (arrow) and a defect in ventricular valves (arrowhead) from 
(Timmer et al. 2005).
Atrial septation occurs after the appendages balloon from the convex parietal side of 
the atrial body. The distinctive structure of the appendages confers morphological 
specificity to the new atria. The primary septum grows as a muscular partition from 
the roof of the primary atrium into the atrial cavity, carrying a mesenchymal cap on 
its leading edge. The two endocardial cushions, the superior and inferior, are 
produced within the initial atrioventricular junction. As the muscular primary atrial 
septum grows, the mesenchymal cap approaches and fuses with the superior 
endocardial cushion of the atrioventricular canal. Concomitantly, a mass of 
mesenchyme (the spina vestibuli) grows into the heart.
129
The merging and fusion of the mesenchymal cap on the primary atrial septum with 
the mesenchymal tissues of the spina vestibuli and the fusion with the superior and 
inferior atrioventricular cushions closes the primary atrial foramen. This process of 
fusion divides the common atrial junction into its left and right components. After 
fusion, the primary septum is adherent to the crest of the ventricular septum and the 
tissue then muscularises (Lamers and Moorman 2002; Anderson et al. 2003; Wessels 
and Sedmera 2003).
Any defect in atrial septation could be as a result of a defect in any of the stages 
detailed above. In order to firstly determine whether or not the myKst mice suffer 
septation defects many more homozygous embryos will need to be studied at a range 
of stages. As the phenotype for these mice is highly variable it is conceivable that 
more severe defects will not be identified immediately, as they could (especially in 
the case of possible heart defects) be the cause of neonatal death. This could possibly 
explain why no heart defects were seen in the embryos sent for MRI analysis. This 
could be overcome by dissecting the hearts from embryos of multiple stages, and 
send them for MRI analysis or even OPT scanning. Careful sectioning in the correct 
plane could also help to identify any anomalies that could cause septal defects. On 
detecting the specific malformations present in this strain, known molecular markers 
for various cardiac cell types could be used to find which other molecules Frem2 
interacts with and how their expression is affected in the mutants.
These methods could help to identify the function of Frem2 in the heart, and why 
expression occurs after E14.5. This is of particular interest as 10% of Fraser 
syndrome patients have been reported to suffer from cardiac malformations, which is 
included as a minor criterion for diagnostic purposes. In particular a patient with a 
FRAS1 mutation had an atrial septal defect (M. van Haelst, personal 
communication).
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4.33.3 Frem2 auditory expression and phenotype
Otoacoustic measurements are based on the response of the ear to sound. Acoustic 
stimuli create hydromechanical waves that travel along the cochlear spiral and are 
partially re-emitted back through the middle ear into the ear canal, where they 
reappear as sound and can be recorded with sensitive, low-noise microphones. The 
re-emitted sounds carry information back to the ear canal about the mechanisms that 
generate and shape them. There are two mechanisms for producing OAEs, non-linear 
distortion arises from the cochlear amplifer causing wave-related mechanical 
interaction on the basilar membrane. The reflection mechanism involves reflection of 
energy from inhomogeneities distributed randomly, but fixed in position, along the 
cochlear partition. Distortion product otoacoustic emissions (DPOAEs) are generated 
by a two-tone complex that results in the production of distortion products arising 
from specific regions of the cochlea and involves both mechanisms (Shera 2004; 
Zehnder et al. 2006).
The otoacoustic emissions (OAE) were carried out using equipment originally 
designed for humans. This was modified by forming a probe to fit snugly into the 
murine ear, however, the frequencies that were tested were at the lower end of the 
audible range for mice. It is possible that rather than being completely deaf, as was 
suggested by the initial OAE tests which were negative, the Frem.2 mutants may be 
unable to detect sounds of the wavelength tested. Different parts of the cochlea detect 
different wavelengths, and as Figure 4.30 shows, the structural abnormality appears 
at the apex of the cochlea, where hair cells are more sensitive to lower frequencies. 
Therefore, as well as testing more mice with equipment designed to be used for mice, 
higher frequencies need to be tested to determine whether at the structurally normal 
regions of the cochlea are able to detect sound. Other methods for assaying auditory 
function include distortion product otoacoustic emissions (DPOAE) and auditory 
brainstem responses. The auditory brainstem response (ABR) is an evoked potential 
response of auditory activity in the auditory nerve and nuclei within the auditory 
brainstem pathways. The threshold, amplitude, and latency analysis of the ABR 
provides information on the peripheral hearing status and the integrity of brainstem 
pathways.
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There are four regions in the ear which could be responsible for auditory defects, the 
ear canal, ossicles, cochlea and auditory nerve. Stenosis or atresia of the ear canal 
can cause deafness. Many cases of Fraser syndrome suffering from deafness do so 
due to anomalies of the external ear, therefore the pinna and ear canals of 
homozygous mice was studied. No external defects were detected and dissection of 
the ear canal failed to show any stenosis. Dissection and staining of the ossicles by 
Ian Smyth showed that the mutant ossicles were normal (Figure 4.37), therefore 
either the cochlea is the region responsible, consistent with Frem2 expression, or 
there could be a neural defect which needs to be investigated by carrying out ABR 
tests.
Figure 0.2: Alician blue and alizarin red bone staining of the osssicles in the middle 
ear of wt (a) and myKst/myKst (b) adults. The morphology of the bones seems to be 
normal in both.
The main sites of Frem2 expression in the cochlea are the Reissner’s membrane and 
the Interdental and Claudius cells of the Organ of Corti. The interdental cells are 
located at the base of the tectorial membrane and secrete the tectorial membrane 
matrix. The tectorial membrane is an extracellular gel-like matrix delicately 
positioned above the hair cells, providing a mass against which the stereocilia can 
bend. The tectorial membrane is composed of collagens (Type V-like collagen, Type 
II and Type IX collagen) and other molecules such as glucose, Af-acetylglucosamine, 
//-acetylgalactosamine, galactose, mannose and //-acetylneuraminic which appear as 
fibres and matrix.
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The supporting cells of the organ of Corti are highly differentiated epithelial cells 
with distinctive morphological features. The Claudius cells are supporting cells and 
play an important role in maintaining ionic homeostasis in the cochlea (Goodyear 
and Richardson 2002; Raphael and Altschuler 2003). The Reissner’s membrane 
separates the perilymph of scala vestibuli from the endolymph of the scala media. It 
is an avascular membrane consisting of two cell layers. The cells that line the scala 
media are simple epithelial cells of the membranous labyrinth which rest on a thin 
basement membrane. The scala vestibuli side of Reissner’s membrane consists of 
mesenchymally derived fibroblasts which can be discontinous (Raphael and 
Altschuler 2003). The cells of the membrane and the junctional complexes between 
them form an ionic barrier to the flow of the K+ ions out of the perilymph, 
maintaining the high concentration of K+ in the endolymph as well as regulating the 
ionic balance and volume of fluids by selectively pumping ions. The Reissner’s 
membrane contains three types of ion channels in the apical membrane of its 
epithelial cells: a stretch-activated nonselective cation, a chloride and a K+ channel 
(Raphael and Altschuler 2003).
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Figure 4.38: Diagram to show the different cell types and extracellular matrix 
components around the Organ of Corti. Frem2 is expressed in the interdental cells 
and Claudius cells. (Raphael and Altschuler 2003).
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In order to establish the function of Frem2 in the inner ear and how deficiencies in 
Frem2 can cause deafness, the localisation of known inner ear markers in Frem2 
mutants should be determined. The effect, if any on these markers could indicate the 
mechanism involved in the auditory dysfunction of the myKst homozygotes. Common 
markers used include Pax2, Eyal, Otx2 and Sixl.
Pax2 is expressed in the medial wall of the otic vesicle; the endolymphatic duct and 
sac and the cochlea. It has an important role in the development of the cochlear duct 
and the acoustic ganglion. Eyal has a possible role in the determination of anterior- 
posterior patterning of the inner ear and sensory cell differentiation, and is expressed 
in the ventral medial otic vesicle; Vllth ganglion; vestibular and cochlear sensory 
regions and the periotic mesenchyme. Otx2 is expressed in the ventral tip of the otic 
vesicle; the lateral wall of the saccule and the cochlea and has an important role in 
otic specification. Sixl is involved in the early growth and patterning of the otic 
vesicle and is expressed in the ventral region of the otic vesicle and the sensory 
epithelia (Cantos et al. 2000; Burton et al. 2004; Ozaki et al. 2004).
4.3.3.4 Exencephaly
Neural tube defects (NTD) are severe congenital malformations resulting from the 
failure of neuralation. This process is responsible for the formation of the neural 
tube, the embryonic precursor of the brain and spinal cord. To create the neural tube, 
the neural folds change from lying horizontally to vertically and shift from being 
convex to concave, so that their tips point towards the midline, touch and fuse. The 
murine neural tube consists of several cranio-caudal zones with four initiation sites, 
from which closure (which occurs in a zipper-like fashion) occurs in the directions 
shown in Figure 4.39, until they reach the edge of the next zone. Failure of neural 
tube closure occurs when the neural folds fail to elevate and become concave. 
Mutations affecting zone B of closure (initiation site 2) result in exencephaly, which 
is a lethal condition due to in utero degeneration of the exposed brain tissue (Juriloff 
and Harris 2000; Gos and Szpecht-Potocka 2002).
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Figure 4.39: a) The zonal pattern of neural fold elevation and the corresponding 
categories of NTD in the mouse. Elevation zones, A-D; Sites of initiation of neural 
fold contact and closure 1-4. The direction of closure is indicated for each initiation 
site, b) A diagrammatic cross section of cranial neural fold elevation showing the 
sequential change in neural fold morphology during the elevation process.
Many different genes can cause exencephaly in mice, including transcription factors, 
gap junction and signal transduction molecules. In particular, laminin a5 mutants 
have exencephaly due to a weakness of the basal lamina caused by laminin a5 
decreasing the amount of lateral force the ectoderm can generate on the neural folds, 
thereby leading to sporadic failure of cranial neural tube closure (Miner et a l 1998).
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Figure 4.40: Exencephaly in E13.5 wt (a) and Lama5 -/- embryos (b). Exencephalics 
lack the skin and skull that normally enclose the brain causing the brain to be 
exposed and failing to develop normally. The skin and skull of the control was 
dissected away to allow direct comparison of mutant and normal brains (Miner et al. 
1998).
Exencephaly in the Frem2 mutants could be the result of a blister forming over the 
neural fold region, thereby preventing the elevation process from occurring. Blisters 
often occur over elevation zones B and C (Figure 4.18b, e) and would prevent the 
two neural folds from making contact and therefore preventing fusion. However, 
neural tube closure occurs earlier (-E8.5) than blister formation. Therefore it is 
possible that a mechanism similar to that in the laminin a5 mutants is responsible for 
the exencephaly. Embryos between E8.5 and E9.5 should be stained and sectioned to 
determine whether Frem2 is expressed in the neural ectoderm at the during neural 
tube closure. To date, only two embryos have been found with exencephaly, and as 
occasionally neurulation failure can occur sporadically in normal mouse populations 
it is not clear whether or not Frem2 has a role in exencephaly. More embryos need to 
be harvested to find out if this is the case.
4.4 SUMMARY
The fi-geo cassette in the myKst genetrap strain enables X-gal staining to be carried 
out to analyse Frem2 expression. Frem2 expression is temporally and spatially 
dynamic, and is expressed in many different tissues including those bearing a 
phenotype such as the eye, ear, heart and kidney as well as in the lung, gut and neural 
tissue. The expression pattern has been used to help discover the role of Frem2 in 
these tissues and has led to the discovery of the my mice having auditory defects 
caused by a structural defect in the cochlea and suffering exencephaly.
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CHAPTER 5. MUTATION SCREENING EYE BLEBS! GRIP1
AND COMPARISON OF GRIP1 
WITH OTHER FRAS/ FREM PROTEINS
5.1 INTRODUCTION
Whilst work was being carried out on Frem2, it came to our attention that a group 
had a mouse with a phenotype very similar to that of the blebbed mutants. This 
mouse was deficient of the protein Gripl. The gene encoding Gripl had not been 
annotated on the Ensembl database, but had been located on mouse chromosome 10 
near the location of the eb locus. Therefore the eb mutant was screened for mutations 
in Gripl.
5.1.1 The Gripl protein
The Glutamate Receptor-Interacting Protein 1 (Gripl) is well characterised. It is 
expressed in the brain and testes but not the heart, liver, skeletal muscle or intestine 
(Dong et al. 1999). The structure of the protein is very different to that of the other 
Fras-Frem proteins. It is completely intracellular and composed exclusively of 
Postsynaptic density-95/ Discs large/ Zona occludens-1 (PDZ) domains, so named 
after the first three proteins found to contain these domains. PDZ domains are protein 
interaction domains with a modular structure of 80-100 amino acids. They typically 
bind peptide motifs located at the C-terminus of transmembrane receptors, adhesion 
molecules and ion channels (Bladt et al. 2002). This enables PDZ domain proteins to 
assemble large protein complexes in specific microdomains of the cell membrane 
(Zhang and Wang 2003) by binding to specific motifs in the last several amino acids 
at the C-terminus of transmembrane proteins (Songyang et al. 1997).
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PDZ Domain
Figure 5.1: The Gripl protein. Gripl is 1127 amino acids in length and contains 7 
PDZ domains, enabling it to interact with other proteins and also form 
hetero/homodimers.
Gripl contains seven PDZ domains (Figure 5.1), though there are three splice 
variants, Gripla-c. GRIP la and GRIP lb have all seven PDZ domains but differ in 
their N-terminal sequence, which in turn effects the number and position of cysteine 
residues and subsequent palmitoylation (Yamazaki et al. 2001). Griplc contains 
PDZ domains 4-7 only and has an additional 35 amino acids at its N-terminus and 12 
amino acids at its C-terminus, which differ from Gripla/b (Charych et al. 2004).
Glutaminergic neurons provide the primary excitory input within the central nervous 
system and are involved in neuronal development, excitotoxicity and synaptic 
plasticity (Gamer et al. 2000). There are three classes of glutamate receptors located 
at glutaminergic synapses; N-methyl-D-aspartate receptors (NMDAs), a-amino-3- 
hydroxy-5-methyl-4-isoxazolepropionic acid-type receptors (AMPARs) and kainite 
receptors (KARs). AMPARs are composed of four homologous subunits (GluRl-4) 
and Gripl interacts through PDZ4 and PDZ5 with the C-terminus of the GluR2 and 
GluR3 subunits. Gripl also interacts with the GluR52b, GluR52c and GluR6 subunits 
of KARs and is important in maintaining the function of synaptic KARs as well as 
differentially regulating AMPARs (Hirbec et al. 2003).
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Gripl interacts with several other proteins, including proteoglycan NG2, receptor 
tyrosine kinase EphB2 and kinesin. NG2 is a single pass transmembrane protein, 
which may function as a signal transducing molecule. Gripl has been shown to act as 
a direct molecular link between AMPARs and NG2 in immature glial cells 
(Stegmuller et al. 2003). It is thought that this binding could result in the 
reorganisation of the actin cytoskeleton causing changes in cell motility and 
morphogenesis (Barritt et al. 2000). Gripl can also directly interact with and steer 
kinesin heavy chains to dendrites as a motor for AMPARs, enabling kinesin to 
transport dendritic proteins such as GluR2 and EphB2 (Setou et al. 2002; 
Hoogenraad et al. 2005).
Other proteins known to interact with proteoglycan NG2 include the multiple PDZ 
domain protein MUPP1 which binds NG2 via PDZ domain 1. NG2 is associated with 
the actin- containing retraction fibres on the trailing edge of migrating cells and may 
be involved in the activation of cytoplasmic signalling cascades associated with 
cytoskeletal reorganisation. Binding to MUPP1 may provide a means for linking 
NG2 to other molecules with a cytoskeletal localisation (Barritt et al. 2000).
Hoogenraad et al. used siRNA to knockout Gripl in cultured hippocampal neurons. 
Gripl knockout caused a loss of dendrites associated with a loss of GluR2, EphB2 
and kinesin. They showed that Gripl is required for the formation and growth of 
dendrites in developing neurons and for the maintenance of dendrites in mature 
neurons. This indicates an important role for Gripl in dendrite morphogenesis as an 
adaptor protein in the kinesin-dependent transport of EphB2 receptors to dendrites.
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5.1.2 The Gripl mouse
G riplA embryos have multiple fluid-filled blisters formed on the head, forelimbs, 
hindlimbs and spinal chord (Figure 5.2) which first become visible at E l2 and later 
become haemorrhagic, resulting in death in utero around E14.5. These blisters occur 
on the dermal (Takamiya et al. 2004) side of the basement membrane, and resemble 
the dystrophic from of epidermolysis bullosa (Figure 5.3). As well as 
cryptophthalmos, syndactyly and polydactyly, G ripl7 mice also exhibit renal 
agenesis. In the absence of Gripl, mesenchymal condensations fail to assemble 
around the ureteric bud. At E l3.5 metanephric tubules are missing and there is a 
large number of apoptotic cells (Takamiya et al. 2004).
Figure 5.2: Serous blisters over the eye, head and upper limb in an Gripl'/' E l2.5 
embryo (Takamiya et al. 2004).
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Figure 5.3: Hematoxylin-eosin-stained sections of the lower limbs of wt (<a and b) 
and G riplA (c and d) E l2 embryos. At higher magnification (b and d), the epidermis 
appears to be detached from the underlying dermis in blistered (arrowhead) and 
nonblistered areas (arrow). (Bladt et al. 2002).
Gripl is expressed in the developing nervous system, olfactory tract and epithelium, 
eye, cochlea, motor neurons and parasympathetic ganglia, skeletal muscle and at the 
dermo-epidermal junction. Gripl has also been shown to co-localise with cadherin 
(Figure 5.4), indicating that Gripl is a component of the basal cell layer of the 
developing epidermis (Takamiya et al. 2004).
pi
-?4
Figure 5.4: Skin sections from wt E12 embryos to showing immunostaining with 
antibodies specific for Gripl (a) and cadherin (b) Expression of Gripl co-localises 
with cadherin (c) in the basement membrane zone (bmz). (Bladt et al. 2002).
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5.1.3 Collagen expression in Gripl and Fras-Frem mutants
In Gripl'7' embryos, (34-integrin, type IV collagen and laminin segregate on the roof 
of the blister, indicating that tissue separation occurs below the lamina densa. This is 
very similar to the position of blister formation in the blebbed mutants. There is also 
reduced expression of collagen V, collagen VI, and collagen VII in the skin 
basement membrane zone at early stages of development, which are restored by 
E l7.5 (Takamiya et al. 2004). Frasl '' mice show loss of collagen VI in the skin 
BMZ, but other collagens are not disturbed (Vrontou et a l 2003). Therefore, 
collagen expression in Frem2 mice was studied to compare the expression of various 
collagens between the G ripl7 mice and mutants of the other Fras-Frem genes.
5.1.4 The eb mouse
The eb mouse presents with clear blisters on the hypodermis of the eyes and digits at 
E12-13, which later become haemorrhagic and resolve soon after birth. At El 1.5, eb 
mice have increased vascularisation throughout the cranial region, including over the 
developing eye. The eye cup forms normally, however, the lens vesicle does not 
always separate completely from the head ectoderm. If there are no eye defects, 
neural tube defects occur, involving an irregular shape of neural tube, which is not 
properly aligned for neural tube closure. However, these neural tube defects could be 
due to inbreeding of the stock ATEB/Le mice (Swiergiel et al. 2000).
Figure 5.5: An adult eb/eb mouse. The mouse is lacking whiskers and has a fluid- 
filled sac covering the left eye (Swiergiel et al. 2000).
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Mutant mice are born with lenses incompletely detached from the surface ectoderm 
and a folded iris of irregular shape. Eye development is severely disrupted due to the 
presence of the large haemorrhagic blisters over the eyes. The kidneys of eb mice are 
polycystic/ absent (Swiergiel et al. 2000).
Due to the similarity of the phenotype of the eb mice and the G riplA mice and the 
fact that they both map to a similar region on chromosome 10, eb DNA was screened 
to determine whether Gripl is mutated in eb mice.
5.2 RESULTS
DNA from the eb mouse was screened for mutations in the gene Gripl as mutants 
deficient in Gripl have a very similar phenotype to the blebbed mutants, and both eb 
and Gripl map to the same region on chromosome 10. DNA from eb mutants from 
the Jackson laboratories was screened for mutations in the Gripl gene using intronic 
primers. Further primers were designed around the region suspected of harbouring a 
deletion.
Immunohistochemistry was carried out on cryosections from wt, myKst and myUcl 
embryos to determine whether there was a change in the expression of collagen IV 
and collagen VI. Full details of the methods used are in Chapter 8.
5.2.1 Gene structure determination/ mutation screening
The Gripl protein was fairly well characterised. From the NCBI database the intron/ 
exon structure of the gene encoding Gripl was obtained (refGene_NM_028736). 
Intronic primers were once again designed to amplify the 23 coding exons. Genomic 
eb DNA was obtained from the ATEB/Le strain, provided by the Jackson 
Laboratories. The eb mutation arose spontaneously on an outbred strain.
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PCR amplification was carried out on each exon and the products used for direct 
sequencing. No mutations were detected in the exons that were amplified, however, 
exons 10 and 11 repeatedly failed to amplify from the eb DNA but amplification was 
successful from C57BL/6 DNA and six other mouse strains (Figure 5.6).
bp
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Figure 5.6: 1% agarose gel showing the results of PCR amplification using the 
primers EBlOf and EB] Ir to amplify across Gripl exons 10 and 11 of eb DNA. The 
background o f  the eb strain used was unknown, therefore five other strains were also 
used and all successfully amplified across this region, resulting in a product of 
1839bp. These exons (10 and 11) are deleted in eb mice and fail to amplify. The 
deleted region is better defined in Figure 5.7
Previously, the polymorphic marker D1 Omit 187 had been used to genotype eb mice, 
with failure o f  the marker to amplify indicating homozygous eb mice. (Swiergiel et 
al. 2000). This marker is located downstream of exon 11, suggesting that the failure 
of the exons to amplify was due to a deletion. Further primers were designed 
betw een exons 9 and 12 to further characterise the deletion (Figure 5.7). The deleted 
segment is between 4.885kb and 5.384kb. The deletion of exons 10 and 11 would 
result in a frameshift and cause premature termination of the conceptual translation 
of the mutant Gripl protein.
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Figure 5.7: PCR identified a deletion in Gripl in eb genomic DNA. The diagram is 
of the genomic region containing Gripl exons 9-11 and is not to scale. The 
downward-pointing arrows labeled a-k indicate the locations of the corresponding 
PCR amplimers shown in the agarose gel (see Table 8.6). The upward-pointing 
arrow indicates the position of D10Mitl87, which was previously reported as failing 
to amplify in eb DNA {ATEB inbred strain). The approximate position of the deletion 
is shown. The bottom panels show the amplimers obtained from control and eb DNA 
after 2% agarose gel electrophoresis. M, 100-bp ladder.
In an attempt to establish the exact size of the deletion long range PCR was carried 
out using the Roche Expand Long Range kit. Primers were selected that successfully 
amplified the eb DNA and flanked the deletion. Failure of the long range PCR to 
work suggested that the deletion was not due to a simple deletion and might involve 
a concomitant insertion event e.g. a transposition.
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5.2.2 Collagen expression in Fras- Frem protein mutants
As expression of collagens V, VI and VII are altered in Grip l v mice and there is a 
loss of collagen VI expression in Fraslv' mice, the expression of collagens in Frem2 
mutants was studied to determine whether there is a reduction in the level of 
collagens IV and VI. Cryosections were cut of wt, myKst and myUcl E l4.5 embryos, 
which were stained with anti-collagen TV and anti-collagen VI antibodies. There was 
no detectable change in the level of expression of these proteins in the skin basement 
membrane zone of mutants (Figure 5.8).
Collagen IV Collagen VI
Figure 5.8: Cryosections of the skin BMZ of E14.5 embryos showing staining with 
collagen IV and VI antibody (red) in myKst and myUcl homozygotes and wt embryos. 
Counterstaining is with Hoechst stain. There is no difference in the levels of 
expression of collagens IV and VI between mutant and wt embryos.
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5.3 DISCUSSION
Screening DNA from the eb mouse for the Gripl gene revealed a deletion spanning 
two coding exons, causing a frameshift resulting in a truncated protein missing the 
final four PDZ domains.
5.3.1 The eb deletion
PCR analysis shows that a total of eight amplifications failed in the region between 
exons 9 and 12, as well as the polymorphic marker D1 Omit 187, which was used to 
genotype eb mice in a paper studying the eb phenotype (Swiergiel et al. 2000).
A conceptual translation shows the deletion results in a frameshift, a premature stop 
codon is introduced after 6 novel residues. If the message is not degraded by 
nonsense-mediated decay, the protein produced would be only 353 amino acids in 
length and missing the last 4 PDZ domains (Figure 5.9). This would result in the 
truncated protein not being able to interact with GluR2, which requires PDZ domains 
4 and 5.
WT TRUNCATED
PROTEIN PROTEIN
B PDZ NovelDomain Residues
Figure 5.9: Conceptual translation of the mutated eb gene results in a truncated 
protein of 353 amino acids, and missing the final four PDZ domains. The wt Gripl 
protein is 1127 amino acids in length.
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The exact length of the deletion could not be determined as long range PCR failed. 
This suggested that a simple deletion was not responsible and perhaps an insertion/ 
deletion (indel) event could have occurred. There are many examples of disease 
causing indels, including one such mutation occurring in the COL7A1 gene, 
8069dell7insGA. The 17-nucleotide deletion and GA insertion resulted in a 15- 
nucleotide deletion within the collagenous domain of the COL7A1 protein. Although 
not affecting the ORF, this mutation interfered with the collagen triple helix and 
causes a dystrophic epidermolysis bullosa phenotype (Sawamura et al. 2005). More 
large- scale indels, of the size of the deletion identified in the eb mice, have also been 
reported. An indel of 1464 bp was identified in intron 18 of the human thyroglobulin 
gene (Moya et al. 2003). To determine whether an indel was responsible for the eb 
mutation, Southern hybridisation could be carried out to establish the size of the 
fragment in the affected area. This would confirm the size of the deletion and/ or 
identify the presence of an insertion.
5.3.2 Collagen expression in Fras-Frem protein mutants
Collagen VI deposition in the skin bmz is defective in Frasl'' mutants. This is 
probably due to the lack of interaction with the NG2-like domain of Frasl. 
Proteoglycan NG2 binds collagens V and VI through its central nonglobular domain 
(Tillet et al. 1997) and anchors them to the cell surface (Nishiyama and Stallcup 
1993).
C0 I6A I ''' mice show abnormal expression of proteoglycan NG2 in myofibres (Petrini 
et al. 2005), therefore a lack of the NG2-like domain of Frasl could result in the 
mislocalisation of collagen VI. As Frasl itself is mislocalised in Gripl'1', this could 
explain why collagens V and VI are in turn mislocalised. Collagen VI deficiency in 
humans causes Bethlem myopathy an autosomal dominant condition resulting in 
progressive muscle weakness, and Ullrich scleroatomic muscular dystrophy 
(UCMD) a recessive condition presenting with distal hyperlaxity and contracture of 
proximal joints (Petrini et al. 2005).
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Expression of collagens IV and VI is unaffected in Frem2 mutants (in both myKst and 
myUcl homozygotes) and collagens V and VI are expressed normally in Freml 
mutants (Smyth et al. 2004). As collagen VI deposition was disrupted in Frasl null 
mutants and the Freml and Frem2 mutants tested are not null mutants, perhaps the 
complete lack of protein is required for loss of collagen localisation. Both Freml and 
Frem2 contain the NG2-like domains that could interact with collagens, therefore 
why collagen binding in the mutants of these genes is unaffected is unclear. Perhaps 
the N-terminal domains of Frasl which Freml and Frem2 lack are required to 
stabilise the interactions with collagens. One of these domains, the von Willebrand 
factor type C domain (VWFC) is known to bind collagens, including collagens IV, 
V, and VI, and integrins, which help molecules to interact with the extracellular 
matrix and can themselves interact with collagen molecules (Sadler 1998; Stupack 
and Cheresh 2002). Although these domains suggest that there could be a direct 
interaction between Frasl and collagen VI, whether or not this is the case is 
uncertain and further work needs to be carried out to determine the exact nature of 
the interaction.
In order to confirm that it is indeed the NG2-like domain of Frasl, which is 
responsible for collagen binding, protein interaction assays could be carried out. A 
full-length clone of Frasl is available which could be used in GST pull-down 
experiments to see if Frasl ‘pulls down’, i.e. interacts with collagen VI. Frasl 
constructs lacking the NG2-like domain could also be used to determine whether 
deleting the domain would abolish the interaction, or if the NG2-like domain alone is 
sufficient for the interaction or whether the VWFC is required.
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5.4 SUMMARY
The Gripl gene encodes a 1127 amino acid protein consisting of 7 PDZ domains 
and maps to the same region as eb. Gripl '' mice have a similar phenotype to other 
blebbed mutants. Mutation screening of the eb strain for mutations in Gripl revealed 
a deletion spanning the two coding exons 10 and 11. If the resulting transcript is not 
degraded by nonsense mediated decay, the protein produced would be 353 amino 
acids, instead of the wt 1127 amino acids and would lack the final four PDZ 
domains. Immunohistochemistry was carried out to determine the effect that the my 
and heb mutations have on the localisation of collagen IV, V and VI in the BMZ. 
Only Frasl nulls seemed to have an effect, resulting in the loss of collagen VI 
deposition. Collagen IV and VI deposition in Frem2 mutants (myUcl and myKst) and 
collagen V and VI deposition in Freml mutants is unperturbed.
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CHAPTER 6. FRAS1 INTERACTION WITH BMPS
6.1 INTRODUCTION
6.1.1 F rasl domains
The Frasl protein is the most structurally complex of the Fras-Frem proteins. As well 
as NG2-like, calx-(3 and transmembrane domains, Frasl has additional N-terminal 
domains: six von Willebrand factor type C (VWFC) and 14 cysteine rich partial furin 
motifs, as subsets of chordin-like domains. In other proteins these motifs are known 
to interact with other extracellular matrix molecules and growth factors, suggesting 
that Frasl may have a role in cell signalling.
TM
VWFC Furin NG2-like Calx-p
Signal
peptide
Chordin-like
Figure 6.1: Schematic of the domain structure of the Frasl protein. Unlike Frem2, 
Frasl has extra N-terminal domains which may enable it to interact with other 
extracellular matrix molecules and be involved in cell signalling. VWFC, von 
Willebrand factor type C domain; TM, transmembrane.
The von Willebrand factor (VWF) is a multimeric glycoprotein that acts as a carrier 
protein of factor VIII, an essential cofactor of coagulation in plasma, and promotes 
platelet adhesion to the damaged vessel following injury. Proteins that incorporate 
VWF domains participate in numerous biological events (e.g. cell adhesion, 
migration, and signal transduction) involving interactions with a large array of 
ligands.
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The von Willebrand factor type c domain (VWFC) is found in multidomain protein/ 
multifunctional proteins and is thought to participate in oligomerisation. The VWFC 
domains are also referred to as chordin-like cysteine rich (CR) repeats due to the 
amino acid conservation of ten cysteine residues. Other proteins besides chordin 
containing these repeats include connective tissue growth factor, thrombospondins, 
and procollagen type IIA. The VWFC domains have been shown to bind members of 
the transforming growth factor-P (TGF-P) superfamily and are proposed to regulate 
growth factor signaling (O'Leary et al. 2004), therefore it is likely that the CR 
domains of Frasl bind TGF-P family members such as BMPs.
NG2-like domains, as mentioned previously, bind collagens V & VI which are an 
integral part of the cell matrix. The binding of these molecules and other 
extracellular matrix molecules can be communicated to the cytoskeleton, affecting 
cell motility and morphology. The chordin-like and furin-like domains may be 
involved in BMP signalling. The furin-like domains lack a proteolytic site, 
suggesting that these domains have no enzymatic function but may be involved in 
sequestering or presenting BMPs.
6.1.2 Bone Morphogenetic Proteins (BMPs)
The transforming growth factor-P (TGF-P) superfamily contains a variety of growth 
factors which all share common sequence elements and structural motifs. The 
proteins in this family exert a wide spectrum of biological responses on a large 
variety of cell types. During embryonic development, many of them have important 
functions in axial pattern formation and tissue specification. In adult tissues, they are 
involved in processes such as wound healing, bone repair, and bone remodelling 
(Dudley et al. 1995; Hsu et al. 1998).
BMPs are a group of over thirty secreted growth factors that share amino acid 
homology of a highly conserved seven-cysteine domain in the carboxy-terminal 
region of the proteins. BMPs are synthesised as precursor molecules and are cleaved 
to release a C-terminal monomer (100-400aa) which forms dimers linked by a single
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interchain disulphide bond. The dimers are released to the extracellular matrix to 
interact with their receptors. The TGF-p family members act by binding 
extracellularly to a complex of serine/ threonine kinase receptors, which 
consequently phosphorylate Smad molecules, resulting in their activation. The 
phosphorylated Smads (P-Smads) translocate to the nucleus, where they modulate 
transcription of specific genes (Botchkarev 2003).
R«c«ptor OUittrtzAtion
Figure 6.2: The canonical BMP signalling pathway. Binding of BMP2, -4 or -7 to 
the BMP serine/ threonine kinase receptor complex activates recruitment and 
phosphorylation of Smadl. P-Smadl dimerises with Smad4 and is translocated to the 
nucleus to regulate gene expression (Botchkarev 2003).
BMPs were originally isolated by their ability to induce ectopic bone and cartilage 
formation in vivo, but it became evident that BMPs also act as multifunctional 
regulators in morphogenesis during development in vertebrates and invertebrates 
with biological activities on various cell types, including monocytes, epithelial cells, 
mesenchymal cells, and neuronal cells (Botchkarev 2003; Canalis et al. 2003).
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BMPs regulate cell proliferation and differentiation, chemotaxis and apoptosis, and 
control fundamental roles such as left-right asymmetry, neurogenesis, mesoderm 
patterning, and the development of a number of organs, such as kidney, gut, lung, 
teeth, limb, amnion, and testis. BMP signals also pattern the ectoderm during 
gastrulation, inducing the epidermis from ectoderm that would otherwise assume a 
neural state (Pizette et al. 2001; Botchkarev 2003; Canalis et al. 2003; Little and 
Mullins 2004).
The differences between the role of different BMPs is highlighted by the varying 
phenotypes of BMP knockout mice. Bmp2-deficient mice die during embryonic 
development and have amnion/ chorion malformations and defects in cardiac 
development. A null mutation of the Bmp4 gene in mice results in defects in the 
extraembryonic and posterior/ventral mesoderm, ear and eye formation and are also 
embryonic lethal. Bmp7 knockout mice are born alive but tend to die within the first 
24 hours after birth. Bmp7'~ mice also have polydactyly of the inner digit of the 
hindlimbs. The mice have skeletal defects, with a smaller overall size compared with 
their normal littermates, and suffered from defects in eye and nephron development 
(Balemans and Van Hul 2002).
6.1.3 Chordin
Another cysteine-rich mediator of BMP activity is Chordin, a 941 amino acid protein 
with a signal sequence and four cysteine-rich domains (CR) domains of about 70 aa 
each enabling the binding of BMP molecules (Sasai et al. 1994). CR1 and 3 have the 
strongest affinity for BMPs, but not as strong as the protein as a whole, as the two 
high affinity sites enable the high affinity binding of the BMP dimer and having 
other adjacent binding sites increases the local concentration of BMP binding sites 
(Larrain et al. 2000).
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Chordin expression in the mouse is seen in most major organs, like brain, lung, liver, 
and kidney, suggesting multiple functions in organogenesis. Expression of chordin 
begins in the Spemann organiser. During gastrulation, the Spemann organiser 
provides patterning information to the adjacent mesoderm and overlying ectoderm by 
mediating secreted factors including chordin, noggin and follistatin. At gastrulation, 
an important mechanism for establishing the appropriate domains of growth factor 
activity involves the selective inactivation of signalling pathways by secreted 
antagonists that block specific ligand/ receptor interactions. Noggin and chordin 
block such signalling by binding BMPs with high affinity, preventing them from 
binding their receptors. In this way, chordin is involved in the regulation of dorso- 
ventral patterning during gastrulation. Chordin binds to ventralising BMPs 
(particularly BMP4) in the extracellular space preventing their interaction with their 
receptors. Chordin binding is specific to BMPs and not to activin or TGF-P 1. 
Chordin protein is therefore able to dorsalise mesoderm and to neuralise ectoderm in 
Xenopus gastrula explants (Sasai et al. 1994; Sasai et al. 1995; Sasal et al. 1995;
Piccolo et al. 1996; Hsu et al. 1998; Larrain et al. 2000; Matsui et al. 2000;
Nakayama et al. 2001; Pizette et al. 2001; Garcia Abreu et al. 2002; Botchkarev
2003; Canalis et al. 2003; Little and Mullins 2004).
As Frasl contains CR domains, it was hypothesized that Frasl could be involved in 
presenting BMPs. As the Frasl protein is so large, the ability of these CR domains to 
bind BMPs was tested by expressing the Frasl CR domains in cells and assaying the 
effect on P-Smadl levels. If the CR domains of Frasl antagonise BMP activity, less 
BMPs would be available to bind to their serine/ threonine kinase receptors and 
phosphorylate Smad molecules, therefore the level of P-Smadl would decrease.
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6.2 RESULTS
The Frasl CR domains were amplified by PCR using linkered primers (Table 8.9)
Constructs cloned into the pCMVmyc vector contain the Frasl CR domains with a 
myc tag. The pDisplay vector was used as it enables expression with a signal 
sequence and transmembrane domain, therefore allowing expression of the construct 
in a similar fashion to full-length Frasl. Two constructs were created, one secreted 
protein and one membrane-bound protein. These were transfected into the murine 
fibroblast cell line NIH 3T3 and following growth for 48 hours, assayed for P-Smadl 
activity by immunohistochemistry.
Figure 6.3: Two of the constructs used to determine whether the CR domains of 
Frasl interact with BMPs. The CR domains were cloned into the pDisplay vector 
using the restriction enzymes Bgl II and Sal I. Two constructs were created, one with 
both the signal peptide and PDGFR transmembrane domains (s-FraslCR-TM) and 
one with only the signal peptide (s-FraslCR). Both constructs have HA and myc 
tags.
and cloned into either the pCMVmyc or the pDisplay™ (Invitrogen) vectors.
Frasl CR s-FraslCR
Frasl CR
pDisplay
5.3 kb
s-FraslCR-TM
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Initially the vector pCMVmyc was used for cloning', the resulting construct was 
called FraslCR-myc. However, although this resulted in a dramatic reduction in P- 
Smadl levels in transfected cells (Figure 6.3 and Figure 6.4), it was decided to use 
the pDisplay vector instead for further experiments as the signal peptide and 
transmembrane domain enable expression of the Frasl CR domains in a known 
location, i.e. secreted or membrane bound, which mimics the expression of in vivo 
Frasl more accurately.
The FraslCR-myc constructs show a decrease in the level of P-Smadl in transfected 
NIH 3T3 cells. P-Smadl has a nuclear location and as Figure 6.4 shows, only limited 
foci of P-Smadl expression can be seen in transfected cells. Figure 6.5 shows that 
there is a small decrease in P-Smadl due to the transfection process itself, but this is 
not sufficient to account for the overall decrease in the level of P-Smadl expression 
in transfected cells.
Untransfected  FraslCR-myc
■
Figure 6.4: Immunohistochemistry of murine NIH 3T3 cells untransfected (left) or 
transfected with FraslCR-myc (right). P-Smadl expression can be seen as a 
collection of brightly stained foci confined to the nucleus (arrows). P-Smadl staining 
is shown in green and staining of the cell nuclei was carried out with Hoechst stain 
(blue). The level of P-Smadl is noticeably reduced in cells transfected with the CR 
domains of Frasl.
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Merged Hoechst stain P-Smad I c-myc
Figure 6.5:
Immuno- 
histochemistry 
showing murine 
NIH 3T3 cells 
untransfected fa­
ct), transfected 
with empty
pCMVmyc vector (e- h) and transfected with FraslCR-myc (i- I). P-Smadl levels are shown by bright green nuclear foci (arrows) which are 
decreased in FraslCR-myc transfected cells compared to untransfected cells, though P-Smadl levels are also slightly lowered in vector-only 
transfected cells. C-myc staining (red) shows the cellular location of the myc fusion protein produced from the transfected plasmid.
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Figure 6.6: Immunohistochemistry 
to show the total Smadl levels in 
untransfected (a- c), vector only 
transfected (d- f) and FraslCR-myc 
transfected (g- i) NIH 3T3 cells. 
Total Smadl (red) is expressed 
throughout the cell, in both the 
cytoplasm (unphosphorylated) and 
the nucleus (phosphorylated). The 
total Smadl levels seem to be 
unaffected by the transfection of 
Frasl CR domains, suggesting that 
the FraslCR domains affect the P- 
Smadl levels specifically.
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Figure 6.7: Immunohistochemistry showing murine NIH 3T3 cells untransfected (a- 
d), transfected with empty pDisplay vector (e- h), transfected with s-FraslCR-TM, 
containing a signal sequence and a transmembrane domain (i- I), and transfected 
with s-FraslCR containing just the signal sequence (m- p). Vector only transfection 
(g) shows a slight decrease in P-Smadl levels, as shown by the brightly stained foci 
(arrows). Transfection of the membrane-bound s-FraslCR-TM construct (k) results 
in a large reduction in P-Smadl levels but not as large as with transfection of the s- 
FraslCR construct (o). C-Myc staining (red) showing where the myc-tagged Frasl 
fragment is expressed shows little transmembrane localisation for s-FraslCR-TM.
Figure 6.8: Immunohistochemistry to show the total Smadl levels in untransfected 
(a- c), pDisplay only transfected (d- f), s-FraslCR-TM transfected (g- i) and s- 
FraslCR transfected NIH 3T3 cells. Total Smadl (red) is expressed in the cytoplasm 
and nucleus of cells and is unaffected by the transfection of Frasl CR domains.
P-Smadl levels are lowered in both s-FraslCR-TM and s-FraslCR transfected cells 
compared to untransfected cells, though P-Smadl levels are also slightly lowered in 
vector only transfected cells. There is a small difference between the s-FraslCR-TM 
and s-FraslCR transfected cells, with the s-FraslCR-TM (containing both the signal 
peptide and transmembrane domains) having slightly less P-Smadl expression than 
the s-FraslCR transfected cells. The total Smadl antibody detects both 
unphosphorylated and phosphorylated Smadl and therefore staining can be seen in 
the cytoplasm as well as the nucleus. The total Smadl levels are unaffected by the 
transfection of Frasl CR domains.
The results show that the transfection process itself results in a small decrease in the 
P-Smadl levels with a larger decrease caused by transfection of the Frasl CR 
constructs. Of the three constructs used, the FraslCR-myc showed the largest effect 
on the P-Smadl levels, followed by the s-FraslCR containing the only the signal 
peptide, and then s-FraslCR, containing the signal peptide and transmembrane 
domains. Transfections do not effect the total Smadl levels as shown in Figure 6.6 
and Figure 6.8, therefore it is the phosphorylation of Smadl resulting from the 
binding of BMPs to their signal transducing receptors that is affected by the 
transfection of the Frasl CR constructs.
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6.3 DISCUSSION
In order to determine whether the chordin-like (CR) domains of Frasl bind BMPs, a 
pilot experiment was carried out in which the CR domains of Frasl were cloned and 
transfected into murine NIH 3T3 cells. Binding of BMPs to their signal transducing 
receptors results in the phosphorylation of Smads, therefore the expression of P- 
Smadl was investigated by immunohistochemistry.
Three Frasl CR domain constructs were created, one in the pCMVmyc vector, and 
two in the pDisplay vector. The pDisplay vector enables expression of the chosen 
insert fused to a signal peptide for extracellular expression, and a transmembrane 
domain, enabling expression of membrane proteins. As Frasl is normally expressed 
in the extracellular matrix, the pDisplay vector was thought to provide a means of 
expressing the chordin domains in a manner as close as possible to its biological 
location within the cell without expressing the entire Frasl protein. This was not 
possible as Frasl is so large (4012aa) and a full-length construct that can be 
expressed in tissue culture is not available. Therefore the secreted construct would 
mimic secreted Frasl and the construct containing the transmembrane domain would 
mimic a cell-tethered Frasl. The CR domains themselves are over 1800 bases in 
length, itself causing problems during the cloning process. Therefore, at best, the 
method of expressing a portion of the protein in vitro will only suggest the 
interactions that could take place in vivo and without the other domains present it is 
not possible to ascertain the exact nature of all of the interactions taking place.
The results show that all three FraslCR constructs showed a decrease in 
phosphorylation of Smadl expression in the transfected cells. It seems that 
transfection itself results in a small decrease in the P-Smadl expression but the 
FraslCR-myc (in pCMVmyc) has the greatest effect on P-Smadl levels. The s- 
FraslCR-TM transfected cells, containing both the signal peptide and 
transmembrane domain showing a slightly larger reduction in P-Smadl levels than 
the s-FraslCR transfected cells.
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As BMPs were not added to the media the BMPs must have been produced by the 
fibroblasts in culture and acted in a paracrine fashion. The results obtained are 
preliminary, but suggest that the Frasl CR domains do indeed bind BMPs, however 
from immunohistochemistry alone a quantitative figure of the level of the decrease 
cannot be established. For this, further experiments need to be carried out, such as 
western blotting or luciferase reporter assays.
Western blots could be carried out to detect the level of BMPs and anti-P-Smadl 
present as well as the level of Smadl by using antibodies against BMPs as well as 
Smadl. The luciferase assays could be carried out using a reporter plasmid such as 
BRE-Luc, which contains multiple Smadl binding sites, and would provide an 
indication of Smadl activity via the intensity of the colour produced. BRE-luc 
reporter activity is induced by overexpression of either Smadl or Smad5 (Monteiro 
et al. 2004).
Another method used to test interactions of proteins with BMPs is to carry out 
animal cap assays in which RNA is injected into Xenopus oocytes and the effect on 
gastrulation is observed. For example, microinjection of Chordin RNA results in axis 
duplication due to the role of chordin in axial patterning, in which dorsalisation of 
the mesoderm occurs due to the blocking of ventral signaling in the form of BMP4. It 
would be interesting to see if Frasl CR domains could exert a similar effect on 
Xenopus embryos (Holley et al. 1995; Hsu et al. 1998; Dale and Jones 1999; Larrain 
et al. 2000; De Robertis and Kuroda 2004; Little and Mullins 2004). In this regard 
the Frasl CR domains were cloned into P-UT2, a vector which enables the synthesis 
of biologically active RNA for injections. This can be used to derive capped mRNA 
for Xenopus oocyte injection, however, time constraints meant that these 
experiments could not be carried out.
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Other ECM proteins have been identified with CR domains that have also been 
shown to interact with BMPs. Criml is a transmembrane protein that causes a 
reduction in the production and processing of preprotein to mature BMP and tethers 
pre-BMP to the cell surface. Tethering of BMPs by Criml may facilitate their slow 
and prolonged release from the surface, regulate the distance over which BMPs can 
act, or may deliver BMPs to receptors on the cell surface (Wilkinson et al. 2003). 
Connective tissue growth factor (CTGF) is a secreted protein that antagonises Bmp4 
activity by interacting with Bmp4 through its CR domain, thereby preventing Bmp4 
binding to BMP receptors (Abreu et al. 2002).
Smadl detects BMP2, -4 and -7 binding to their receptors. Smadl was chosen as 
these BMPs seem to be the most closely related to the Fras-Frem proteins in terms of 
the phenotypes of their knockout mutants and their expression patterns. Bmp2 and 
Bmp4 are expressed in many tissues during development including the developing 
limb, during odontogenesis and in the developing lens. These molecules may be 
involved in promoting inductive tissue interactions and mediating mesenchymal- 
epithelial interactions. Bmp7 is expressed throughout eye and renal development and 
is also required for skeletal development. Bmp2 and Bmp4 null mutants are 
embryonic lethal, but Bmp7 null mutants survive for up to 10 days postnatally and 
die due to renal failure. As well as renal and skeletal abnormalities, Bmp7 mutants 
can exhibit polydactyly and anophthalmia, with variable penetrance (Dudley et al. 
1995; Luo et al. 1995; Jena et al. 1997; Pizette et al. 2001; Trousse et al. 2001). 
Therefore these mutants share many of the eye, limb and renal phenotypes as the 
Fras-Frem mutants, suggesting that these phenotypes in the Fras-Frem mutants may 
be attributable to disturbed BMP signalling, which in turn disrupt mesenchymal- 
epithelial interactions and organ development.
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6.4 SUMMARY
The NG2-like/ chordin-rich (CR) domains of Frasl are predicted to bind BMPs in a 
manner similar to that of the BMP antagonist chordin. The CR domains of Frasl 
were cloned into vectors enabling expression in murine NIH 3T3 cells, creating three 
constructs, all myc tagged, one with a signal peptide, one with both a signal peptide 
and a transmembrane domain and a third with just a myc tag. The signal peptide and 
transmembrane domain were used to express the CR domains in a manner similar to 
that of native Frasl. The binding of Bmp2, -4 and -7 result in the phosphorylation of 
Smadl, therefore P-Smadl levels were determined in transfected cells by 
immunohistochemistry. All three constructs show a decrease in the level of P-Smadl 
expression, suggesting that the CR domains of Frasl do have some BMP 
antagonistic properties.
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CHAPTER 7. OVERALL DISCUSSION
7.1 PROJECT SUMMARY
The five blebbed mutants provide a model for Fraser syndrome (Winter 1990; 
Darling and Gossler 1994). As Frasl is mutated in the bl mouse (McGregor et al. 
2003) and not all Fraser syndrome families showed linkage to FRAS1, it was decided 
to look for further Fraser syndrome genes and blebbed loci. Database searching 
identified a gene on human chromosome 13ql3.3 with homology to FRAS1 and with 
a murine orthologue on murine chromosome 3, near the region to which the my locus 
had been mapped. This locus was named FREM2.
Initially, three consanguineous patients with Fraser syndrome were identified as 
having a region of homology around the FREM2 locus. Mutation screening identified 
a change, c5914G-»A (E1972K) in two of the three families, both of Spanish gypsy 
ancestry but not sharing a common ancester. This change was not found in 262 
control individuals and was therefore confirmed as a disease causing mutation and 
was subsequently identified in a third family. The E1972 residue is located in the 
second of five Calx-|3 domains and is thought to play a role in the binding of 
calcium. The mutation reverses the charge of the amino acid from a negative 
glutamic acid to a positive lysine and is likely to affect calcium binding, though 
calcium binding assays have so far been inconclusive.
Mutation screening was carried out to determine whether Frem2 was the gene 
responsible for the my phenotype. No mutations were identified in the myUcl and 
myHule strains and real-time PCR analysis showed myUcl embryos have approximately 
equal levels of expression of Frem2 as wt embryos. However, a mutant with a 
genetrap insertion in Frem2 (myKst) was identified that is allelic to myUcl and has a 
blebbing phenotype. This mutant is not a complete null as there is some expression 
of Frem2 downstream of the genetrap insertion, though these mutants have a nearly 
ten-fold reduction in the level of Frem2 expression. In addition, a nonsense Frem2
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mutation, c5640C -*A (pY1880X), was identified in an ENU induced strain, myFn 
(Timmer et al. 2005) all confirming a mutation in Frem2 underlies the my 
phenotype.
As Frasl and Frem2 share many phenotypes compound Frasl I Frem2 mutants were 
created. It was found that double mutants (blbl/ mymy) are viable, with an increase in 
the severity of the phenotype as some showed a reduction in size compared to their 
wt littermates.
X-gal staining was carried out on the myKst genetrap strain as the genetrap contains a 
/3-geo cassette. Frem2 is expressed in many different tissues including those bearing 
a phenotype such as the eye, ear, heart and kidney as well as in the lung, gut, neural 
tissue and many epithelial structures. Expression analysis led to the discovery of the 
my mice having auditory defects potentially caused by a structural defect in the 
cochlea and the discovery of exencephaly. Many of the phenotypes of the my mice 
can be attributed to the disruption of epithelium-mesenchyme interactions such as 
those during limb and eye formation that result in syndactyly and cryptophthalmos 
respectively.
As well as identification of Frem2, further blebbed genes were identified during the 
course of this project.
An ENU-induced mutant was discovered called bat with a phenotype including 
cryptophthalmos, syndactyly and unilateral renal agenesis (Smyth et al. 2004). The 
bat mutant maps to the 3Mb interval on chromosome 4, to which the head blebs 
(heb) mutant maps. The gene was found to share similarity to Frasl and was 
therefore named Freml (Frasl related extracellular matrix gene). Freml has 36 
coding exons which encode a 2191 amino acid protein, similar to Frem2, but lacking 
the transmembrane domain. Mutation screening of Freml in bat mice identified a T 
to C transition at position 2 in the splice donor site of intron 25 causing the complete 
skipping of exon 25. This results in a frame shift and the introduction of a premature 
stop codon in exon 26 and the premature termination of the protein. Screening heb
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for mutations in Freml revealed a LINE1 insertion in exon 17 causing a 
rearrangement of the exon.
Expression analysis of Freml indicates that it is expressed in epidermal appendages 
including the vibrissae, teeth and mammary glands as well as in the eyelid and 
kidney. Unlike Frasl and Frem2, Freml is expressed in the dermal cells underlying 
the epidermis of the head, limbs, and eyelids, whereas Frasl and Frem2 are 
expressed in the epidermis.
Signal
Figure 7.1: The domain structure of Freml. Freml is a secreted protein which lacks 
the transmembrane domain of Frem2 and has a C-type lectin domain (CTLD). The 
CTLD structure has a characteristic double-loop stabilised by two highly conserved 
disulphide bridges located at the bases of the loops. The second loop is structurally 
flexible and is involved in Ca2+-dependent carbohydrate binding and interaction with 
other ligands (Zelensky and Gready 2005).
The gene responsible for the eb phenotype was discovered in a similar manner. 
G ripl7 mice have a similar phenotype to the other blebbed mutants. The Gripl gene 
maps to the same region on chromosome 10 as eb. The gene encodes a 1127 amino 
acid protein with no structural similarity to the Fras/ Frem proteins, instead it 
consists of 7 PDZ domains. Mutation screening of the eb strain for mutations in 
Gripl revealed a deletion spanning the two coding exons 10 and 11. The resulting 
protein, if produced, would be 353 amino acids, and would lack the final four PDZ 
domains.
Calx-B C-type lectin
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Immunohistochemistry showed that Frasl ' embryos exhibit a lack of deposition of 
collagen VI in the BMZ. Further immunohistochemistry was carried out to determine 
the effect that Freml and Frem2 mutations have on the localisation of collagen IV, V 
and VI in the BMZ. Collagen IV and VI deposition in Frem.2 mutants (myUcl and 
myKst) and collagen V and VI deposition in Freml mutants is unperturbed. This may 
be due to the Frasl mutants being null mutants and therefore having no NG2-like 
domains present to interact with collagen VI, or the N-terminal domains of Frasl 
may be involved in the interaction with collagens. The NG2-like/ chordin-rich (CR) 
domains of Frasl as well as being predicted to interact with collagens, are also 
predicted to bind BMPs in a similar manner to that of the BMP antagonist chordin.
The CR domains of Frasl were cloned and transfected into murine NIH 3T3 cells. A 
signal peptide and transmembrane domain were used to express the CR domains in a 
manner similar to that of native Frasl. The binding of BMP2, -4 and -7 result in the 
phosphorylation of Smadl, therefore P-Smadl levels were used to determine the 
amount of BMP binding in transfected cells by immunohistochemistry. P-smadl 
expression was reduced in transfected cells, suggesting that the CR domains of Frasl 
do have some BMP antagonistic properties.
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7.2 OVERALL DISCUSSION
7.2.1 Genotype-Phenotype Correlation
The Frasl and Frem2 mouse mutants have a very similar phenotype in that they both 
develop cryptophthalmos, syndactyly and renal abnormalities. However there are 
also some subtle differences between the two strains, for example the auditory 
defects and exencephaly seem to be specific to the Frem2 mutants. As the nature of 
and the molecular mechanisms behind the auditory defect are yet to be elucidated it 
is unclear the role that Frem2 has in ear development but as Frasl does not seem to 
be expressed in the ear, this may be the reason behind the difference in phenotype. 
As the my mice tend to present with more blebs in the hindbrain and back regions 
this could explain the exencephaly.
In terms of the clinical phenotypes, it is difficult to make genotype-phenotype 
correlations as mutations in FREM2 have been identified in only three cases, all of 
whom have the same E1972K mutation. However it is interesting that renal 
abnormalities are less frequent and umbilical and heart defects have not yet been 
seen in the cases of Fraser syndrome as a result of mutations in FREM2. Patients 
with a FRAS1 mutation are reported to have more frequent renal, genital, anal, 
umbilical and laryngeal anomalies compared to the non- FRAS1 cases.
The frequencies at which various clinical features are present can only be determined 
once they have been reported by the referring clinician. It has been found that not all 
patients have a full examination/ autopsy so the presence or absence of all the 
clinical features of the Fraser syndrome spectrum is not always known. This can also 
be the case for the mouse phenotypes. Until a phenotype is suspected, it is not always 
investigated, for example until Frem2 expression was discovered in the ear, auditory 
defects were not considered. Therefore it is very difficult to make genotype- 
phenotype correlations, especially as only 11 FRAS1 and 3 FREM2 mutations have 
been identified and no Fraser syndrome mutations have been identified for GRIP1 
and FREML
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CLINICAL FEATURES FRAS1 NON-FRAS1
Cryptophthalmos 86% 84%
Syndactyly 95% 95%
Ambiguous genitalia 71% 63%
Renal agenesis/ hypoplasia 86% 71%
Laryngeal abnormalities 57% 45%
Tracheal abnormalities 14% 11%
Ear abnormalities 76% 74%
Nasal abnormalities 48% 55%
Cleft lip/ palate 5% 11%
Umbilical abnormalities 21% 20%
Exencephaly 5% 3%
Anal stenosis/ atresia 38% 29%
Congenital heart disease 10% 11%
Table 7.1: The frequencies of clinical features in FRAS1 patients and non-FRASl 
patients.
CLINICAL FEATURES FREM2 NON-FREM2
Cryptophthalmos 100% 84%
Syndactyly 100% 95%
Ambiguous genitalia 50% 67%
Renal agenesis/ hypoplasia 25% 80%
Laryngeal abnormalities 50% 49%
Ear abnormalities 50% 76%
Nasal abnormalities 50% 53%
Cleft lip/ palate 0% 9%
Umbilical abnormalities 0% 20%
Exencephaly 25% 2%
Anal stenosis/ atresia 25% 33%
Congenital heart disease 0% 11%
Table 7.2: The frequencies of clinical features in FREM2 and non-FREM2 patients.
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7.2.2 Fras-Frem interactions
Gripl and Frasl have overlapping expression in many embryonic tissues, including 
the skin, oral and nasal cavities, ureteric bud and the gastrointestinal system. Frasl 
and Gripl also co-localise at the basal surface of epidermal cells. Based on this, and 
the fact that Frasl contains a putative PDZ-binding domain (Songyang et al. 1997), 
GST pulldown assays were carried out to establish whether Gripl and Frasl interact 
with one another (Takamiya et al. 2004).
U
Figure 7.2: Western blot showing the PDZ dependent interaction of GST-tagged 
Gripl with GluR2C (a known interactor of Gripl), Frasl and BAC27425 (Frem2). 
The interaction of Gripl with Frasl is abolished by mutation of the terminal valine of 
the PDZ-binding sequence (TEV) to a glycine. Therefore, the Frasl-Gripl 
interaction is PDZ-dependent (Takamiya et al. 2004).
Frasl is normally expressed on the basal side of keratinocytes, however in G ripl'’ 
embryos Frasl expression is reduced and there is abnormal retention of Frasl in the 
keratinocyte layer. This does not affect basement membrane integrity in itself or 
expression of ECM proteins such as collagen IV and laminin-a5. However, 
deposition of collagens V and VI, as well as Frasl, is defective in Gripl ' embryos 
suggesting that Gripl is required for the correct presentation of Frasl to the basal 
epidermis and this in turn affects the recruitment of NG2 and collagens V and VI 
(Takamiya et al. 2004).
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Figure 7.3: Schematic to show the possible pathway between the Fras-Frem 
proteins. Gripl interacts with Frasl and Frem2 through their C-terminal PDZ domain 
binding sites, and is probably responsible for the positioning of Frasl and Frem2 to 
the basal epidermis. The NG2-like motifs of Frasl suggest that it interacts with 
integrins and collagens and may play a role in their localisation in the BMZ. Frasl 
may also interact with other molecules in the ECM and could be involved in cell 
signalling. Modified from Smyth et al. 2004.
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7.2.3 Possible mechanisms behind bleb formation
7.2.3.1 Platelet derived growth factor signalling
Platelet derived growth factors (PDGFs) are involved in the survival, proliferation, 
migration, differentiation and function of a variety of specialised mesenchymal and 
migratory cell types and the deposition of the extracellular matrix and tissue 
remodelling factors, both during development and in adulthood. They are mitogenic 
during early development and drive the proliferation of undifferentiated 
mesenchyme. During later development, PDGFs have been implicated in tissue 
remodelling and cellular differentiation and in the inductive events involved in 
patterning and morphogenesis (Hoch and Soriano 2003).
PDGFs function as secreted homodimers, linked by disulphide bonds and are 
activated by proteolytic cleavage. PDGF receptors (PDGFRs) are tyrosine kinases 
which dimerise on ligand binding to activate their cytoplasmic tyrosine kinase 
domains. These autophosphorylate several tyrosine kinase residues to create docking 
sites for signalling proteins and adaptors that initiate signal transduction. Four 
PDGFs exist, A-D, with two PDGFRs, a  and p (Hoch and Soriano 2003).
Pdgfc1' mice exhibit a similar phenotype to the bleb mice, including subepithelial 
oedema and blistering in the frontal and frontonasal regions, and the dorsal side of 
the limb and spinal chord. The cleavage plane lies in the sublamina densa zone on 
the dermal side of the basement membrane, reminiscent of dystrophic epidermolysis 
bullosa. They also exhibit spina bifuda occulta and cleft palate (Ding et al. 2004). 
Pgdfa mutants display atrial and alveolar septal defects, and have a thin dermis. 
Pdgfb mutants also exhibit oedema, haemorrhagic blistering and glumerulosclerosis. 
These phenotypes may be a result of a loss of PDGF signalling in the epithelium 
resulting in diminished PDGF signalling in the mesenchyme (Betsholtz 2004).
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PDGFs are expressed in the epidermis and their receptors expressed in the subjacent 
mesenchyme. The PDFR positive cells in the mesenchyme respond to PDGF 
signalling by proliferation, resulting in the formation of mesenchymal clusters that 
act as signals to trigger epithelial folding. Therefore epithelial-mesenchymal 
interactions are part of the conserved mechanism for epithelial folding at sites where 
large epithelial surfaces are needed to form for reabsorption and respiration (in the 
alveoli), or in the formation of large specialised vascular surfaces for plasma 
filtration (glomerulus) (Hoch and Soriano 2003).
Pdgf-B knockout mutants die from excess haemorrhaging of blisters. Pdgf-B/ Pdgf-P 
signalling promotes the proliferation of vascular smooth muscle cells (vSMC) and 
pericytes (PC) surrounding blood vessels. Inactivation of this signalling results in a 
lack of pericytes, causing microaneurysms, leakage and haemorrhaging compounded 
by a shortage of vSMCs and PCs, which control endothelial cell differentiation and 
function, around arterioles and venules. The PCs of the kidney glomerulus 
(mesangial cells) are completely missing in Pdgf-B/ Pdgfr-|3 null mutants. Renal 
endothelium cells express Pdgf-B and the mesangial cells express Pdgfr-p. 
Mesangial cells deposit ECM (mesangial matrix) that make focal contact with the 
glomerular basement membrane. Where Pdgf-B/ Pdgfr-p signalling is disrupted, 
mesangial cells do not migrate into the glomerular space, resulting in 
glumerulosclerosis (Betsholtz 2004).
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Figure 1.4: (a) PDGFs in cell migration and angiogenesis. In the developing kidney, 
PdgfB/ Pdgfrp signalling is essential for the migration of Pdgfr/3-expressing 
mesangial cell precursors (blue) from (i) the cleft of the S-shaped nephron into (ii, 
iii) the glomerular space. These cells give rise to the glomerular capillary bed (red) 
and its mesangial cells (iii). In Pdgfb- and Pdgfrfi-null embryos, few Pdgfr/3 
expressing precursors migrate to the nephron cleft, and these cells fail to enter the 
glomerular space; capillary beds fail to form in these embryos and capillary 
aneurysms are observed in the glomerular space (iv). (b) PDGFs in epithelial folding. 
Pdgfra-expressing mesenchymal cells cluster at sites of future epithelial folding 
during lung, skin and intestine morphogenesis. Late in embryogenesis, Pdgfra- 
positive mesenchymal cells (blue) in the lung migrate to sites of alveolar septation 
(i), a postnatal process in which the air sac epithelium invaginates and is lined with 
specialized matrix. Septation does not occur in the absence of the Pdgfra-positive 
cells, whose development requires PDGF-A during embryogenesis. Modified from 
Hoch and Soriano 2003.
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As PDGFs are involved in mesenchymal proliferation, disruptions in signalling result 
in disruptions in morphogenesis. Since PDGF mutants display epidermal blistering, it 
is possible that the cause of the blistering is due to disruptions in PDGF signalling 
affecting epithelial-mesenchymal interactions. Mesenchymal tissue influences the 
morphogenesis, proliferation and differentiation of a variety of embryonic epithelia, 
e.g. in the tooth, skin, mammary and salivary glands. The regulation of 
bioavailability of PDGFs in the extracellular space is carried out by ECM proteins 
including extracellular proteases that activate latent PDGF-C and -D. PDGF-A and -  
B have carboxy-terminal retention motifs that play a role in the compartmentalisation 
of the factors, promoting the formation of gradients and facilitating presentation of 
the ligands to the relevant target cells (Hoch and Soriano 2003; Betsholtz 2004; Ding 
etal. 2004).
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Figure 7.5: Diagram to show the possible interactions that could occur with Frasl, 
based on the domain structure. Early experiments suggest that BMPs bind to the 
chordin-like domains and that the NG2-like domains bind collagens. The NG2-like 
domains may also bind fibroblast growth factors (FGF), platelet derived growth 
factors (PDGF) and integrins. The binding of these molecules could be 
communicated to the cytoplasm and therefore Frasl could be involved in cell 
signalling.
179
7.23.2 Epidermal adhesion
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Figure 7.6: Schematic showing the main components of the epidermal basement 
membrane zone. Blistering in Fraser syndrome and the blebbed mutants occurs 
below the level of the lamina densa.
Maintenance of the epidermis relies on the secure adhesion of the keratinocytes to 
one another and adhesion of the basal keratinocytes to the underlying epidermal 
basement membrane. When these are disrupted the loss of epidermal adherence 
results in the formation of blisters. At the dermal-epidermal junction, the main 
adhesion units are the hemidesmosomes, which are composed of inner and outer 
plaques that bind to intracellular keratin intermediate filaments and connect to the 
BMZ via anchoring filaments. The keratin intermediate filaments bind plectin and 
BPAG1 which interact with integrin a6p4 and collagen XVII. Integrin a6p4 is a 
receptor of laminin 5 and can transduce signals from the ECM to the interior of basal 
cells, modulating the organisation of their cytoskeleton and their proliferation, 
apoptosis and differentiation (Fassihi et al. 2006).
Integrins are the main surface receptors for mediating cell-cell and cell-matrix 
interactions. They are heterodimeric transmembrane receptors composed of non- 
covalently associated a  and p chains that recognise ECM components such as 
laminins and collagens. Integrins interact with ECM components via their 
extracellular domains, while their cytoplasmic domains play a critical role in cell 
anchorage by interacting with the cytoskeleton and providing a connection between 
the internal and external environment. They also mediate signal transduction through 
their cytoplasmic tails following activation by ligands.
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Thereby integrins provide a link between the inside and outside of a cell and are 
involved in cytoskeletal rearrangement as well as signal transduction (Watt 2002). 
Skin blistering, exencephaly and syndactyly occur in murine mutants of cx3 and a6  
integrins, It is thought that the similarity of the phenotype of these mutants is due to 
both integrins a3 and a6  acting as receptors for laminin 5 (De Arcangelis et al. 
1999; De Arcangelis and Georges-Labouesse 2000; Stupack and Cheresh 2002; 
Pozzi and Zent 2003).
The RGD sequence is a cell-adhesion motif recognised by integrins including those 
containing the av  subunit (e.g., av p i, av|33, av|35 and avp6) or the pi subunit 
(a5p i and a8pi). Freml contains an RGD motif, which has been shown to bind the 
av-containing integrins and a8 p i, which would enable it to participate in signal 
transduction. Integrin a8 p i is indispensable in renal morphogenesis, but its loss can 
be compensated for by other RGD-directed integrins during hair morphogenesis 
(Kiyozumi et al. 2005). Frasl and Frem2 lack the RGD motifs of Freml, but may 
interact with integrins through other domains.
Basement membranes are highly specialised sheet-like structures that surround or 
separate tissues and contain laminins, collagen IV, nidogen and proteoglycans. 
Laminins are heterotrimeric glycoproteins and are the main basement membrane 
components of most tissues. Laminins regulate cell growth and differentiation, 
migration and adhesion, particularly laminin a5 which is responsible for the integrity 
of the connection of the epithelium to the basement membrane. Laminin a5 null 
mutants display several abnormalities including exencephaly, limb malformations 
and renal abnormalities. This correlates with its role in branching morphogenesis and 
its expression in the basement membrane, which are compromised in the null 
mutants resulting in glomerular basement membrane and dermal-epidermal BMZ 
defects (Miosge et al. 2002). A weakness in the basement membrane could also be 
responsible for the failure of neural tube closure, resulting in exencephaly (Miner et 
al. 1998).
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Immunogold histochemistry has shown Frasl localisation underneath the lamina 
densa, similar to collagen VII and collagen XVII localisation. Collagen VII is a 
component of the anchoring fibrils and collagen XVII co-localises with the fibrillar 
structures underneath the lamina densa. This has led to the proposal of Frasl being a 
component of the anchoring complex which adheres the basement membrane to the 
underlying matrix (Petrou et al. 2005). Anchoring fibrils originate at the lamina 
densa and either loop back into it, or extend into the anchoring plaques in the matrix 
of the underlying dermal connective tissue. Anchoring fibrils often entrap collagen 
fibrils in the dermis, ensuring dermal-epidermal cohesion. The major structural 
component of the anchoring fibrils is collagen VII (Bruckner-Tuderman et al. 1999). 
Mutations in Collagen VII cause dystrophic epidermolysis bullosa, a skin blistering 
disorder in which the level of blister formation is below the lamina densa (Das and 
Sahoo 2004). Laminin 5 bridges a6p4 integrin with collagen VII. In vitro studies 
demonstrated that laminin 5 binds the amino-terminal NC-1 domain of collagen VII. 
Disruptions to this anchoring complex destroy dermal-epidermal integrity, resulting 
in the formation of blisters. Therefore, if Frasl is a part of this anchoring complex, 
the loss of dermal-epidermal adhesion and the subsequent blistering would be 
explained.
Integrins and laminins play an important role in epidermal adhesion, as do collagens. 
An absence of Frasl results in the mislocalisation of collagen VI and early 
experiments suggest that the chordin-like (CR) domains of Frasl interact with BMPs. 
The NG2 proteoglycan binds Fgf2 and PDGF-AA directly and could also interact 
with integrin a3|31 (Fukushi et al. 2004), therefore it would be interesting to 
determine whether the NG2-like domains of Frasl, Freml and Frem2 also interact 
with these molecules. Mutants of these molecules share very similar phenotypes to 
the blebbed mutants, suggesting that the same mechanisms are affected. The absence 
of Frasl could therefore affect the signalling of these molecules, resulting in 
epidermal fragility and subsequent blister formation, which physically interferes with 
the epithelial-mesenchymal interactions required during eye and limb formation, 
resulting in cryptophthalmos and syndactyly.
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However, these phenotypes could also be caused by a defect in mesenchymal 
development caused by abnormal PDGF signalling. PDGFs could also bind to the 
NG2-like domains of Frasl, Freml and Frem2, and extracellular proteins are thought 
to play a role in the regulation of the bioavailability PDGF-A and -B  by binding 
their carboxy-terminal residues. Defects in the mesenchyme would also result in 
disruption of epithelial-mesenchymal interactions. Whatever the role of the Fras- 
Frem family of proteins, it is clear that their requirement for maintaining the integrity 
of the epidermal BMZ is only essential during a specific time window at which 
blister formation occurs. This is the major difference between Fraser syndrome and 
other blistering disorders as blistering only occurs in utero and there is no postnatal 
blistering and skin development proceeds normally. The Pdgfc'' mutants die shortly 
after birth so it is unclear whether the epidermal blisters they present with in utero 
persist after birth. Until further work is carried out to confirm the localisation of 
Frasl and the interacting partners of the Fras-Frem proteins, the precise mechanism 
behind the blistering and the resulting phenotypes will remain unclear.
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7.3 FURTHER WORK
7.3.1 Mutation Screening
Much work remains in order to elucidate the functions of the Fras-Frem proteins and 
understand the mechanisms behind the Fraser syndrome and blebbed phenotypes. 
Some work still remains in sequencing and mutation screening. No Fraser syndrome 
mutations have been identified for FREM1 and GRIPl. This may be due to the loss 
of these proteins having a more severe effect in humans, or could be due to chance 
and there have now been some families with possible linkage to these genes. To date, 
12 mutations have been identified in FRAS1 and 3 in FREM2 and more families with 
linkage to these genes require screening.
Only once mutations have been identified in all the Fras-Frem genes will genotype- 
phenotype correlations be able to be made correctly. It seems that there may be slight 
differences in the clinical features present in cases with mutations in the different 
genes, though these will only be confirmed after analysis of a larger cohort of 
patients. This seems to be the main difference between the mouse mutants and the 
Fraser syndrome patients as the mice seem to have very similar phenotypes that are 
generally indistinguishable from each other, with the exception of the auditory 
anomalies of the Frem2 mice. Also, the mouse mutants do not seem to have the anal 
and genital abnormalities that some patients suffer from. Therefore screening more 
patients and trying to identify genotype-phenotype correlations may provide an 
insight into functional differences between the various proteins.
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7.3.2 Role of proteins in organogenesis
The main features of Fraser syndrome, cryptophthalmos and syndactyly, can be 
attributed to the loss of epithelial-mesenchymal interactions during eye and limb 
formation caused by the physical interference of the blisters at crucial points in the 
development of these organs. However, the Fras-Frem proteins have also been 
shown to have important roles in the development of organs such as the heart, kidney 
and ear which have abnormalities unrelated to the presence of blisters.
In particular, Frasl plays a role in renal development where it is required for the 
reciprocal signalling between the ureteric bud and the renal mesenchyme. 
Disruptions to these interactions in the absence of Frasl result in the apoptosis of the 
renal mesenchyme which could cause the subsequent renal agenesis. Further work 
needs to be carried out to determine whether or not the apoptosis of the mesenchyme 
is sufficient to cause renal agenesis. Caspase inhibitors will be used to establish 
whether reducing apoptosis will prevent agenesis. Frem2 mutants also develop renal 
cysts, not all of which are consistent with the expression of Frem2. The stage at 
which these cysts occur in needs to be identified as well as possible mechanisms 
behind the cyst formation.
Both Frasl and Frem2 are expressed in the heart and it has been reported (Timmer et 
al. 2005) that Frem2 mutants exhibit atrial septal defects. As yet, these defects have 
not been identified in the myKst or myUcl strains, but many more embryos need to be 
studied. Dissection of the hearts should be carried out before any structural analysis 
is carried out (e.g. MRI) in order to identify any defects. This could be done by 
sectioning or MRI analysis of the hearts, as opposed to the whole embryos. Once 
defects have been confirmed molecular markers for septation such as Creatine kinase 
B (CK-B) and Pitx2 could be used to determine at which stage cardiac development 
is impeded and which pathways are affected (Lamers and Moorman 2002).
185
The auditory defects in the Frem2 mutants are very interesting. All of the mice tested 
(15) had some level of defect, with only 2 showing some level of response, decreased 
compared to normal, to the startle response test. Initially the auditory defect was 
thought to be as a result of the blistering of the face and head, but has this been the 
case the defect would have been more random, with less mice suffering from the 
defect. Also, in order to confirm that the blebs causing the eye defects were not 
responsible for the ear defects, mutant mice with unilateral and without 
cryptophthalmos were tested using OAEs and were found to have bilateral auditory 
dysfunction. Dissections also show that there were no constrictions of the ear canal 
that could have been caused by blebbing. Further mutants need to be analysed by ear 
canal dissection, OAE and startle response in order to obtain a broader picture of the 
extent of the hearing defect.
OPT scanning showed that the defect may be a structural one, at the apex of the 
cochlea and scanning and transmission electron microscopy showed there is no 
defect in the hair cells of the cochlea. The apex of the cochlea transduces low 
frequency sounds, which were not responded to by the mice tested by OAEs. 
Therefore the OAE needs to be repeated using the full range of frequencies audible 
by mice to determine which sound frequencies are inaudible. Further work needs to 
be carried out to determine what is causing the structural defect in the cochlea. 
Common markers such as Pax2, Eyal, Otx2 and Sixl could be used to identify the 
stage at which the defect occurs. The other blebbed strains should also be tested to 
determine whether the Frem2 mice are the only blebbed mutants with auditory 
defects. Fraser syndrome patients with hearing problems will also be scanned using 
MRI to determine whether they suffer from the same defect. Most of the patients 
with ear abnormalities have physical defects of the pinna and ear canal, attributable 
to blistering. However the hearing defect in one patient persisted after operations to 
correct the physical defects in the ear canal and pinna, giving further evidence of a 
defect in the inner ear.
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7.3.3 Functional analysis
As the genes have been identified for the all of the known blebbed mutants, the next 
step is to determine their function and identify the mechanisms behind the 
phenotypes. Whether or not the Fras-Frem proteins interact is not clear. From the 
similarity of the phenotypes it is likely that they are all involved in the same 
pathway. As antibodies against Frasl and Frem2 were previously unavailable, the 
expression of Frasl was not investigated in Frem2 mice, and vice versa. It is known 
that Frasl localisation in the BMZ is compromised in Gripl'1' mutants, which 
confirms the theory that Gripl is responsible for trafficking Frasl to the basal 
epidermis. It is likely that this is also the case for Frem2, though experiments to 
confirm this need to be carried out. This could be done by testing expression of 
Frem2 in Gripl mutants. Expression of Freml in Frasl and Frem2 mutants also 
needs to be carried out to determine how Freml is involved with the other proteins, 
particularly as it is secreted and has complementary expression to Frasl and Frem2, 
in the dermis. Co-localisation studies could be carried out using immunogold 
histochemistry to determine the location within the basement membrane of Freml 
and Frem2, in a similar method to that carried out for Frasl (Petrou et al. 2005).
Further work needs to be carried out to identify/ confirm the binding partners of 
Frasl and the other Fras-Frem proteins. To confirm the results of the BMP binding 
assays, western blots need to be carried out to better demonstrate the reduction in the 
level of P-Smadl, and luciferase assays need to be performed to obtain more 
quantitative results. Animal cap assays are also planned to establish whether the CR 
domains of Frasl are able to induce axis duplication.
Confirmation that it is the NG2-like domains of Frasl which interact with collagen 
VI is needed. The interacting partners of large ECM proteins such as the Fras-Frem 
proteins have been identified by carrying out BIAcore binding assays and solid phase 
binding assays. The BIAcore surface resonance binding assays were used to identify 
fibrillin-1 interactions with heparin sulphate. Fibrillin-1 has four heparin sulphate 
binding sites, therefore to test these interactions biotinylated heparin sulphate was 
immobolised onto SA sensor chips with pre-immobilised streptavidin to allow biotin
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capture. Fibrillin-1 protein fragments were injected onto the chips and the response 
for each injection was calculated. Specific binding to Heparin sulphate and not 
Hyaluronan or Chondroitan sulphate was demonstrated by this method (Cain et al. 
2005). Alternatively, solid phase binding assays could be carried out in which 
multiwell plates are coated with purified recombinant proteins and the non-specific 
binding sites are blocked. These proteins are then incubated with soluble ligands and 
washed. Ligands binding to the protein of interest can be identified by incubation 
with the relevant primary antibody. This method was carried out to identify Perlecan 
interactions with Fibrillin-1 (Tiedemann et al. 2005). These techniques could be used 
to determine whether or not Frasl interacts with collagen VI or integrins, especially 
as full-length protein (which is unavailable currently for Frasl) is not required as 
only protein fragments containing the relevant binding domains are needed, which 
would also determine which domains are required for particular interactions.
Cell migration assays could be carried out to determine the affect of adding/ 
knocking out the Fras-Frem proteins on keratinocyte migration. Most methods to 
study cell migration in vitro use systems with 2D surfaces. These 2D assays enable 
the migratory activity of cells to be studied in response to natural or pharmacological 
modulators or into the corresponding regulatory signal transduction, such as binding 
of FGFs/ PDGFs. The cells are plated on a bare glass or plastic surface, or on a 
surface coated with a matrix. Components typically used are ECM components like 
collagen type I or type IV, fibronectin, laminin. In 3D assays the cells are embedded 
within a matrix, which is closer to the in vivo situation. The most commonly used 3D 
matrix is collagen type I-based, as it is the predominant ECM component in the body 
and it is the main constituent of the connective tissue. The migratory behavior of the 
cells is visualized by time-lapse videomicroscopy (Entschladen et al. 2005). 3D 
migration into BD Matrigel™ could also be carried out. The BD Matrigel™ matrix 
is a solubulised basement membrane preparation composing of (amongst others) 
laminin, collagen IV and heparan sulphate proteoglycans. The BD Matrigel™ matrix 
polymerises to produce biologically active matrix material resembling the 
mammalian cellular basement membrane, therefore it is useful for use in in vitro 
modeling systems. Keratinocytes expressing Frasl could be used in these studies and 
the effect of adding FGFs/ PDGFs could be observed. If FGFs/ PDGFs do bind to 
Frasl the resulting signal transduction causing cell migration could be studied.
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7.4 RESOLUTION OF AIMS
The aims of this project were to identify the genes responsible for the remaining 
blebbed mutants and their human orthologues responsible for Fraser syndrome and to 
determine the interacting partners of Frasl and the other Fraser syndrome proteins, 
which may go some way to establishing the function of the proteins.
This project has led to the identification of FREM2 as being another gene involved in 
Fraser syndrome, demonstrating genetic heterogeneity, and mutations in Frem2 
underlying the my phenotype. The Gripl gene has been shown to underly the eb 
phenotype, though no human mutations have so far been identified. A further gene, 
Freml has also been shown to underlie the heb phenotype by our collaborators.
Work has also been initiated to determine the interacting partners of Frasl, which 
have been shown to modulate the activity of BMPs and affect the localisation of 
collagens, possibly along with integrins, PDGFs and FGFs. Therefore the aims of the 
project have been fulfilled. Much work is yet to be carried out to elucidate the 
function of the Fras-Frem family of proteins and to determine the mechanism by 
which some of the phenotypes occur. The results obtained so far suggests that the 
work to come will yield some important and interesting information, not only into 
the development of the disorder, but also the processes behind the development of 
various organs and systems.
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CHAPTER 8, MATERIALS AND METHODS
8.1 MATERIALS
8.1.1 Clinical History
Diagnosis of Fraser syndrome was made for all families used in this study, based on 
the criteria of (Thomas et al. 1986; Slavotinek and Tifft 2002) The patients described 
are part of a larger resource of Fraser syndrome patients and their families.
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Figure 8.1: Pedigree and clinical pictures of family 1. Family 1 is consanguineous 
and was referred by Dr. Perez Aytes, Valencia, Spain. The affected patient was bom 
at 32 weeks and died at birth due to respiratory failure, secondary to laryngeal 
stenosis. The patient had a dysplastic nose with hypoplastic alae nasi, a short thorax, 
abdominal distention, an absent bladder, ureter and right kidney with a hypoplastic 
left kidney. Skin syndactyly of the hands and feet, anal atresia and ambiguous 
genitalia were also present, the karyotype of the affected child was 46XX. The 
pedigree (a) and facial features of the affected foetus (b, c) showing the beak-shaped 
nose, bilateral cryptophthalmos, syndactyly of the left hand and a low set dysplastic 
ear.
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Figure 8.2: The pedigree (a) and facial features (b) of the affected patient from 
family 2. The unilateral cryptophthalmos can be clearly seen. Family 2 are also 
consanguineous with a single living affected female child and were referred by Dr. 
Nicole Philip, Marseille, France. She was born at 35 weeks gestation and 
demonstrated complete cryptophthalmos of the right eye and a malformed left globe. 
She presented with a small mouth, an abnormal frontal hairline and ambiguous 
genitalia. She also had bilateral skin syndactyly of the hands, digits 2 to 4 on the left 
and 3 to 4 on the right, and her left foot showed 2-3 syndactyly.
Family 3 are from Barcelona, Spain and are multiply inbred with two Fraser 
syndrome patients. The first couple has 3 healthy and 2 affected children. No 
information is available on the first affected child but the second affected boy (IV:3) 
was born after a term pregnancy with a blepharophimosis (narrowing of the palpebral 
fissure) and a laryngomalacia (soft larynx). He has cutaneous syndactyly and typical 
facial features of Fraser syndrome. Another consanguineous couple in this family has 
two healthy children and had a termination of a third pregnancy (IV:4) after a 
prenatal ultrasound at 14 weeks had detected encephalocele and syndactyly. Post­
mortem examination confirmed the prenatal findings and revealed a unilateral 
blepharophimosis (horizontal narrowing of the palprebal fissure).
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Figure 8.3: The pedigree for family 3 (a) and the clinical features for affected 
patient IV:3, showing bilateral cryptophthalmos and syndactyly of the hands and feet 
(b) and affected patient IV:4 showing the encephalocele and syndactyly (c).
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8.1.2 Control DNA
All controls were unrelated. Fifty Spanish control samples came from the same city 
(Valencia) as family 1, courtesy of Dr. Perez Aytes. An additional 100 samples were 
obtained from elsewhere in Spain. The other ‘Caucasian’ controls were from the UK. 
We also used 18 samples from Spanish gypsies and 2 samples from Portuguese 
gypsies, again courtesy of Dr. Perez Aytes.
8.1.3 Reagents
All of the reagents that were used were of AnalaR grade and obtained from Sigma 
Aldrich or BDH Laboratory supplies, except where indicated. Glassware, solutions 
and media were autoclaved at 15pst, 121°C for 20 minutes as required. Water was 
purified using a MiliRo 15 Water Purification System (Milipore SA) and further 
purified where necessary using a Milli-Q reagent Grade Water Ultrafiltration System 
(Milipore SA) and sterilised by autoclaving.
Electrophoresis grade agarose was obtained from Gibco-BRL Life Technologies and 
NuSieve GTG low melting point agarose from FMC Bioproducts. Bacto-agar, 
bactotryptone, bactopeptone, agar and yeast extract were from Difco Laboratories. 
Absolute alcohol and isopropanol were from Hayan Ltd. Proteinase K was obtained 
from Qiagen. NaOH pellets were from Fisons Scientific Equipment. dNTPS were 
supplied by Bioline. Histoclear was supplied by National Diagnostics.
X-gal solution was purchased from Promega. Superfrost and Superfrost + slides were 
purchased from VWR International. Nuclear Fast Red was from Vector. 1% aqueous 
eosin and OCT embedding mediumwere from RA Lamb. Ruthenium red was 
purchased form Fluka amd Stains-all from Sigma. DPX mountant was purchased 
from BDH. NBT/ BCIP tablets and Complete protease inhibtor cocktail tablets were 
purchased form Roche.
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8.1.4 Non-standard materials
In addition to standard laboratory equipment, the following items were also used. 
BioMax autoradiography film (Kodak) was used for detecting western blots. Art 
aerosol resistant barrier tips were obtained from Molecular Bioproducts. Glassware 
was obtained from Pyrex® (USA) and Schott Duran (Germany). Plastic-ware was 
from Becton Dickson Labware or Bibby Sterilin Ltd. 0.2ml individual PCR tubes, 
0.2ml tube strips and Thermofast® 96 well plates were obtained from ABgene. Plate 
seals were from Hybaid. Sterile loops were obtained from Nunc Nalgene®. 
Whatmann 3M paper and Hybond C+ membranes from Amersham Pharmacia 
Biotech were used for Western blotting. Trizol for RNA extraction was supplied by 
Invitrogen.
DNA electrophoresed on agarose gels were visualised through ethidium bromide 
fluorescence detected at 300nm on an Alpha Innotech Corporation Multiimage Light 
cabinet. Gels were photographed on a Polaroid Direct Screen Instant camera using 
Polaroid film (Polariod Corporation). PCR amplification and cycle sequencing 
reactions were performed on an Eppendorf Mastercycler gradient thermocycler. 
DNA sequence analysis and microsatellite repeat analyses were performed on a 
MegaBACE 1000 DNA sequencer (Amersham Pharmacia Biotech). An 820 Rotary 
Microtome and a Bright 5050 Cryostat were used to prepare sections. Embryos were 
photographed on a Stemi 2000-C microscope. Sections were viewed on a Zeiss 
Axioplan2 microscope and photographed using Zeiss Axiophot2 and Prog Res 3012 
software (Kontron Elektronic). Fluorescent microscopy was carried out on a Zeiss 
Axioimager using Axiovision v 4.4 software.
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8 .1.4.1 Oligonucleotides
Oligonucleotides were synthesised to order by either MWG-Biotech or Qiagen.
8 .1.4.2 Nucleotide size markers
lOObp DNA ladders were purchased from Invitrogen and lkb DNA ladders were 
purchased from Sigma Aldrich. Rainbow protein molecular weight markers were 
purchased form Amersham.
8 .1.4.3 Cells and tissue culture
Effectene was purchased from Qiagen. DMEM and D-PBS were purchased from 
Gibco. DH5a subcloning effieciency cells and BL21 Gold competent cells were 
purchased from Stratagene.
8 .1.4.4 Antibodies
All antibodies were used at a dilution of 1:100, unless otherwise stated in brackets 
following the antibody. Mouse anti-collagen IV antibody was purchased from 
Chemicon Ltd, mouse anti-collagen VI antibody was obtained from Rockland. Anti­
smooth muscle actin (SMA) monoclonal IA4 and horseradish peroxidase conjugated 
antibody to anti SMA were purchased from Dako. Fluorescein isothiocyanate- 
conjugated D. biflorus lectin was acquired form Vector Labs and Tamm-Horsfall 
protein was obtained form Biodesign. Mouse anti-P-Smadl (1:50) antibody was 
purchased from Cell Signalling. Mouse anti-Smadl (A-4) and mouse anti-Actin (C- 
2) antibodies were acquired from Santa Cruz biotechnology. Secondary Alexa 
conjugated donkey anti-mouse antibodies were purchased from Molecular probes 
(1:400). Anti-cMyc antibody (9E10) and Hoechst stain were purchased from Sigma.
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8.1.4.5 PCR amplification and purification products
The Qiagen HotStar® PCR system was used for PCR reactions. In a final volume of 
25pl each reaction contained 0.75units of Taq DNA polymerase, 10 x buffer 
(containing Tris-Cl, KC1, (NH4)2S04 and MgCl2), 1.5mM total MgCl2 and 800pM 
dNTPS.
Sephadex® G-50 superfine powder was from Amersham Pharmacia Biotech. For 
Exo-SAPit reactions, Exonuclease I from New England Biolabs and Shrimp Alkaline 
Phosphatase from USB Corporation were used.
8 .1.4.6 Commercial kits
The DYEnamic ET and BigDye® Terminator v3.1 Cycle sequencing kits for 
MegaBACE and MEGABACE ET440R size standards were purchased from 
Amersham Pharmacia Biotech.
QIAquick Gel extraction and PCR purification kits, and mini- and maxi-prep kits 
were from Qiagen Ltd. The Superscript II® RNase H- reverse transcriptase system 
was supplied by Invitrogen. The Roche Expand Long Template PCR System was 
used for long-range genomic PCR. Effectene from Invitrogen was used for cell 
transfection.
8 .1.4.7 Enzymes
Restriction enzymes were obtained from New England Biolabs or Invitrogen. T4 
DNA ligase was obtained from Promega. All enzymes were used with the 
appropriate buffers, as recommended and supplied by the manufacturers.
8 .1.4.8 Vectors
The pGEX-4TI vector was obtained from Amersham, the pCMV-Myc vector was 
obtained from Clontech and the pDisplay was purchased from Invitrogen.
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8.1.5 Stock solutions, Buffers and Media
8 .1.5.1 Genomic DNA extraction
1 x TE buffer lOmM Tris-HCL, ImM EDTA, pH 8.0
Tail Lysis buffer lOOmM Tris pH 8.5, 5mM EDTA, 0.2% SDS,
200mM NaCl, 100//g/ml Proteinase K
8 .1.5.2 PCR and Electrophoresis buffers
10 x HotStar buffer Tris-Cl, KC1, (NH4)2S04, MgCl2
1 X TAE buffer 40mM Tris-acetate, ImM EDTA, pH 8.0
Orange G loading buffer 10 x Ficoll-Orange G: 0.25% Orange G, 
25% Ficoll, 0.25M EDTA
8 .1.5.3 Bacterial Growth media
L-Broth
LB agar
Ampicillin
Chloramphenicol
10g/l Bacto-tryptone, 5g/l Yeast extract,
5g/l NaCl
L-Broth + 15g/l agar added prior to autoclaving 
50mg/ml, filter sterilised 
15mg/ml, filter sterilised
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8.1.5.4 Solutions for X-gal staining
Rinsing buffer 2mM MgCl2, 0.01% DOC,
0.02% NP-40 in PBS
Staining buffer 20mM Potassium ferricyanide, 2mM MgCl2,
20mM Potassium ferrocyanide, 0.01% DOC, 
0.02% NP-40, 2% X-gal in PBS
8 .1.5.5 Solutions for in situ hybridisations
Hybridisation buffer
NTMT
10 x TBST
PTW
In situ Blocking buffer
50% Formamide, 1.3 x SSC, 100//g Heparin 
50//g Yeast RNA, 5mM EDTA pH 8.0, 
0.002% Tween 20, 0.005% CHAPS,
lOOmM NaCl, lOOmM Tris-Hl (pH 9.5), 
50mM MgCl2, 1% Tween-20
250 mM Tris-HCl (pH 8.0), 125 mM NaCl, 
25mM KC1, 0.1% Tween 20
Ca2+ and Mg2+ free PBS, 0.1% Tween 20
10% Sheep serum, 1% BSA in 1 x TBS
198
8.1.5.6 Solutions for protein gels/ western hybridisation
10 x SDS PAGE Running buffer 
Transfer buffer
10 x TBS
Blocking buffer 
2 x sample loading buffer
Buffer A (Ruthenium red)
Stains-All Solution
Resolving gel
Stacking gel
250mM Tris-HCl, 1.92M Glycine, 1% SDS
12.5mM Tris Hcl, 96mM Glycine, 0.05% SDS, 
20% Methanol
125mM NaCl, 25mM KC1, 250mM Tris-Hcl 
(pH 8.0)
3% Non-fat milk in 1 x TBS
18.75mM Tris-HCl pH 6.8, 4% SDS,
20% Glycerol, 2% p-mercaptoethanol,
0.1% Bromophenol blue
60mM KC1, 5mM MgCl2, lOmM Imidazole, 
pH 6.8
0.005% Stains-All, 5% Formamide,
25% Isopropanol, 15mM Tris pH 8.8
10% Acrylamide, 3.75mM Tris pH 8.8,
0.1% SDS, 0.1% Ammonium persulphate,
10/d TEMED
10% Acrylamide, 25mM Tris pH 6.8,
0.1% SDS, 0.1% Ammonium persulphate,
10/d TEMED
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8.2 WEBSITES USED
BayGenomics 
Ensembl 
ESEfinder 
NCBI BLAST 
NCBI dbSNP 
Primer3
Restriction Mapper
SDSC Biology Workbench
SMART
http://baygenomics.ucsf.edu/
http: //www. ensembl. org/
http: //rul ai. cshl. edu/tool s/ES E/
http://www.ncbi.nlm.nih.gov/blast/
http://www.ncbi.nlm.nih.gov/projects/SNP/
http://frodo.wi.mit.edu/cgi-bin/
primer3/primer3_www.cgi
http://www.restrictionmapper.org/
http://workbench.sdsc.edu/
http://smart.embl-heidelberg.de/
UCSC Genome Bioinformatics http://www.genome.ucsc.edu/
8.2.1 Accession numbers
FREM2 XM_929884
Frem2 NM_172862
Gripl NM_028736
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8.2.2 Bioinformatics
8.2.2.1 Gene structure determination
The number of exons and intron-exon boundaries for FREM2, Frem2 and Gripl 
were identified by using the Ensembl and UCSC Genome Bioinformatics databases. 
The genes were identified on the databases and the ESTs and predicted transcripts 
running in the same direction as the studied gene were analysed. Overlapping 
transcripts or transcripts containing domains of interest (e.g. calx-p domains) were 
incorporated into a single transcript. The genomic sequence of the transcript was 
then downloaded and blasted against cDNA libraries. The regions of the genomic 
sequence that aligned to sequences from cDNA libraries were identified as exons. 
The intron-exon boundaries were confirmed by identification of splice site donor and 
acceptor sites. Once the intron-exon boundaries had been obtained, intronic primers 
were designed using the Primer3 programme (see 8 .3.4.2). This process was repeated 
as further transcripts and ESTs were added to the databases.
8.2.2.2 Calx-pstructural analysis
As the E1972K mutation was the first missense mutation to be identified in either 
Fraser syndrome or the blebbed mutants and the calx-p domains were unknown, a 
bioinformatics specialist Martin Taylor, a former colleague of our collaborator Ian 
Smyth, was contacted to determine the possible role of the calx-p domains and the 
possible effect the mutation would have on the domain structure and subsequent 
protein function. The results of this investigation showed that calx-P is related to the 
cadherin fold with statistical significance and both calx-p and cadherin domains
• ^  i
exhibit a high affinity for Ca ions. Sequence:sequence, sequence:structure and 
structurerpredicted structure alignments (Figures 2.5 and 2.5a) all support a cadherin 
fold for calx-p and show that Ca coordinating residues of cadherin are conserved in 
calx-p. Three Ca ions are intercollated between adjacent cadherin domains, the 
structural equivalent of residue E l972 is directly involved in the coordination of at 
least one of these ions, and the E1972K mutation would be likely to abolish the 
binding of at least one to all three Ca2+ ions, affecting the structure of FREM2 and 
possibly abolishing protein-protein interactions.
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8.3 METHODS
8.3.1 Isolation of DNA
8.3.1.1 Extraction o f DNA from tail tips
The tail tips were placed in separate eppendorf tubes and 500 pi of tail lysis buffer 
was added. These were incubated overnight at 55°C for digestion of protein matter to 
occur. The tubes were then placed on ice for 2 minutes prior to the addition of 500 pi 
of isopropanol. The tubes were then mixed and centrifuged at 12000 rpm for 20 
minutes. The supernatant was removed and the pellet resuspended in 400 pi of 1 x 
TE, pH 8.0.
8.3.1.2 Maxi-preparation o f plasmid DNA
This method was used to isolate and purify IMAGE clone DNA and plasmid DNA 
from bacterial culture. The IMAGE clones were ordered from the HGMP Resource 
Centre and arrived stabbed onto LB agar containing either 50 pg/ml ampicillin or 27 
pg/ml chloramphenicol. These were stored at4°C until required.
Overnight culture (bacterial culture described later) was harvested by centrifugation 
at 6000 rpm for 15 minutes at 4°C. The pellet was resuspended in 10 ml of buffer PI. 
10 ml of buffer P2 was added, mixed and incubated for 20 minutes on ice. This was 
then centrifuged at 13000 rpm for 30 minutes at 4°C. The supernatant was removed 
and re- centrifuged at 13000 rpm for a further 15 minutes to remove any remaining 
residue. Meanwhile, a Qiagen column was equilibrated by adding 10 ml of buffer 
QBT. The supernatant was added to the column, then column was washed twice with 
30 ml of buffer QC. The DNA was eluted with 15 ml of buffer QF. 10.5 ml of 
isopropanol was added, mixed and centrifuged at 11000 rpm for 30 minutes at 4°C. 
The supernatant was removed and 500 pi of 1 x TE, 3 ml of 95% ethanol and 150 pi 
of buffer PE were added. This was then centrifuged for 10 minutes at 11000 rpm. 
The pellet was washed with 5 ml of 70% ethanol by centrifugation at 11000 rpm for 
10 minutes at 4°C. The supernatant was removed and the pellet allowed to air dry for 
5-10 minutes before the DNA was re-dissolved in 200 pi of 1 x TE. The insert 
sequence was checked by direct sequencing prior to use.
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8.3.2 Quantitation of DNA
A 2 pi aliquot of DNA was diluted in 198 pi of sterile distilled water and its 
absorbance measured at 260 nm using a JENWAY 6505 UV Visual Spectrometer. 
The concentration of the DNA was then calculated from the A260 value (1 unit = 
50 pg of double stranded DNA).
8.3.3 RNA extraction and transcription
8 .3.3.1 RNA extraction
Extraction was carried out from embryos. These were weighed and cut into smaller 
pieces for use in the homogeniser to homogenise the tissue in 1 ml Trizol/ 50-100 mg 
tissue. A needle and syringe were used to homogenise the tissue further. The samples 
were then incubated at room temperature for 5 minutes. 0.2 ml chloroform/ ml of 
Trizol was added and shaken by hand for 15 seconds. This was incubated at room 
temperature for 2-3 minutes and centrifuged at 10000 rpm for 15 minutes at 4°C. The 
RNA in the upper aqueous phase was removed into a new tube. 0.5 ml of 
isopropanol was added per ml Trizol used. Following incubation at room temperature 
for 10 minutes, samples were centrifuged at 10 000 rpm for 10 minutes at 4°C. The 
pellet was washed in 75% Ethanol (at least 1 ml Ethanol/ ml Trizol), vortexed, and 
centrifuged at 75 000 xg for 5 minutes at 4°C. The Ethanol was removed and the 
pellet air-dried briefly. The pellet was dissolved in 500 pi of sterile DEPC-treated 
water. The absorption of the RNA was measured at 260 and 280 nm to check for 
contamination and run on an RNA gel to check for degradation
8 .3.3.2 Reverse transcription
In an RNAse-free tube, 2.5 pg of RNA and 300 ng of random primers were added 
and brought to a final volume of 11 pi with DEPC-treated water. This was incubated 
at 70°C for 10 minutes and transferred to ice. For each sample 2 pi\ of 100 mM DTT, 
2 pi of 5mM dNTPs and 4 pi\ of first strand buffer were mixed and added to the 
primers/ RNA mix. The tubes were incubated at 42°C for 2 minutes. 1 pi\ of the 
reverse transcriptase Superscript II was added and incubated at 42°C for 1 hour. 
Following this first strand synthesis, the products were used for PCR.
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83.3.3 Real-Time PCR
Real-time PCR was carried out in an ABI 7000 machine. Each reaction was set up in 
triplicate for accuracy. For each reaction 30 ng of cDNA was used, 5 pmol of each 
primer (either exonic primers for the target gene, Frem2 or the internal control gene, 
Gapdh) and 12.5 \i\ of 2x Sybr Green (Qiagen), in a total reaction volume of 25 ]i\. 
The samples were kept on ice until inserted into the machine to reduce primer 
dimers.
The reaction programme was run as follows: 95°C- 15 mins, 40 x (95°C- 15s, 55°C- 
30s, 72°C- 30s). The results were downloaded into an Excel document and analysed 
using the DART-PCR version 1 programme to obtain expression values (R0) for each 
triplicate/ experimental group. The expression values were then normalised (sample 
RJ  Gapdh R0) and the fold difference was calculated (normalised R0 of one 
experimental group/ normalised R0 of experimental group).
8.3.4 Amplification of DNA by Polymerase Chain Reaction (PCR)
8 .3.4.1 Selection o f primer pairs for genotyping
The primer sequences for amplifying known STS sites were found using Ensembl 
and the Genome database and ordered through either MWG or Qiagen. Microsatellite 
repeats were amplified by using forward primers labelled with either 6-FAM or TET 
fluorescent dyes, which emit blue or green light respectively. The primer sequences 
used for genotyping and their optimal conditions are given in Table 8.1.
83.4.2 Primer design for direct sequencing
PCR primers for amplifying exons were designed from the genomic sequence using 
the Primer3 programme, ensuring they had 50-60% GC content, were 20-22bp in 
length, had no repeat sequences and were approximately 50bp away from the 
beginning/ end of the exon. Forward and reverse primers were selected that had 
similar melting temperatures. The primer sequences used for direct sequencing and 
their optimal conditions are given in Tables 8.2- 8.6.
203
8.3.4.3 Genotyping and Sequencing PCR
The following reaction conditions were used for most genotyping and sequencing 
PCRs. Some reactions required a higher concentration (up to 3 mM) of MgCl2. Each 
reaction was carried out in a volume of 25 pi, containing:
2 pi of genomic DNA (20-50 ng)
2.5 pi 10 x HotStar buffer
2.5 pi dNTP mix (200 pM of each dNTP)
2 pi of each primer (5 pmol/ pi)
0.5 pi MgCl2 (1.5 mM)
0.15 pi HotStarTaq polymerase (0.75 units)
13.35 pi sterile water
A negative control was prepared for each reaction, using 2 pi of sterile water instead 
of DNA as well as a positive control using 2 pi of control DNA, known to give a 
product of the correct size. The tubes/ plates were sealed and placed in the 
thermocycler. The samples were denatured at 95 °C for 15 minutes to activate the 
HotStar Taq polymerase, which was used to reduce any non-specific priming and 
extension. This was followed by 35 cycles of amplification, consisting of a 
denaturation step for 30 seconds, an annealing step at an optimal temperature for the 
primers used for 10 seconds, and an elongation step at 72°C for 30 seconds. These 
cycles were followed by a final elongation step at 72°C. The PCR products were 
checked by electrophoresis of an aliquot of each sample.
8.3.4.4 PCR Optimisation
The optimum annealing temperature for each primer pair was established by carrying 
out gradient PCR. This varies the annealing temperature from 50°C increasing in 
subsequent lanes to 60°C. The standard PCR reaction mix as described and control 
DNA were used. Initially an MgCl2 concentration of 1.5 mM was used, the optimal 
concentration could be established by increasing the concentration in 0.5 mM 
increments.
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8.3.5 Agarose gel electrophoresis
The concentration of the agarose gel used was dependent on the size of the fragments 
that were being electrophoresed. The agarose was weighed and added to the 
appropriate volume of 1 x TAE buffer. This was then heated in the microwave to 
dissolve the agarose and then cooled and the 10 mg/ml ethidium bromide added to a 
final concentration of 0.2 mg/ml. The gel was then poured into a gel tray of a suitable 
size containing a comb. The gel was left to set for approximately 30 minutes. The gel 
was then placed into a tank and covered with 1 x TAE. The comb was then removed 
and the samples added. The samples were prepared by adding a suitable volume of 
loading dye to the sample and mixing. The appropriate DNA ladder was also loaded 
and electrophoresis carried out at 50-220V until the fragments had separated 
sufficiently. The DNA fragments in the gel were then visualised by exposure to UV 
light on a transilluminator, and photographed.
8.3.6 Purification of PCR products
PCR amplification was carried out and electrophoresed on an agarose gel. Samples 
for which only one band was present were purified by ExoSAP-IT in order to remove 
excess primers, nucleotides and single stranded DNA. For samples containing more 
than one band, gel extraction was carried out to purify the fragment of the desired 
size.
83.6.1 ExoSAP-IT
For each 20 pi PCR reaction, the following were added:
2.0 pi Shrimp alkaline phosphatase (2 units)
0.5 pi Exonuclease I  (10 units)
0.5 pi dilution buffer
2.0 pi sterile water
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This was mixed and then incubated in a thermocycler at 37°C for 15 minutes and 
then 80°C for a further 15 minutes to inactivate the enzymes. The exonuclease 
digests any single stranded DNA (such as the primers) and the shrimp alkaline 
phosphatase catalyses the release of 5’-phosphate groups from DNA and dNTPs, 
preventing digested fragments from reannealing.
8.3.6.2 Gel extraction
Gel extraction was carried out using the Qiagen QIAquick gel extraction kit and 
following the manufacturers instructions. The desired bands were excised from the 
gel and placed in a 2ml eppendorf tube and weighed. Three times the gel volume of 
buffer QG was added to each tube and incubated at 55°C for 10 minutes to solubilise 
the gel. One gel volume of isopropanol was added to each tube and mixed. The 
solution was then added to a spin column and centrifuged at 12000 rpm for 1 minute. 
The filtrate was discarded and a further 0.5 ml of QG were added to each column and 
centrifuged again at 12000 rpm for 1 minute to remove any remaining agarose. The 
filtrate was removed and 0.75 ml of buffer PE were added to each column and 
incubated at room temperature for 2-5 minutes, prior to centrifugation at 12000 rpm 
for 1 minute. The filtrate was removed and the columns placed in a clean eppendorf 
tube. 30 pi of buffer EB was added to the centre of each column and incubated for 1 
minute at room temperature. The columns were then centrifuged at 12000 rpm for 1 
minute to elute the DNA.
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8.3.7 Genotyping
8.3.7.1 Preparation o f genotyping plate
Microsatellite amplification products were diluted 1 in 20 in sterile water. These 
dilutions were then used as the PCR pool for the subsequent steps. As different 
reactions contain fragments of different sizes and labelled with different dyes, 
different PCR products can be pooled together for each individual and detected in a 
single lane. For each PCR pool, the following was set up in a 96 well skirted plate:
2.0 pi PCR pool 
0.5 pi ET-ROX size standards
7.5 pi sterile water
The size standards enable accurate sizing of PCR products of up to 550 bp. The 
samples were then denatured for 2 minutes at 95°C and run on the MegaBACE.
8.3.7.2 Running genotyping on the MegaBACE 1000
Prior to genotyping, matrix tubes and buffer tubes and plates need to be prepared. Six 
matrix tubes were taken from storage at 4°C and brought to room temperature. Six 2 
ml tubes and a skirted 96 well plate were filled with 1 x linear polyacrylamide (LPA) 
buffer (provided by Amersham Pharmacia Biotech). The capillaries in the 
MegaBACE were rinsed with distilled water and filled with matrix. Following matrix 
equilibration and a short pre-run, the capillaries were rinsed again. A preinjection 
step was carried out to reduce the salt content of the samples. Following this step, the 
samples to be genotyped were injected into the MegaBACE at 3000 V for 45 
seconds. Both the cathode and anode stages of the MegaBACE need to have LPA 
buffer present (in a plate/ tubes) to complete the current flow. The run can then 
commence at 10000 V for 75 minutes. The run results were analysed using the 
Genetic Profiler programme.
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8.3.7.3 Genotyping mice
Homozygote my mice can be identified by their obvious phenotype. To distinguish 
between wt and heterozygous myUcl mice a SNP (dbSNP; rs6252442) was identified 
in intron 18, in wildtype mice allele at this location is a C, in mutants it is a G. 
Following PCR amplification using the primers FS2MGT2, the region containing the 
SNP was sequenced and the allele present identified, therefore wt, heterozygous and 
homozygous mice and embryos can be distinguished.
To distinguish between wt and heterozygous myKst mice, a PCR was carried out using 
primers contained within the fi-geo cassette of the mutants. Presence of a PCR 
product indicates the presence of the genetrap cassette. This method enables wt mice 
to be distinguished between heterozygous and homozygous mice and embryos, 
however it does not distinguish between heterozygous and homozygous mice and 
embryos, which has to be done on the basis of phenotype. At embryonic stages 
earlier than El 1.5, at which point blebs first appear, there is no way of distinguishing 
between heterozygotes and homozygotes. The point of insertion has not been 
determined. The genetrap cassette inserted into intron 4, which is 40 kb in length, 
and as yet it has not been possible to confine the region into which it has inserted. 
Once this has been done PCR primers can be designed which will distinguish 
between heterozygotes and homozygotes.
PCR primers have been designed which enable genotyping of the bl mice which have 
the mutation 7313CC-»AA. Two sets of primers are used, one set for amplification 
of the wt sequence and the other for the amplification of the mutant sequence. The 
two products are of different sizes and can be readily distinguished on a 2% agarose 
gel.
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8.3.8 Sequencing
8.3.8.J Cycle sequence
Cycle sequencing reactions were set up using either the DYEnamic ET dye 
Terminator Cycle Sequencing kit or BigDYE (Amersham Pharmacia Biotech) for the 
MegaBACE. This uses the dideoxynucleotide chain termination method for 
sequencing. The dideoxynucleotides are incorporated into the DNA sequence during 
the annealing step and act as chain terminators by preventing further 
deoxynucleotides from being incorporated in to the product. The dideoxynucleotides 
are incorporated at different positions along the length of the molecule to be 
sequenced. Each of the dideoxynucleotides is labelled with a different coloured 
rhodamine dye and flourescein. Fluorescein absorbs light energy from the incident 
laser light and transfers it to the rhodamine dye, which then emits light at the 
characteristic wavelength for that dye. This can then be detected and the nucleotide 
identified.
For the DYEnamic ET dye Terminator system, 3 pi (100-200 ng of DNA template) 
of ExoSAP-ITed PCR product was added to a mix containing 1 pi of either the 
forward or reverse primer (5 pmol/pl) 2 pi of the DYEnamic ET dye Terminator 
premix, 2 pi of dilution buffer and made up to 10 pi with sterile water. The plates 
were sealed and placed in the thermocycler for 26 cycles of denaturing at 95°C for 
20 seconds, annealing at 53-57°C for 15 seconds and extension at 60°C for 4 
minutes.
For the BigDYE system, 3 pi (100-200 ng of DNA template, 200-300 ng plasmid 
DNA) of ExoSAP-ITed PCR product was added to a mix containing 1 pi of either 
the forward or reverse primer (5 pmol/pl) 1 pi of the BigDYE premix, 2 pi of 
dilution buffer and made up to 10 pi with sterile water. The plates were sealed and 
placed in the thermocycler for 36 cycles of denaturing at 95°C for 20 seconds, 
annealing at 53-57°C for 5 seconds and extension at 60°C for 4 minutes. Prior to 
reaction clean-up, 20 pi of sterile water was added to each reaction.
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8.3.8.2 Sephadex clean-up
Sephadex plates were prepared by adding dry Sephadex powder to 96 well plates and 
adding 300 [i\ of sterile water. The plates were then incubated at room temperature 
for 3 hours to swell the resin and then stored at 4°C. Prior to use, the plates were 
brought to room temperature and then centrifuged at 910 x g for 5 minutes at room 
temperature with an alignment frame and collection plate underneath the sephadex 
plate, to compact the resin. Excess water was discarded. The resin was then washed 
to remove any salts or ions present by adding 150 pi of sterile water to each well and 
centrifuging at 910 x g for 5 minutes at room temperature. The water in the 
collection plate was again discarded. The cycle sequencing products were then added 
to the centre of each well and centrifuged at 910 x g for 5 minutes at room 
temperature. The products were collected in a fresh skirted 96 well plate under the 
sephadex plate.
8.3.8.3 Running sequencing on the MegaBACE
Prior to sequencing, matrix tubes and buffer tubes and plates need to be prepared. Six 
matrix tubes were taken from storage at 4°C and brought to room temperature. Six 2 
ml tubes and a skirted 96 well plate were filled with 1 x linear polyacrylamide (LPA) 
buffer (provided by Amersham Pharmacia Biotech). The capillaries in the 
MegaBACE were rinsed with distilled water and filled with matrix. Following matrix 
equilibration and a short pre-run, the capillaries were rinsed again. The samples to be 
sequenced were then injected into the MegaBACE at 2000 V for 60 seconds. The run 
can then commence at 9000 V for 100 minutes. On completion of the run, the 
Cimmaron 3.12 ALIGNED base caller was used to assign the bases present in the 
sequence.
8.3.8.4 Sequence Analysis
The Sequencher 4.1 programme was used to analyse the sequences produced. Files in 
ABD format were downloaded into Sequencher, along with a file containing the 
known sequence for that exon/ region. These were then aligned to each other. 
Anomalies where the sequences did not align or where there was a discrepancy 
between the sequences were then checked to identify any possible changes in 
sequence that could be a mutation.
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8.3.9 Restriction enzyme digestion
For most digests, 1 ng of DNA was digested with 1.5 units of the required restriction 
enzyme(s) with the appropriate buffer in either 25 pi or 50 pi reactions. Bovine 
serum albumin (BSA) was added if required. The reaction was incubated at 37°C for 
either 2 hours or overnight. In some cases, the enzyme was heat inactivated by 
incubation at 65°C for 10 minutes. For BsrGI digests, to confirm the presence of a 
mutation, 5 pi of PCR product was used with 0.5 units of enzyme and the appropriate 
buffer and BSA in a 25 pi reaction. This was incubated at 37°C for 2 hours. 
Following digestion, the products were run on a 2% agarose gel.
8.3.10 Cloning DNA
Once the insert DNA had been successfully amplified, both the insert DNA and 
vector DNA were digested with the appropriate restriction enzymes and their 
corresponding buffers at 37°C either for two hours, or overnight. The DNA was then 
run on an agarose gel to separate the digested DNA from any undigested DNA. The 
band containing the DNA of the desired length was then cut from the gel and the 
DNA extracted using the gel extraction method described earlier. 2 pi of the insert 
DNA and the vector DNA were then run on an agarose gel alongside molecular 
weight markers to determine the concentration of the DNA. The concentration of the 
DNA was used along with the size of the DNA to estimate the volume of insert DNA 
and vector DNA to use for the ligation step, using the formula:
ng vector x kb insert x 3 (molar ratio of insert/ vector) = ng of insert DNA to 
kb vector 1 use
Once this was calculated, the ligation was set up using the appropriate volumes of 
insert DNA and vector DNA, 1 unit of T4 DNA ligase, 1 pi of 5 x ligase buffer and 
made up to 10 pi with ddHzO and was incubated at 16°C overnight.
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8.3.10.1 Bacterial transformation
5 pi of ligated DNA was added to 100 pi of competent DH5a or BL21 cells in a 14 
ml faclcon tube and incubated on ice for 30 minutes. The cells were then incubated at 
42°C for 90 seconds and then on ice for 2 minutes. 1 ml of preheated LB was added 
to the cells and then incubated at 37°C for a further 45 minutes in an orbital shaker, 
before being centrifuged for 1 minute at 6000 rpm to pellet the cells. The cells were 
resuspended in 200 pi of LB and spread onto LB agar plates containing the 
appropriate antibiotic and incubated overnight at 37°C.
8.3.10.2 Bacterial culture
Single colonies were inoculated into 2 ml of LB containing the appropriate antibiotic 
and incubated in an orbital shaker at 37°C for 4 to 6 hours. 1 ml was then inoculated 
into 100 ml of LB containing the appropriate antibiotic in a sterile conical flask and 
incubated at 37°C in an orbital shaker overnight. For glycerol stocks, 140 pi of the 
overnight culture was added to 40 pi of 80% glycerol and stored at -80°C.
Colonies were tested to determine whether the ligation had occurred correctly by 
either carrying out colony PCR or by restriction enzyme digestion of maxi- 
preparated DNA. Colony PCR involves inoculating the colonies into sterile PCR 
tubes and carrying out PCR using appropriate primers. The PCR reaction includes an 
extra denaturing step at 95°C for 15 minutes to denature the cells and release the 
DNA.
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8.3.11 Calcium Binding Assays
8.3.11.1 Calx-j3 domain cloning
For the calcium binding assays, the second FREM2 calx-p domain was amplified 
from human kidney cDNA using primers containing linkers for BamHI and EcoRI, 
which were used to clone the domain into the pGEX-4TI vector, enabling eukaryotic 
expression. Another construct containing the mutation was also cloned using a 
second set of primers to introduce the mutation (Figure 8.7). These primers were 
used with the linkered primers to clone the mutated domain into pGEX4TI. Once the 
constructs were correctly ligated they were transformed into E.coli BL21 Gold 
competent cells (Stratagene) to enable expression of the GST-fusion proteins.
8.3.11.2 Induced expression o f GST-fusion proteins
A single colony was used to inoculate 1 ml of LB + Ampicilllin and cultured at 37°C 
overnight with shaking at 250 rpm. The next morning, 50 p\ of the overnight culture 
was used to inoculate 1 ml of LB (containing no antibiotic) and incubated at 37°C 
with shaking for 2 hours. For the non-induced control, 200 p\ of the culture was 
removed at this stage and placed on ice. IPTG was added to the remaining culture, to 
a final concentration of 20 mM. The culture was then incubated for a further 4-6 
hours to induce expression of the GST fusion proteins. 10-20 p\ of the samples were 
then loaded onto a polyacrylamide gel.
8.3.11.3 SDS- polyacrylamide gel
10% polyacrylamide gels of 1 mm thickness were used for all polyacrylamide gel 
electrophoreses. First the resolving gel was poured, and once set, the stacking gel 
was poured on top and combs added.
Samples for electrophoresis had 2x sample loading buffer added, before denaturation 
at 95°C for 5 minutes. The samples, plus markers, were then loaded onto the gels and 
run in 1 x SDS PAGE running buffer at 200 V for 1 hour.
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8.3.11.4 “Stains-All” staining
Following electrophoresis, the gels were rinsed in 25% isopropanol three times and 
then washed twice in 25% isopropanol for 15 minutes. This was followed by 30 
minute washes in 100% isopropanol, water and then a final wash in 100% 
isopropanol. The gels were then incubated in Stains- all (l-ethyl-2- [3-( 1-ethyl- 
naptho [1,2-d] thiazolin-2-ylidene) -2-methylpropenyl] naptho [1, 2-d] thiozolium 
bromide) staining solution in the dark for an hour. Finally the gels were rinsed in 
25% isopropanol, dried using a vacuum drier and photographed.
8.3.11.5 Western blotting
Following electrophoresis, the gels were dismantled and placed in Western blotting 
apparatus as shown below:
-White side of cassette 
"Sponge
Whatmann '    ■<------------Membrane
paper^^3M r j ' 1 1 ~ Gel
-Sponge
'Black side of cassette
Figure 8.4: Diagram showing western blotting apparatus.
The sponges, Whatmann 3M paper, membrane and gel were soaked in transfer buffer 
prior to being used. The case was then clamped together, placed in the chamber and 
filled with transfer buffer. The blot was then run at 200 Amps for 2 hours at 4°C.
8.3.11.6 Ruthenium red staining
Following transfer to a nitrocellulose membrane, the membrane was washed in 
buffer A twice for an hour at room temperature. The membranes were then overlaid 
with 25 mg/ litre ruthenium red in buffer A for 30 minutes. The membranes were 
washed in buffer A and photographed.
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8.3.12 Embryology
Matings were set up overnight using the desired animals and females were checked 
for vaginal plugs (indicating mating) the following morning, this was taken to be 
embryonic day E0.5. The females were then separated from the males and once the 
embryos had reached the desired stage, the females were culled by cervical 
dislocation and the embryos harvested into ice cold PBS. The embryos were then 
dissected from the uterus and either fixed whole in 4% paraformaldehyde (PFA)/ 
PBS or were dissected further, for example to obtain embryonic hearts, which were 
also fixed in 4% PFA/ PBS. Fixation was either carried out at room temperature 
overnight (for in situ hybridisation or embedding) or for 1 hour at 4°C for X-gal 
staining.
8.3.13 X-gal staining
For whole mount staining of embryos upto E12.5 the embryos were harvested and 
briefly fixed in 4% PFA/ PBS for 1 hour at 4°C. These were then washed in rinsing 
buffer twice for 30 minutes each and then incubated in staining buffer 3 hours - 
overnight at 37°C in the dark. The embryos were then rinsed in PBS and postfixed in 
4% paraformaldehyde. For light microscopy, the embryos were dehydrated, cleared 
in Hisotoclear and embedded in paraffin wax. Sections were taken at 8-12 pim and 
counterstained with eosin or nuclear fast red.
For embryos older than E l2.5 the embryos were fixed in 4% PFA/ PBS for 1 hour at 
4°C, equilibrated in 30% sucrose/ PBS and embedded in OCT for cryosectioning at 
8-12 pim. The sections were then dried at room temperature for 2 hours, fixed for 2 
minutes in 4% PFA/ PBS and rinsed twice in PBS. The sections were then incubated 
in X-gal staining buffer for 2 hours- overnight at 37°C in the dark, postfixed, rinsed 
in PBS and counterstained with eosin or nuclear fast red.
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8.3.14 In situ hybridisations
8.3.14.1 Probe linearisation
The vector containing the probe of interest was linearised using an enzyme on the 
opposite side of the insert to the promoter. For Frasl in situs an image clone for 
Frasl exons 72-73 (transmembrane domain) was obtained in a pCMV-Sport6.1 
vector. Upon ensuring the vector had been linearised by running on an agarose gel, 
Proteinase K was added to a final concentration of 50 pglm\ and the sample 
incubated at 37°C for thirty minutes. Phenol/chloroform extraction was then carried 
out twice to purify the sample. This was followed by ethanol precipitation in which 
0.1 x volume of the sample of 3M sodium acetate and 2.5 x sample volume of 100% 
ethanol were added to the sample. This was then incubated at -70°C overnight. Next 
the sample was centrifuged at 4°C for 15 minutes. The pellet was rinsed in 150 //I of 
70% Ethanol and centrifuged for a further 5 minutes and resuspended in ddH20  for a 
final concentration of ~1 mg/ml,
8.3.14.2 Transcription
The linearised probe was transcribed with the appropriate enzyme (T3, T7 or SP6 
polymerase). For sense (control) the Frasl probe was linearised with Notl and 
transcribed using SP6 polymerase. For the antisense Frasl probe the construct was 
linearised with Sail and transcribed using the T7 polymerase. For a 30 p\ reaction, 1 
pg f DNA template was used as well as 20 mM of nucleotide mix, including 
digoxygenin labelled-UTP, 40 units of RNAse inhibitor and 10 mM DTT. This was 
incubated at 37°C for 2 hours, upon which the probe was precipitated by addition of 
100 //I 1 x TE, 10 p\ of 4M LiCl and 300 p\ absolute ethanol and then incubating at 
-70°C overnight. The probe was centrifuged at 4°C for 15 minutes and washed firstly 
with 70% ethanol and then absolute ethanol. The pellet was dissolved in 15-25 p\ 
water for a final concentration of ~1 mg/ml. The probe was denatured by heating to 
95°C for 3 minutes and diluted to a final concentration of 500-1000 ng/ml in 
hybridisation buffer and stored at -20°C until required.
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8.3.14.3 Embryo pretreatments
Embryos were dissected and fixed in 4% PFA/ PBS for 4 hours- overnight, 
depending on their size. The embryos were then placed in absolute methanol, in 
which they were stored at -20°C until required. The embryos were rehydrated 
through 75%, 50% and 25% methanol in PTW, allowing the embryos to settle 
between the changes (2-5 minutes). Next, the embryos were washed twice in PTW 
for 10 minutes each. Proteinase K was then added to a final concentration of 10 
pg/m\ and the embryos were incubated at room temperature for 30 minutes. The 
Proteinase-K was then removed and the embryos were rinsed with a small volume of 
PTW, before being post-fixed in 4% PFA/ PBS for two hours.
8.3.14.4 Prehybridistaion and hybridisation
The post-fixing solution was removed and the embryos were washed twice briefly 
with PTW. The embryos were then incubated for lOminutes in hybridisation solution 
at room temperature. The embryos were then placed in fresh hybridisation solution 
and incubated at 68°C for 2 hours to overnight. Following prehybridisation, the 
hybridisation solution was replaced with the appropriate probe, diluted in 
hybridisation solution and incubated at 68°C overnight.
8.3.14.5 Post-hyhybridisation washes
The probe was removed and the embryos rinsed twice in a small volume of pre­
warmed hybridisation solution at 68°C. The embryos were then washed three times 
with pre-warmed hybridisation solution for 15 minutes each at 68°C. Next the 
embryos were washed for 20 minutes with prewarmed 1:1 hyb soln: TBST at 68°C. 
The embryos were then rinsed three times for 5 minutes with 1 x TBST at room 
temperature and washed three times for 30 minutes with 1 x TBST at room 
temperature. The embryos were then blocked in in situ blocking buffer for 3 - 4  
hours. This was followed by incubation with antibody incubation medium, which 
consisted of a 1:2000 dilution of anti-DIG-AP antibody at 4°C overnight on a rocking 
platform.
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8.3.14.6 Post-antibody washes
Following incubation with antibody incubation medium, the embryos were rinsed 
three times with 1 x TBST and then washed three times for an hour each in 1 x TBST 
on a rocking platform at room temperature. Next, the embryos were washed twice for 
10 minutes with NTMT at room temperature.
8.3.14.7 Developing
To develop the staining, the embryos were incubated in NBT/ BCIP solution in the 
dark until the colour had developed sufficiently. After the colour had developed, the 
reaction was stopped by washing twice for ten minutes in 1 x TBST. The embryos 
were post-fixed in 0.1% formaldehyde for 2 hours- overnight at room temperature.
8.3.15 Preparation of sections
8.3.15.1 TESPA treatment o f slides
Slides were dipped in 10% hydrochloric acid/ 70% ethanol, followed by distilled 
water and then 95% ethanol. The slides were then dried in an oven at 80°C for 5 
minutes and allowed to cool. The slides were next dipped in 2% TESPA in acetone 
for 10 seconds. After washing twice with acetone, then distilled water, the slides 
were dried at 37°C, ready for use.
8.3.15.2 Processing and cutting paraffin sections
To prepare embryos for mounting in paraffin, the fixed embryos were washed in PBS 
twice for thirty minutes and then washed in 0.83% NaCl twice for thirty minutes. 
The embryos were then dehydrated in 1:1 0.83% NaCl: absolute ethanol twice for 
thirty minutes, 70% ethanol twice for thirty minutes, 85% ethanol for thirty minutes, 
95% ethanol for thirty minutes and absolute ethanol twice for thirty minutes. The 
embryos were then cleared in Histoclear twice for thirty minutes and then incubated 
in 1:1 Histoclear: Paraffin for 20 minutes at 70°C. Finally the embryos were 
incubated in paraffin three times for 30 minutes -  1 hour at 70°C before being 
orientate appropriately in moulds.
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Sections were prepared from pre-embedded whole mount in situ embryos. 8-12 pim 
sections were cut using an 820 Rotary Microtome Sections were floated onto 
TESPA-treated slides, covered and allowed to dry.
8.3.15.3 Processing and cutting cryosections
Fixed embryos were rinsed in PBS and then placed in 30% sucrose/ PBS to 
equilibriate. Once equilibriated, the embryos were briefly placed in OCT to remove 
any residual sucrose. The embryos were then placed in moulds in the correct 
orientation and covered in OCT. The mountant was frozen by placing the samples on 
dry ice. The samples were then cut at 10-12 pim on a cryostat and collected on 
Superfrost + slides and stored at -80°C until required.
8.3.15.4 Counter staining
The slides were de-waxed in 250ml of Histoclear twice for 10 minutes, and then 
placed in 250ml of 100% ethanol for 5 minutes to remove the Histoclear. The slides 
were transferred through a series of ethanol, 90% ethanol, 70% ethanol and then 50% 
ethanol for 5 minutes each. The slides were then transferred to 250ml of distilled 
water for 2 minutes, then fresh distilled water for a further 2 minutes. Cryosectioned 
samples were placed straight from PBS into distilled water. All slides were then 
placed in either 1% eosin for 10 minutes or were placed in nuclear fast red for 30 
seconds and briefly dipped in distilled water to remove any excess stain. Finally the 
slides were dipped quickly through the ethanol series of dilutions, beginning with 
50% ethanol and terminating in 100% ethanol. The sections were then mounted 
under coverslips in DPX.
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8.3.16 Immunohistochemistry on cryosections
Cryosectioned samples were dried for 2-3 hours at room temperature. The samples 
were bordered using a wax pap pen and rinsed in 1 x TBS three times for 5 minutes 
each. The samples were then blocked using 1% fetal calf serum/ TBS for an hour at 
room temperature. The samples were then rinsed in 1% TBS and incubated with the 
appropriate primary antibody at the required dilution in blocking buffer either 
overnight at 4°C or for an hour at room temperature. The primary antibody was then 
removed and then samples rinsed again in TBS three times for 5 minutes. This was 
followed by incubation with the corresponding secondary antibody at the required 
dilution in blocking buffer, along with Hoechst stain for nuclear staining, for an hour 
at room temperature, in the dark. The samples were then rinsed again in TBS and 
mounted under a coverslip in 20% glycerol, with the edges of the coverslip sealed 
with nail varnish to prevent dehydration. The samples were kept in the dark until 
ready to be photographed.
8.3.17 Optical projection tomography (OPT)
OPT generates “optical sections” to be made through a specimen by focusing on a 
particular plane of that specimen. The various sections can then be mapped together 
to form a 3D representation of the specimen. The specimen is embedded in a column 
of 1% low melting point agarose gel. The specimen was placed in apparatus that 
rotated it through 360 degrees, through angular steps of 0.9 degrees, around a single 
axis while holding it in position for imaging. A digital image of the static specimen 
was taken at each of the 400 rotated positions. To reduce scattering and refraction of 
light as it passed through the specimen, the rotating specimen was immersed in 
Murray’s Clear during imaging (a 1:2 mixture of benzyl alcohol and benzyl 
benzoate). After the 400 images were taken, virtual sections were independently 
reconstructed using a back-projection algorithm producing high-resolution 
representations of sections through the specimen.
2 2 0
Samples lightly X-gal stained were fixed and sent to the MRC Human Genetics Unit 
in Edinburgh for OPT analysis. The samples were then prepared and scanned as for 
unstained specimens. Reconstruction of the embryo gave a detailed 3D description of 
the expression pattern. The production of a 3D data set for the specimen enables the 
sample to be virtually sectioned in any orientation, allowing accurate determination 
of the sites of expression (Sharpe et al. 2002).
apparatus for rotating 
the specimen
agarose
cy lin d er
lenses of microscope
Figure 8.5: A schematic of OPT microscopy. The specimen is rotated within a 
cylinder of agarose while held in position for imaging by a microscope. Light 
transmitted from the specimen (blue lines) is focused by the lenses onto the camera- 
imaging chip (CIC) and reconstructed to form a 3D image of the specimen (Sharpe et 
a l 2002).
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8.3.18 Auditory function analysis
8.3.18.1 Startle response test
In order to test auditory function the startle response test was carried out, in which a 
“click-box” emitting a high frequency signal is used to determine whether or not 
mice respond to the auditory stimulus. The mice to be tested were held on the 
forearm (to detect small twitching responses) and the high frequency signal was 
emitted from the click box, which was held a foot away from the mouse. The testing 
was carried out away from other mice quiet environment in order to prevent distress 
to the other mice. The response was graded, with 1 corresponding to a startle 
response, 0.5 corresponding to a small startle or ear twitching and 0 corresponding to 
no response.
8.3.18.2 Oto-acoustic emissions (OAEs)
Adult mice were anaesthetised and a probe was securely placed in its ear. The probe 
emits sounds of varying frequencies into the ear, and the sound reflected back is 
measured, therefore any defects resulting in the sound not being reflected can be 
detected. This was repeated for both ears of each mouse tested.
8.3.18.3 Reaching response
The reaching response test measures the ability of a mouse to right itself on being 
held upside down, therefore detects vestibular defects. The mouse is held upside 
down by its tail and lowered towards a surface. Mice normally curl up towards their 
tail and on sighting the surface reach towards it.
2 2 2
8.3.18.4 Preparing cochleas
The inner ear was dissected from the skull of adult mice. The cochlea is encased in a 
bony covering, the bulla, which was removed. To prevent disruption of the 
membranes of the cochlea it was not pierced as usual. In order to soften the bony 
material of the cochlea, the lightly fixed cochleas were placed in 0.5M EDTA for 2-3 
days, following this the cochleas were stained with X-gal solution and rinsed twice in 
PBS for 30 minutes each. The cochleas were then placed in 30% sucrose overnight 
with rotation to equilibriate them. OCT was aliquoted into a glass vial and a vacuum 
drawn over it for 30 minutes to de-gas it. The cochleas were then transferred into the 
de-gassed OCT and maintained overnight with rotation to allow the OCT to penetrate 
fully into the cochlea. A vacuum was drawn over the cochleas in OCT for 10 minutes 
to remove any air bubbles in the cochleas. The cochleas were then embedded in OCT 
by orientating them in the correct position over dry ice.
8.3.19 Cell culture
8.3.19.1 Transfection
Murine NIH 3T3 cells were cultured in DMEM media containing 10% bovine calf 
serum and 1% penicillin/ streptomyocin. Cells were transfected using the Effectene 
system (Invitrogen). For each well of a twelve well plate, 500ng of DNA was added 
to 40 p\ of buffer EC. Following addition of 2 p\ of the enhancer buffer, the sample 
was mixed and incubated at room temperature for 2-3 minutes. 3 p\ of the Effectene 
was then added to each sample and incubated at room temperature for 10 minutes to 
allow complex formation. The cells were rinsed in PBS and 500 ml of fresh media 
was added to each well. 150 p\ of media was also added to each sample, mixed and 
200 p\ of the media/ sample mix added to each well of cells. Following incubation 
for 24 hours, the media was changed.
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8.3.19.2 Immunohistochemistry
Forty eight hours post transfection, cells grown on coverslips in 12 well plates were 
fixed using 100% ice cold methanol for 10 minutes. This was followed by three 
washes of five minutes in lx PBS. The coverslips were then blocked in 1% BSA/ 
PBS for an hour at room temperature. The coverslips were then rinsed in PBS and 
the appropriate pimary antibody applied at the correct dilution in blocking buffer. 
The coverslips were incubated in the primary antibody at room temperature 
overnight and then rinsed three times for 5 minutes each in PBS. This was followed 
by incubation with the secondary antibody (at the correct dilution in blocking buffer) 
for an hour at room temperature in the dark. The coverslips were then rinsed three 
times for five minutes each in PBS and Hoechst stain was applied at a dilution of 
1/2000 to each coverslip for five minutes. The coverslips were then rinsed in PBS 
and mounted on slides in 20% glycerol, sealed with nail varnish. The samples were 
kept in the dark until ready to be photographed.
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8.4 PRIMER TABLES
Marker
Allele
size
Range
(bp)
Het.
index
Primer sequences 
forward and reverse, 
(5’ to 3’)
Anneal.
Temp.
(°C)
Mg
Cone.
(mM)
VT
D13S1491 128- 160 - AAGCCACACACAGATGCTAGG CCT CAGCCT CCAT AAT CT CA 55 1.5 tetra
D13S218 187- 195 0.68 G ATTT G AA AAT G AGCAGT CC GT CGGGCACTACGTTT AT CT 55 1.5 di
D13S138 102-110 0.69 TT GATTT G A AAAT GAGCAGT CC CCCTGCAGGGTATGTGTGT 55 1.5 tetra
D13S1288 175-197 0.66 TT CAG AG ACCAT CACGGC CT GGAAA AAT CAGTT G AAT CCT AGC 55 1.5 di
D13S139 127 - 143 0.68 G AGGT CT CT AGCAATAGGT AA AGGG TCTCTGGACGTAAGGGATGTTTA 55 1.5 di
D13S1253 130- 144 0.80 CCT GCATTT GT GTACGT GT CAG AGCCGT GGT AGT AT ATTTTT 55 1.5 di
Table 8.1: Microsatellite repeat markers on chromosome 13q used for genotyping. 
VT; variation type.
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Primer Pair
Primer sequences 
forward and reverse 
(5’ to 3’)
Anneal.
Temp.
(°C)
Mg
Cone.
(mM)
Product 
Size (bp)
FREM2 laf FREM2 lar CCCCGGCT ACAGGAGGAC CT GCGGGT AGT GGAGGAGT 55 1.5 847
FREM2 lbf FREM2 lbr GT G ACT CGGAACTT GCCT CT GCCG AG ACT G ACCCT CAT AG 55 1.5 821
FREM2 lcf FREM2 lcr GCGCCT CTTT G AACTGG AAT GCTGTAGCCCGGACTGAT 55 1.5 848
FREM2 ldf FREM2 I dr TGGCAGCAGCAGGACATA GCACCA CAT GATGTCTGTCA 55 1.5 850
FREM2 lef FREM2 ler GCCACAT GAG AGT GT CT GGA TT CCACCCCTTT AT GG ACAC 55 1.5 848
FREM2 Iff FREM2 Iff CCAT CCTGCCT GTT GAT AGC CTCTTGCCCCAAATGGAC 55 1.5 992
FREM2 Igf FREM2 lgr TT ATT CGTT AT GGGCC AGGA T GCCAT CAT GTTT GT AGCT G A 55 1.5 801
FREM2 lhf FREM2 Ihr CAGT GGT CACCAT CCACAAG GCCT AT CCTT GCC ACTTT C A 55 1.5 810
FREM2 2f FREM2 2r T GT CAGCGATT GAAT GTAT GT G CCT GTTGCTTGTTT CTTT AGCA 55 1.5 490
FREM2 3f FREM2 3r GGCCACAT GGCG AGT GC T CCATTTT CCT GT CAACACAT C 55 1.5 542
FREM2 4f FREM2 4r TT CCTCCTTTT CCT CCCACT AT A AGAGG ACTCGT C A A AGGT GA A 55 1.5 448
FREM2 5f FREM2 5r GCT ATTGCAGTT CT AGGGGTGT GC AGCC A ACTTT G A A ACCT AAT 55 1.5 539
FREM2 6f FREM2 6r G A AGT CCCT A AG AGG A AGCACA ACAATATACCCAGCCAACTGCT 55 1.5 371
FREM2 7f FREM2 7r T GAAACAT GGATAAAGTTCAGCAGC TGGA AGCCCT AGCAA AC A AACAA 55 1.5 545
FREM2 8f FREM2 8r TTGGCAAGTGACTGAATGGAGA T GCAG AT ACCA A A AGGGCATT C 55 1.5 518
FREM2 9f FREM2 9r CCCCAT ACGAATAAGTGCTGGT CCCCATTT GTTT GT CTTTTT GC 55 1.5 533
FREM2 lOf FREM2 lOr AGCTTTT CCTT CCACACACGT C AAC AA AATT GCACTT GT ACCCCTT 55 1.5 507
FREM2 Ilf FREM2 11 r CACCCAAATATACTGGACCACA TC AGT CCTT G AGTTT CG AC A A A 55 1.5 499
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Primer Pair Primer sequences forward and reverse (5’ to 3’)
Anneal.
Temp.
(°C)
Mg
Cone.
(mM)
Product
Size (bp)
FREM2 12f  
FREM2 12r
GCTCT CCAGGGGCT CT GAGT AT 
AAT GA ACCTTT GTT CGGT GA AG A
55 1.5 497
FREM2 13f 
FREM2 13r
AT AAACAGCAT GTGGAAATTGG 
C A A AGC ATT GT GT CT GGC AT A
55 1.5 643
FREM2 14f 
FREM2 14r
GGCCACTAACTGTCTGCTGTGA 
GA AAG A AGTGG AAGGACTT GAAGC
55 1.5 474
FREM2 75/ 
FREM2 15r
GATT ACAGGCAT GAGCCACGT C 
AGTT GTCTGGT CCCTT GCT GT C 55
1.5 648
FREM2 16f 
FREM2 16r
TGCTGT C ATTT CCT CTT CT CAAT G 
CACAT ATT GCACAAA ATTT AAAGCCC
55 1.5 525
FREM2 17f  
FREM2 17r
TTCATTTTGGCTCCCTTTTCTG 
TT GT GG ATT AT GAGGT GAAGCT GA
55 1.5 483
FREM2 18f 
FREM2 18r
ACAGCCCAGTTTCTTCATCTGC 
GGAATCGGAT GT CAAGGT CAAA
58 1.5 536
FREM2 19f 
FREM2 19r
GCTTTGTCTCTGACTTTGCCGT 
A AAGGGC AAAT CT CT CCT CATT C
58 1.5 430
FREM2 20 f 
FREM2 2 Or
G ACTT GAT CCCACCAGTTTT GC 
ACACCAGCCAGAGTGGGTAAAG
58 1.5 473
FREM2 21 f  
FREM2 21 r
GTAGATGAGGGTGGCAAGGA
CTCCCAAAGTGCTGGGACTA
58 1.5 425
FREM2 22 f 
FREM2 22r
ACTGCACTCTAGCCTGGGTGAC 
ACGCT GGGTTT AT GG AGTGCT
60 3.0 550
FREM2 23f 
FREM2 23r
AGTGCTTTGCACAGAGCCTTG 
GT GAGT AACCCT ACCGT GGT GC
58 1.5 539
Table 8.2: Intronic primers used for PCR amplification and sequencing of FREM2. 
Exon 1 is very large and therefore was split into 8 amplimers.
227
Primer pair
Primer sequences 
forward and reverse, 
(5’ to 3’)
Anneal.
Temp.
(°C)
Mg
Cone.
(mM)
Product 
size (bp)
MFREM2 I f  
MFREM2 lr
ACTGTTT CAGCCCAAGG AGA 
GGTT AGCCT CT GCCACACTC 55 1.5
591
MFREM2 2 f  
MFREM2 2r
TT AAAAAT AGTT GGAGAGCAAAACT 
AGCCTT AAA ATT CAAT GT GTT AT GT 53 1.5
600
MFREM2 3 f  
MFREM2 3r
CTGGCTTTGGAAGTTTCGAC 
CT AGAGAGCACGGT GGGAAG 58 1.5
569
MFREM2 4a f 
MFREM2 4ar
TTTCCCCTT CCT CTCCT CT C 
GGCTGAGG AT G AGGT CA AAA 58 1.5 846
MFREM2 4b f 
MFREM2 4br
GAAGAGGAGGT GACCGT GAA 
ACGAGACACCCAGAAT GACC 58 1.5 848
MFREM2 4 c f 
MFREM2 4cr
GT CCACTT CGT CCTGGGT AA 
GCACCAGGCT CAGAGAAATC 58 1.5
768
MFREM2 4df 
MFREM2 4dr
GT CTT CGACAGGCT CCACT C 
GGACAATT CCACTT GGAGGA 53 1.5 822
MFREM2 4 e f 
MFREM2 4er
CCAG AGTACCAGCAGGAAGG 
CATG AT CCCCCT A ACCAGT C 53 1.5 820
MFREM2 4 ff 
MFREM2 4fr
TT CCT CAGTGGT GT GAGCT G 
GTGGT CACACG A A ACACTGG 58 1.5
839
MFREM2 4g f 
MFREM2 4gr
GAATAACAAGGTGGCCATGC 
GT GGGCAT CTT GT CAGGT CT 58 1.5 832
MFREM2 4h f 
MFREM2 4hr
T AGGC AGCCAGT CCCT GTT A 
CCA AGTT CT CCAGCTT CCAG 53 1.5 798
MFREM2 5 f  
MFREM2 5r
CAAT GAAACCAAGGAT GACGAA 
AT CTGGGT GCAGGAT CAGATTT 55 1.5 460
MFREM2 6 f  
MFREM2 6r
CCT CT GT CATTT CATTTT CAGC 
GT CAGGACACTGGGTGGT CT 55 1.5 500
MFREM2 7f 
MFREM2 7r
CACTCAT GCACCTT GACACA AA 
CCT GA AAGAGGGAGGGATTT CT 55 1.5 519
MFREM2 7 c f  
MFREM2 7cr
CATGT GAT GT AGCAGT CAGGAA 
CT CT AGT GATT AAACCATAG 55 1.5 991
MFREM2 8 f  
MFREM2 8r
T CCCT AT CT CCAT CGACACACC 
CACTCCAAGGCCGTTTT GTT 66 1.5 533
MFREM2 9 f 
MFREM2 9r
GCCCCTAG AG AT GT AGCACGA 
CCT CCCT G ACACGGTT CTTTT 60 1.5 443
MFREM2 I Of 
MFREM2 lOr
CCAGT CACTAGGAAACAGCAATGA 
GGACAGT CAGGGCT ACACAGAGA 60 1.5 549
228
Primer pair
Primer sequences 
forward and reverse, 
(5’ to 3’)
Anneal.
Temp.
(°C)
Mg
Cone.
(mM)
Product 
size (bp)
MFREM2 1 I f  
MFREM2 11 r
T GGCT CACGATT CT GAT GTTAC 
AGGCCCT GATT C ATT GTCTG 60 1.5 470
MFREM2 12f 
MFREM2 12r
GCCT CT CTTTT AGGCCT CT CAC 
T AT GC AG AC ACC AGT CTTTT CC 60 1.5 570
MFREM2 13f 
MFREM2 13r
GGGCTTAAGGCACTGTGTCCA
TGGGAGCGTGGTGCTACTGTT 60 1.5 541
MFREM2 14f 
MFREM2 14r
GAG ACT GCCCTTT AT ATT CCC A 
AGAGACACAACTCCCAGGACAT 60 1.5 540
MFREM2 15f 
MFREM2 15r
T CCTGGCTT CTT GT G AACAG 
CAGCTTTT AT GTGGCT GCT G 55 1.5 594
MFREM2 15bf 
MFREM2 15br
CACTCCCTCCCTCTGTCTTCT 
CT CAGTT GTTT GCAGGT CCA 55 1.5 361
MFREM2 16f 
MFREM2 16r
GCATTGGATCTTCTGGAACTTG 
T CCCTT CAAGT AAGCACACACTG 53 1.5 408
MFREM2 17f  
MFREM2 17r
GG AAACAGCACTCATTT GT C 
CT CTACCACCAGCCCACATT 55 1.5 993
MFREM2 18f 
MFREM2 18r
T AGT GAAGACT GCTGCAAATGG 
C ACAGCT GGG AAT AAAAATT CAG A 60 1.5 604
MFREM2 19f 
MFREM2 19r
T GT CGGGTT GT GT AT GCATTTT 
CTC AC A A GCCT GTT GG AG AGGT 60 1.5 534
MFREM2 20f 
MFREM2 20r
A ACAT AGGTTTTCCCACCATT CA 
TTT GGTTT GCCTCCTT CAT CTT 55 1.5 649
MFREM2 20cf 
MFREM2 20cr
TGCATTCTACACAGGATTTGC 
GACATT CTT CAT GTGCTGTT AGC 55 1.5 1188
MFREM2 21 f  
MFREM2 21r
CTCCCGAGT GTT GGGATT AAAG 
ATTTT AAGG AACT CT GGCGCAC 55 1.5 570
MFREM2 21cf 
MFREM2 21cr
CATGCAATAGACT GTATGCCT GA 
GGCAA ATT CAAGGAGTGCAT 55 1.5 974
MFREM2 22f  
MFREM2 22r
TGTCTGT AT GGT GGCAGTTTTC 
CAAGT GCT GGGATT AA AGGCT A 55 1.5 451
MFREM2 22cf 
MFREM2 22cr
CCAAGGCT G A A ACTT GAATAGG 
AGCAAGGCCATTTGTCATCT 55 1.5 999
MFREM2 23f 
MFREM2 23r
AT CG A AT GT CA AGGT CA A AGGT 
ACTATCT GCCCAGGGGAT AAAT 53 1.5 471
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Primer pair
Primer sequences 
forward and reverse, 
(5’ to 3’)
Anneal.
Temp.
(°C)
Mg
Cone.
(mM)
Product
size (bp)
MFREM2 24 f 
MFREM2 24r
ATC A G ATCCCATTA C A G ATGGC 
ATT GTGCCT CTT GGT GTTT CTT 53 1.5 555
MFREM2 25f 
MFREM2 25r
GCTGCAGCCCTT AGGT ACAC 
TGGTT CTGTGGTCTGTGT GTC 55 1.5 975
MFREM2 26f 
MFREM2 26r
CCAAGTTTGCAAGGACAGAAA
CCTTGTCTGAGTCCCTGAGAG 53 1.5 515
MFREM2 27f  
MFREM2 27r
CCACCATT A AACAGGCTT CAAC 
CG AACTGT CT CAAGT GT CAAGG 60 1.5 522
MFREM2 28f 
MFREM2 28r
AT AT GTTGG AT GTTT GTT CCCC 
AT AAG AGCCT GAG ATT G AGCCC 60 1.5 467
MFREM2 5UTRf 
MFREM2 5UTRr
CACCAACT CT CCTT AGCACCTT 
T GTT CT CAAGCT GACTTTCT GC 55 1.5 802
MFREM2 3UTRJf 
MFREM2 3U TRlr
GCAGAGCCACTACAACGACA 
GT G AGGCCGATT AACGAG AG 55 1.5 768
MFREM2 3UTR2f 
MFREM2 3UTR2r
TTT GG ATCT G A ATT GCTT CT C A 
AACGATCAAAGTGACAGAACACA 55 1.5 686
Table 8.3: Intronic primers used for PCR amplification and sequencing of mFrem2 
exons and UTRs. Exon 4 is very large and therefore was split into 8 amplimers. 
Some exons required nested PCR, therefore have two sets of primers. Set c were 
used first, the products were purified using ExoSAPit and reamplified using the 
second set of primers.
230
Prim er Pair
Prim er sequences 
forward and reverse 
(5’ to 3’)
Annealing
Temp.
(°C)
Mg
Cone.
(mM)
Product 
Size (bp)
M Y I f  
M Y lr
ATGATTCCAAGACACTCAGAC
GGATCCAGCCAGACTTCG 53 3.0 610
M Y 2f  
M Y 2r
TCCCTACAGAGGAAGCTATAGTGG
TTCTCCGTAACGAGGCAAAG 55 1.5 500
M Y 3f  
M Y 3r
ACCCAGCTGGAGATTGTGAC
AGGCAGAGGTGAGGTTGAAA 55 1.5 559
M Y 4f  
M Y 4r
GCTTGTGAGGATTCGAGGAG
GCAGAGTCGCTACTGGGAGA 55 1.5 594
M Y 5f  
M Y 5r
TCAATATCGGCCGCTCAC
TATATCCTGTTGCCGCCACT 55 1.5 578
M Y 6f  
M Y 6r
TCAG CTGGTTTTTGTCCTGTT 
GAAGACCAACGTGCCCAGT 55 1.5 496
M Y 7 f 
M Y 7r
CGGATGGTGGTACAGGAATC
ACTCATCCCCGCTATTCCA 55 1.5 598
M Y 8f  
M Y 8r
ACACAGGCCCCCAAACAC
CTCAGGGGCTTGGCTGTC 55 1.5 600
M Y 9f  
MY 9r
GAGGGCTCTGTTGTCTACGC 
G A ATT CCCT CAT G A A C ATTT C 55 1.5 564
M Y lO f 
M Y 1 Or
CACAGAGGAGTGGAGCCTGT
CCCTGGTCCATAACGGATAA 55 1.5 588
M Y I l f  
M Y l l r
CCGAGACACCCAGAATGACC
CCCATCGGTGACTTGAAACT 55 1.5 641
MY 12f 
M Y 12r
CACCATTACCAGGGCTCCTA
CCGTCAGTCACGGTGAAG 55 1.5 495
M Y 13f 
M Y 13r
TTCACGGTCACCTCCTCTTC
GGGTTCTCAAAGCTGCTCAC 55 1.5 562
M Y 14f 
M Y 14r
TTCACCCAAGCTGACATTGA
TCCCTTGCTGTGTGTAGCAG 55 1.5 673
M Y 15f 
M Y 15r
CCTTCCAAGTGGTTCTCTCG
ATTCTGTTTTCCGGGACCTC 55 1.5 600
M Y 16f 
M Y 16r
TTCCAGGTCCTTTTGAGCAT 
CCCTG CCT CGT GTA A C AT CT 55 1.5 578
M Y 17f  
M Y 17r
CACTTGCAACGAGAATGACG
CCTTTGGAGGGATCATCGTA 55 1.5 591
M Y 18f 
M Y 18r
GACGGGGTGAGAGAGATGAG
GAAGCCATGGTGGGTCTTTA 55 1.5 804
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Primer Pair
Primer sequences 
forward and reverse 
(5’ to 3’)
Annealing
Temp.
(°C)
Mg
Cone.
(mM)
Product 
Size (bp)
MY 19f  
MY 19r
TGAACACCAATGGGAATGAA
AAGAGAGCCTTGCAGCTCAG 52 3.0 731
MY 20f  
M Y 20r
CGTTTCCTACGTGTTCCACTC
TCAAGGTCAAAGGTGACAGG 55 1.5 497
M Y 2 1 f
M Y 2 Ir
GAATTCACTCCATCCAACCAGGAGT
GAATTCCAAGGCAACCTGAAAGAGT 52 3.0 560
M Y 2 2 f  
MY 22r
GAATTCGTACAGCCCAGCGAATGC
GAATTCTTCCGTGGGGGACCT 55 1.5 500
MY 23f  
MY 23r
GAATTCGGGGAACAAACATCCAACAT 
G A ATT CACA CCTCCG AGCTGT CGTT G 55 1.5 299
Table 8.4: Exonic primers for RT-PCR amplification and subsequent sequencing of 
mFrem2.
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Prim er
pair
Prim er sequences 
forward and reverse 
(5’ to 3’)
Annealing 
Temp. (°C)
Mg Cone. 
(mM)
Product
size (bp)
EB IF  
E B 1R
TGACATGTAGCGGACCTCTG
GACCTGGGGAATCCACCTAT 55 2.0
394
E B 2F
E B 2R
GAGCTGACATTCAGAGCATCC
GCAGGTTGCAAGATGAATCC 55
2.0 461
E B 3F
EB 3R
GGCAGAAACCCCAGAGAGA
CACGCACGCTGTGCTTCT 55 3.0 591
E B 4F
EB4R
GGACAATCAGAGATAGTAGCACACC
CGAATGCCAATGCTCTTACA 55 2.0
820
EB 5 F 
EB 5 R
AATTGCCTTGCTTGCTCTGT
TCAAGCCATCCCTATCAACA 55 2.0 680
E B 6F
EB6R
CCATTCCCATTGTCAAATGTC
GGTGGTGTCCGGATCTACAG 55 2.0 600
E B 7F  
EB 7R
ACTGCAGGCAACCAGATTGT
AGGTGACACCGAGGTCAAAC 55 2.0
632
E B 8F
EB8R
GTTCCAGGCAGCGTAGAGAG
TCTGGAGTGGCATTTCATCA 55 2.0
822
E B 9F
E B 9R
CCCACCCCAAAATGTTTAAG
TGCTTGTCACTAGGGACTCTGA 55 2.0 584
EB91F
EB91R
CAGTGACTCATGGTGGCTGT
CTAATGAAGCCAGGCTGGAG 55 2.0 769
E B92F
EB92R
GGAGGAGCTGGTAGCTGAGA
TGAATGCATGGCAGGAGTTA 55 2.0 569
EB93F
EB93R
TGCTCACCTGCCTGTATTTG 
CCCTG A A ACTTA CCC AG AT CG 55 2.0 550
EB94F
EB94R
GCCCAGGCTGTGTAGACCT
GCCGTGGAGACTTTCATCTT 55 2.0 829
E B 95F
EB95R
TTCAACGCCTTTGTGTGAGT
GGCCATGAGAGACCCAATCT 55 2.0 339
E B 10F  
EBP 10R
CTAATTCTGCGCCGTAGAGC
CGTGTGACGTGATGATGAGA 55 2.0 420
EB10F
EB10R
CTAATTCTGCGCCGTAGAGC
AGACTCAGGGCCTCACACAC 55 2.0 842
EBP 1 IF  
EBP 11R
GTTGTCACCGTGCCTTTCTT
ACCAGCAATGACCCAAAGAG 55 2.0 531
E B11F  
EB 11R
TGACACTGTGTGCCTGATGT
ATTCTCAGTGCGACGGCATA 55 2.0 842
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Primer
pair
Primer sequences 
forward and reverse 
(5’ to 3’)
Annealing 
Temp. (°C)
Mg Cone. 
(mM)
Product 
size (bp)
EB112BF
EB112AR
AGACAGGGAGTGGTTGTTGG
GAGGATGGAAGACGGCATAA 55 2.0 417
EB112A4F  
EB 112A4R
GGACAGAGAGACAGACACACACA
CAGTACCCCGGAGTTCTTGA 55 2.0 400
EB 112A3F 
EB 112A3R
AGCGTCTTTGATTCCCAGGT
ATGGGGGACTTTTGGGATAG 55 2.0 467
EBU 2A2F
EBU2A2R
GCAGATCTCTTTAGCTCCTTGG
CAGAAGGTGTCCCAACTGGT 55 2.0 482
EB 112CF 
EB 112C2R
TAATTGGCACTGGACAACCA
TGGGCTGACTGAAGACAGAA 55 2.0 499
EB12F
EB12R
AGGTCTTCCTCGGTTGGTG
TGATAATCTGACCAGAATGAGCAG 55 3.0 839
EB13F
EB13R
TTGCCCACAATTGTAACTGG
GCATCCATTCACCTACTGGAC 55 2.0 553
EB14F
EB14R
AGCCTCCTCTGTCCCAAGA
TCTTCTGAGCCCTTACATCCA 55 2.0 583
EB 15F 
EB 15R
GGTCACCTGACCTGAACGAG
TGTCTAAAGGGGACATGATGG 55 2.0 556
E B16F  
EB 16R
TACCGGCATAGCATCCATCT
TTCCATTGCCTCAGAGTGGT 55 2.0 600
EB17F  
EB 17R
ACTTGCAGAGGCAGAAGGTG
GATCGGGCTCTCCTAACACA 55 2.0 689
EB18F
EB18R
GTACTCTCAGAGAAGTGACACAGG
CACTAGGGAACTGCACTGTTG 55 2.0 598
EB 1920F 
EB 1920R
CCGGAAACAATCCATTTGAC
GGGCTAGCTCCTTAGCGATT 55 2.0 675
EB21F
EB21R
TCCATTGGATTCGAGATGTG
CTGAGCCCACAGGAGAAGTC 55 2.0 549
EB22F
EB22R
GGCGAGACTCTTCTCCTTTG
ACATTCAAACGCAAACCACA 55 2.0 588
EB23F
EB23R
GAGAGGTGACCTTCCTGTGG
TGGCCACTCTTTTAAGAAACC 55 2.0 699
Table 8.5: Primers used for PCR amplification and sequencing of the GRIP1 gene. 
Primers that failed to amplify eb DNA, i. e. that are located within the deleted region 
are highlighted.
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Primer pair Primer
letter
Primer position Primer sequences 
forward and reverse (5’ to 3’)
E B 9F
EB9R A
- CCCACCCCAAAATGTTTAAG
TGCTTGTCACTAGGGACTCTGA
EB91F
EB91R B
Intron 9 nucleotide 
3032-3631
CAGTGACTCATGGTGGCTGT
CTAATGAAGCCAGGCTGGAG
EB92F
EB92R C
Intron 9 nucleotide 
5012-5580
GGAGGAGCTGGTAGCTGAGA
TGAATGCATGGCAGGAGTTA
EB93F
EB93R -
Intron 9 nucleotide 
5428-6014
TGCTCACCTGCCTGTATTTG
CCCTGAAACTTACCCAGATCG
EB94F
EB94R -
Intron 9 nucleotide 
5878-6706
GCCCAGGCTGTGTAGACCT
GCCGTGGAGACTTTCATCTT
EB95F
EB95R -
Intron 9 nucleotide 
5542-5880
TTCAA CG CCTTTGTGTG AGT 
GGCCATGAGAGACCCAATCT
EB10F  
EBP 10R D
Intron 9 nucleotide 
6515-6935
CTAATTCTGCGCCGTAGAGC
CGTGTGACGTGATGATGAGA
EB10F
EB10R E
- CTAATTCTGCGCCGTAGAGC
AGACTCAGGGCCTCACACAC
EBP I IF  
EBP 11R F
Intron 10 nucleotide 
417-635
GTTGTCA CCGTGCCTTTCTT 
ACCAGCAATGACCCAAAGAG
E B11F  
EB 11R G
- TGACACTGTGTGCCTGATGT
ATTCTCAGTGCGACGGCATA
EB112BF
EB112AR H
Intron 11 nucleotide 
2140-2557
AGACAGGGAGTGGTTGTTGG
GAGGATGGAAGACGGCATAA
EB 112A4F 
EB 112A4R -
Intron 11 nucleotide 
2581-2980
GGACAGAGAGACAGACACACACA
CAGTACCCCGGAGTTCTTGA
EB 112A3F 
EB 112A3R -
Intron 11 nucleotide 
2344-2811
AGCGTCTTTGATTCCCAGGT
ATGGGGGACTTTTGGGATAG
EB 112A2F 
EB 112A2R I
Intron 11 nucleotide 
3014-3495
GCAGATCTCTTTAGCTCCTTGG
CAGAAGGTGTCCCAACTGGT
EB112CF  
EB 112C2R J
Intron 11 nucleotide 
4250-4748
TAATTGGCACTGGACAACCA
TGGGCTGACTGAAGACAGAA
EB12F
EB12R K
- AGGTCTTCCTCGGTTGGTG
TGATAATCTGACCAGAATGAGCAG
Table 8.6: Primers that failed to produce an amplification product with the eb DNA, 
but produced a product for control C57BL/6 DNA, along with the position of the 
primers. The primer letter correspond to the letters used in Figure 5.7.
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Primer Pair
Primer sequences 
forward and reverse 
(5’ to 3 ’)
Annealing
Temp.
(°C)
Mg
Cone.
(mM)
Product
Size
(bp)
Exons
FS2M 5_2f 
FS2M 5_2r
ATTGGCTCCTGGAAACTTGTCA
AGCTGTTCATTCCCATCAGG
53 1.5 321 4-5
mGapdh f  
mGapdh r
TTCACCACCATGGAGAAGGC
GGCATGGACTGTGGTCATGA 58 1.5 237 -
FS2M GT2f 
FS2M GT2r
CCTCCCACACTGTCAGAAGA
CCAAGTTCTTGTAGTGAGTGACCA 55 1.5 485 -
B G a lf  
BGal r
GCTGCAGGGAGAGTTGAGA
CACCACCAGGTTCACTTCCT 55 1.5 244 -
B lw tf  Bl wtr CTGATATTTTACAGAAGACAAATCC AT AT AT ATGCC AGG ATGTAAC A 55 3.0 284 -
Bl m utf 
Bl mutr
TGTGGAGCTTCTGTCCTTCTT
ATTGGTGATGACGACTGGTGGTTA 60 3.0 219 -
Table 8.7: Primers used for RT-PCR and real-time PCR for my {FS2M5J2), primers 
for control gene amplification (mGapdh) and the primers used to genotype the myUcl 
(FS2M GT2), myKst (BGal) and Bl (Bl wt and mut) mice. The FS2M GT2 primers 
amplify the region in intron 18 containing the dbSNP rs6252442 used to distinguish 
mutants (G) from wt mice (C). The BGal primers amplify a region of the P~geo 
cassette of the Frem2 genetrap mutants. Currently, heterozgous and homozygous can 
not be distinguished by PCR as the precise location of the genetrap insertion is 
unknown.
gatgtgggggtcttccattcccacagtgttcactgtggagcttctgtcctt^tttacataaccagcaaagataaaaatcca
ggactggccccttcctggggcctctgaggaacagctctcagaactcctctgatcttacctcctgggcactcaacctggaac
tgaagaaagggaactggaaacctcccatgacaaaatactgtttctgatattttacagAAGAUA^ATCCCCA
CCAGTCGTCATCACCAATAGAGGGCTGGTCTTAGATGAGAACTCGGT
GGAGAAAATCACTACTGCACAGCTGTCGGCCACCGACCAGGACAGC
AAACCTACAGAACTCATCTACAGGATCACCACTCAGCCCCAGCTGGG
CCACCTGGAACATGTGGCCTCCCCAGgtacgtggtcctctcttgctccatctagccctaggttc
acttcccctaagcaagtgctggggactgttacatcctggcatatatatatatatatatatatatatatatatatatatatagtct
BOLD TEXT = EXON 47 wt primer
ITALICS = SITE OF MUTATION (CC TO AA) mutant primer
Figure 8.6: The location of the Bl genotyping primers. The final two bases of the wt 
forward primer detect the wt sequence (cc), and the final two bases of the mutant 
reverse primer detect the mutant sequence (aa).
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Primer pair Primer sequences 
forward and reverse 
(5’ to 3’)
Anneal
Temp.
(°C)
Product
size (bp)
FREM2Ca2f
FREM2Mutr
at GGA TCCGCC ACTGTTG AG ATCGTTG A 
GGAAGGTTTCCTCCTCCTTGTACAAAGAGTCATCAA 55 330
FREM2Mutf
FREM2Ca2r
TTGATGACTCTTTGTACAAGGAGGAGGAAACCTTCC 
atGAA 7TCCATC ACTTTCGCTGCC AGT A 55 542
FREM2Ca2f
FREM2Cci2r
at GGA TCCGCC ACTGTTG AG ATCGTTG A 
at(MA 7TCCATC ACTTTCGCTGCC AGTA 55 872
Table 8.8: The primers used to clone the Calx-P domain for calcium binding assays. 
Linkered primers to introduce BamHI and EcoRI sites are shown in italics. To clone 
the wt sequence, the FREM2Ca2 primers were used together. To introduce the 
mutation 5914G—>A (red), the FREM2Mut primers were used with the corresponding 
FREM2Ca2 primers. The resulting products contain a region of overlap and were 
therefore “sewn” together using the FREM2Ca2 primers. Extra bases were added 
(lowercase) before the restriction enzyme sites to aid digestion. All PCRs used 1.5 
mM MgCh.
fla/w///GCCACTGTTGAGA TCGTl\iAtccaggagatgagccaactgtgtttattccccagtccaaatactccgttgaagaag
atgttggtgagctgttcattcccatcaggaggagcggagatgtgagccaggagttgatggtggtctgttatacccaacaaggaacagcaactggaa
ctgtgccgacttccgtgttgtcttactctgattacatatccaggcctgaggaccacaccagtgttgtccgctttgacaaagatgaacgggagaaactgt
gtcggatagtcataa 1 1 bA  1 Ga C I T 1^ 1 GTACGAGGAGGAGGAAACCTTCCatgtccttctgagcatgcccat
ggggggaagaatcggatcagagttcccaggggctcaagttacaatcgttcctgacaaagatgatgaacccatcttttacttcggtgatgtggaatact
ctgtggatgagagtgctggctatgtggaagtgcaggtgtggagaacgggcactgacctgtccaagtcttctagtgtcacagtgaggtctcggaaaa
cagatcctccctctgcagatgctggaacagactatgtgggcatcagccgtaatttagattttgcacctggagtcaacatgcagcctgttcgtgttgtcat
tctggatgaccttggacaaccagcgctggagggaattgagaaatttgaactggtgcttcgcatgcctatgaacgcagcccttggcgagcccagcaa
agccacagtgtccataaatgactctgtctccgatttgcctaagatgcaattcaaagaacgaatataTACTGGCAGCGAAAGTGAT
G EcoRI <------------------------------------------<------
+  <r
Figure 8.7: The sequence of the calx-(3 domain used for the calcium binding assays. 
The location of the primers used for PCR amplification is indicated. The green 
sequences/ lines represent the linkered primers and the blue sequences/ lines 
represent the primers used to insert the E1972K mutation (red).
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PG EX-4T-1
T hrom bin
Leu Val P ro  A rg^G ly S e r i  P ro  Glu P he P ro  Gly Arg Leu Glu Arg P ro  His Arg Asp 
CTGGTT CCG CGTGGATCC,CCG .GA ATTC,CCGG £TCGA CTCGAG CGG CCG CATCGTGACTGA 
‘ BamH I ' EcoR I ^ f i l  ^ 1 X h o l N o ,i  S to p  c o d o n s
BspM I
pG E X
-4900 bp
p4.5
Apa I
pBR322
Figure 8.8: Vector map for pGEX-4TI (Amersham). The calx-P domain of FREM2 
was cloned in using the BamHI and EcoRI sites.
Primer pair Primer sequences forward and reverse 
(5’ to 3 ’)
FS1 CR Ecof 
FS1 CR Notr
ccGGAATTC ggATG CAGCAGGGACAGTGTGTGTC 
aaggaaaGCGGCCGC TTA ACTGATCTTTGTGGCTGCAC
FSJ CR Bglf 
FS1 CR Salr
attAGATCT CAGCAGGGACAGTGTGTGTC 
attGTCGAC ACTGATCTTTGTGGCTGCAC
FS1 CR Sal MYC stopr
att GTCGAC TTA CAG AT CTT CTT C AG AA AT A AGTTTTT GTT C ACTGAT CTTT GT GGCT GCAC
Table 8.9: Primers used for cloning the chordin rich (CR) domains of Frasl (aa 500- 
1050). Linkered primers were used to introduce restriction enzyme sites (italics). 
Extra bases (lowercase) were added before the restriction enzyme sites to aid 
digestion and to maintain the correct frame. Initiation and stop codons (bold) were 
also added where required. To create a construct lacking the transmembrane domain 
of pDisplay, a stop codon was added after a myc tag (underlined). All PCRs were 
carried out at 55°C, with 1.5 mM MgCl2. EcoRI and Notl were used to clone the CR 
domains into pCMVmyc. Bgl II and Sal I  were used to clone into pDisplay. The PCR 
products were approximately 1893 bp.
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w * .  = Forward seq u en c in g  
prim er
sx uz m  et: a»
C ACC ATG GCA TCA ATG CAG AAG CTG ATE TCA GAG GAG G AC CTG CTT
M-rcuq
«eo tat too n o  cc
ATG GCC ATG GAG GCC CGA ATT CGG TCG ACC GAG ATC TCT CGA GGT ACC GCG GCC GC 
S/»f“  fcoftl SWI* BgJ II X b o f  N o t I
Figure 8.9: Vector map of pCMV-Myc (Clontech), used for cloning of Frasl CR 
domains. The CR domains were cloned in using the EcoRI and Notl sites.
pDisplay
5.3 kb
Figure 8.10: Vector map for pDisplay (Invitrogen) used for cloning the CR domains 
of Frasl. The signal peptide and transmembrane domain enable secreted/ 
tansmembrane expression of the cloned protein.
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Fraser syndrome and mouse blebbed phenotype caused 
by mutations in FRASl/Frasl encoding a putative
extracellular matrix protein
Lesley McGregor1, Ville Makela2, Susan M D arling1,3, Sofia Vrontou4, Georges Chalepakis4, Catherine Roberts1, 
Nicola Smart1, Paul Rutland2, Natalie Prescott2, Jason H opkins3, Elizabeth Bentley3, Alison Shaw3, Emma Roberts3, 
Robert Mueller5, Shalini Jadeja1, Nicole Philip6, John N elson7, Christine Francannet8, Antonio Perez-Aytes9, Andre 
Megarbane10, Bronwyn Kerr11, Brandon W ainwright12, Adrian S W oolf13, Robin M W inter2 & Peter J Scambler1
Fraser syndrome (O M IM  219000) is a multisystem 
malformation usually comprising cryptophthalmos, syndactyly 
and renal defects1. Here we report autozygosity mapping and 
show that the locus FS1 at chromosome 4q21 is associated 
with Fraser syndrome, although the condition is genetically 
heterogeneous. Mutation analysis identified five frameshift 
mutations in FRAS1, which encodes one member of a family of 
novel proteins related to an extracellular matrix (ECM) 
blastocoelar protein found in sea urchin. The FRAS1 protein 
contains a series of N-terminal cysteine-rich repeat motifs
previously implicated in BMP metabolism, suggesting that it 
has a role in both structure and signal propagation in the ECM. 
It has been speculated that Fraser syndrome is a human 
equivalent of the blebbed phenotype in the mouse2, which has 
been associated with mutations in at least five loci including 
b P  As mapping data were consistent with homology oIFRAS1 
and bl , we screened DNA from bl/b l  mice and identified a 
premature termination of mouse Frasl. Thus, the bl  mouse is a 
model for Fraser syndrome in humans, a disorder caused by 
disrupted epithelial integrity in utero.
Figure 1 D evelopm ental an o m a lie s  of 
in d iv id u a ls  w ith F raser syndrom e a n d  b l  m ice , 
(a) Ind iv idual w ith F raser synd rom e with 
c ry p to p h th a lm o s  of both  eyes, (b) Indiv idual 
w ith F rase r syndrom e w ith c u ta n e o u s  
syndacty ly , (c) Adult b llb l  m ouse  w ith 
c ry p to p h th a lm o s . (d ,e) A dult b l/b l  m ice  w ith 
syndac ty ly  of th e  h in d lim b . (f) An E 1 4 .5  b l/b l  
em bryo w ith a p ro m in en t b le b  over th e  rum p 
and  sm a lle r  b leb s  over th e  h ead  an d  fo relim b, 
(g-j) T ransm ission  e lec tro n  m ic ro g rap h s  
show ing d e rm al-ep id e rm al ju n c tio n  in 
h e te rozygous  (g,h) an d  b l/b l  (i,j) em bryos a t 
E l l . 5  (g ,i) an d  E 1 4 .5  (h,j). P artia l sep a ra tio n  
of a de rm al cell from  th e  d e rm al-ep id e rm a l 
ju n c tio n  c a n  be seen  a t  th e  le ft e d g e  of th e  
pho tom icrog raph  in i, and  a b leb  c an  be seen  
in j. Arrows in d ica te  th e  b a se m e n t m em b ran e , 
w hich is a t ta c h e d  to  th e  ep id e rm al layer b u t 
not th e  derm al layer in b l/b l  em bryos. 
M agnification  i s x l 5 ,0 0 0 .
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Figure 2 Homozygosity of 4 q 2 1  m arkers in Fraser syndrom e, (a) P ed ig rees  of fam ilie s  1 -8 .  
H aplotype analysis for fam ily 1 is shown for th e  interval en co m p assin g  m arkers D4S2367  and  
D4S2361, with homozygosity in individual V.3 th roughou t th e  analyzed region an d  in individual V.9 
betw een m arkers D4S2363  and  D4S2964. (b) Fine reso lu tion  m aps of th e  FRAS1 region of 
4 q l 3 - 2 1  in fam ilies 1 -6 ; th e  vertical bars  rep re sen t th e  sm a lle s t region of hom ozygosity in each  
affec ted  individual. A ffected indiv iduals from  fam ilies  7 an d  8  had  a num ber of heterozygous 
m arkers across th e  region and therefo re  show ed no ev idence  of linkage to  4 q l 3 - 2 1 .  The FRAS1 
critical interval was de te rm ined  to  be from  D4S2393  to  D4S2922, a region of approxim ately  1 .5  
cM. The ex ten t of th e  region of hom ozygosity com m on to  ped ig rees  1 - 5  is in d ica ted  by th e  arrows. 
M arker D4S3139  is not polym orphic in h u m an s b u t is in FGF5, Fgf5 b eing  th e  d ista l flanking 
m arker to  bl. Four c an d id a te  g en es  w ere sc ree n ed  for m u ta tions: NR4A1, ANXA3, PDM8 and 
FRAS1. Their relative positions a re  in d ica ted  by red bars . The FGF5 locus in h u m a n s  (m arked by an 
aste risk ) in non-polym orphic.
Fraser syndrom e presents w ith c ryp tophthal­
m os (90% ), cutaneous syndactyly (62%; Fig. 
1), ear abnorm alities (59% ), renal agenesis 
(45% ) and  congenital heart defects (12%; ref.
1). In  45%  o f  cases, affected individuals are 
stillborn o r die in the first year; surviving 
infants are often developm entally delayed. 
Several o f  these abnorm alities are found in 
areas tem porarily  fused during  em bryogene- 
sis, suggesting that failure to  rem odel these 
regions is secondary to  an abnorm ality  o f  
apoptosis4. A ttention has also been draw n to 
sim ilarities betw een Fraser syndrom e and the 
effects o f  hypovitam inosis A4-6.
We initiated an autozygosity scan o f Fraser 
syndrom e pedigrees, concentrating first on  
pedigree 1, which included two affected indi­
viduals and m ultiple inbreeding loops (Fig.
2). Hom ozygosity on  chrom osom e 4q 
encom passing m arkers D4S2363-D4S2964, 
approxim ately 1.5 cM, co-segregated w ith 
affection status in pedigree 1. M ultipoint lod 
score analysis generated a lod o f 3.0 across 
this region assum ing an autosom al recessive 
m odel w ith com plete penetrance7. We 
detected homozygosity overlapping this 
interval in seven additional families. There 
was no shared ancestral haplotype, and hap­
lotype analysis d id  not allow any further n a r­
rowing o f  the interval. The linked region 
contains the genes A N X A 3  (encoding annexin 
A3), FGF5 (encoding fibroblast g row th factor 
5) and  BMP3 (encoding bone m orphogenetic 
protein 3). The m urine hom ologs o f  these 
genes are linked to bl, w ith  A nx3  showing a 
single recom binant in 479 meioses (E.B. and 
S.M.D., m anuscrip t in preparation).
We identified candidate genes in the 
hom ozygous region (Fig. 2), and we detected 
no m utations in A N XA3, NR4A1 (nuclear 
receptor subfamily 4 group A m em ber 1, also 
called N A K l; a gene w ith sim ilarity to 
Drosophila melanogaster NUM B-associated 
kinase) o r PRDM 8  (PR dom ain-contain ing  
8). The Ensembl server predicted four genes 
proximal to  AN XA3, each o f  which had 
sequence sim ilarity to genes encoding m em ­
bers o f  the same set o f  ECM proteins. In addi­
tion, the m ouse hom ologs o f these sequences 
were present in a gene-targeting event giving a 
null phenotype (lacZ inserted at codon 162) 
closely resembling that o f  the various blebbed 
m utant mice (G.C., m anuscript subm itted). 
Thus, we concluded the four predicted genes 
were part o f  a single large gene. We generated 
the hum an cDNA sequence from  expressed- 
sequence tag (EST) clones and determ ined 
genomic organization by com parison with the 
corresponding genomic DNA. The gene, 
FRAS1, encodes a predicted protein o f 4,007 
am ino acids w ith 85% identity to  Frasl. We
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Figure 3 M utations of F R A S1  or F r a s l in ind iv iduals  w ith F raser 
syndrom e or in th e  bl m ouse, (a -e ) E lec tropherog ram s of m u ta tio n s  
iden tified  in five u n re la ted  fam ilie s  w ith F raser syndrom e. We observed  
hom ozygous m u ta tio n s  in all a ffe c te d  ind iv idua ls  av ailab le  from  
ped igrees 1 -6 . (a) D etection  of a 8620C -V T  (Q 2863X ) n o n sen se  
m utation  in exon 5 8  in fam ily 1. (b) D etection  of a 9 0 3 1 C -» T  (Q 3000X ) 
nonsense  m utation  in exon 61  in fam ily 2 . (c) D etection  o f a 5 6 0 5 in s T  
fram esh ift m utation  in exon 4 1  in fam ily 3 . This m u ta tion  re su lts  in 
term ina tion  of th e  protein th re e  am ino  a c id s  later, (d) D etec tion  of a 
38 2 9 C -F T  (Q 1266X ) non sen se  m u ta tion  in exon 2 9  in fam ily 4 .
(e) D etection of a 43 0 1 C -» G  (S 1423X ) n o n sen se  m u ta tio n  in exon 3 1  in 
fam ily 5 . (f) N onsense m uta tion  7313C C-»A A  (S 2 2 0 0 X ) w as d e te c te d  in 
exon 4 7  in th e  b l m ouse. This m u ta tion  w as not d e te c te d  in n in e  o th e r 
m ouse s tra in s  (the  exac t background of b leb b ed  is unknow n; P. G lenister, 
pers. com m .). All m u ta tions  a re  shown in th e  s e n s e  s tra n d  an d  were 
verified on reverse-strand  seq u e n c in g . The DNA supp ly  w as ex h au s te d  in 
family 6 , so  m uta tion  analysis  could  not be co m p le ted .
A R T R G G A fl T R 6  T
a  A *
Exon 58 Family 1 
(8620 C-»T) Q2863X
A R C R G G
Exon 29  Family 4 
(3829 C—»T) Q1266X  
T T C R 6  R
Exon 61 Family 2 
(9031 C-»T) Q3000X
R R C R 6  T
A
ACT 6 R 6
Exon 31 Family 5  
(4301 C->G) S1423X  
R C I  C R G
/YVYW
R T I T T  T T T T
I
Exon 41 Family 3 
5605insT (Frameshift) 
R T  T T T T T T
Exon 47  bl Mouse 
(7313C C —>AA) S2200X  
R T C C C C
designed prim ers to amplify the 75 individual protein-encoding exons 
o f FRASl for direct sequencing. In pedigree 1 we detected the  sequence 
change 8620C—»T resulting in prem ature term ination  o f the protein 
product (Q2863X; Fig. 3a). We found four additional m utations in 
unrelated families that m apped to 4q (Fig. 3 b -e), each predicted to 
result in loss o f  function. There was no correlation between the  posi­
tion o f the m utations in the predicted protein sequence and  the  specific 
Fraser syndrom e phenotype.
We undertook  gross anatom ical analysis because the  bl phenotype, 
unlike that o f  my, another blebbed strain8, has n o t been well d ocu­
mented. The bl/bl mice had cryptophthalm os and distal lim b defects 
(Fig. l c - e ) .  Examples o f  a bleb overlying the rum p, lim b bu d  and 
head can be seen in Figure If. Transmission electron m icroscopic 
analysis o f  bl mice indicated that separation o f  the  basem ent m em ­
brane from  the derm is began at around em bryonic day (E) 11.5 
before developm ent o f  overt blebs (Fig. lg - j) ,  consistent w ith  results 
of earlier studies o f  the my  phenotype9.
& Figure 4  Expression of FRAS1  or F ra sl. (a) Expression of FRAS1  in hum an  tissue . Rows A-C of a M ultiple Tissue Expression array (C lontech) were hybridized with hum an  FRAS1  cDNA. The filter was stripped  and  
rehybridized with a  hum an ubiquitin  cDNA (rows A '-C '). A l,  w hole brain;
A2, left cerebe llum ; A3, blank; A4, heart; A5, esophagus; A6, tran sv erse  
colon; A7, kidney; A8, lung; A9, liver; A10, promyelocytic leukem ia, HL- 
60 ; A l l ,  fetal brain; A12, yeast total RNA; B l,  cerebral cortex; B2, right 
cerebellum ; B3, a ccu m b en s nucleus; B4, aorta; B5, s tom ach ; B6, 
descend ing  colon,- B7, skele ta l m uscle; B8, p lacen ta; B9, p an creas ; B IO , 
HeLa S3; B 11, fetal heart; B 12, yeast tRNA; C l ,  frontal lobe; C2, co rpus  
callosum ; C3, tha lam us; C4, left atrium ; C5, duodenum ; C6, rec tum ; C7, 
spleen; C8, bladder; C9, adrenal gland; CIO , chronic m yelogenous 
leukem ia, K -562; C l l ,  fetal kidney; C 12 , E sch erich ia  c o l i  RNA. (b) Whole- 
m ount hybridization of E 1 2 .5  wild-type forelim b bud , show ing expression  
of F rasl in th e  apical ectoderm al ridge, (c) W hole-m ount hybridization of 
E 15 .5  wild-type h indlim b bud, showing expression of F ra s l  in th e  
interdigital sp ace s, (d) Transverse section  of w ild-type forelim b bud a t 
E l 1 .5 ; arrow ind ica tes expression a t ap ical ectoderm al ridge, (e) Transverse 
section of wild-type hindlim b bud a t E l  1 .5 ; arrow in d ica tes  expression  a t 
apical ectoderm al ridge, (f) Transverse sec tion  of w ild-type em bryo a t E12 
at level of h indlim b bud. Expression can  be seen  in th e  ep ith e lia  of th e  skin 
(s), peritoneal lining (p), m esonephric  d u c t (m) an d  posterio r card ina l vein 
(v). (g) Transverse section  of a w ild-type E 12  em bryo a t th e  level of th e  eye 
showing expression in ep ithe lia  of th e  skin (s) an d  a b u ttin g  th e  b asem en t 
m em brane of th e  lens c ap su le  (I). The gap  betw een skin and  lens is a  tea r 
tha t occurred  during  sam ple  processing .
We isolated genom ic DNA from  bl/bl em bryos and  am plified 74 
pro tein -coding  exons for sequencing. We detected the  m uta tion  
7313CC—>AA, which resulted in a p rem ature  stop codon  (S2200X; 
Fig. 3f). Thus, m uta tions in FRASl cause one form  o f  hu m an  Fraser 
syndrom e and  m uta tions in Frasl underlie  the bl phenotype in 
m ouse. T he sim ilarity o f  the bl and  F rasl-knockout phenotypes sug­
gests th a t the  m uta tions we describe are null.
a
1
A
B
C
A' *
B'  •
cr*
2 3 4 5 6 7 8 9 10 11 12
•  *
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L E T T E R S
FRASl is expressed in  m any ad u lt tissues, w ith  h igher levels o f  
expression in  kidney, pancreas and  th e  thalam us o f  the  b ra in ; it was 
relatively highly expressed in  fetal kidney and  heart (Fig. 4a). We 
exam ined expression o f  Frasl in  m ouse em bryos from  E9.5-E14.5 
using w hole-m ount hybrid ization  and  sections o f  w hole m ounts. 
Frasl was particularly  highly expressed in the  apical ectoderm al 
ridge o f  the lim b buds from  E10.5-E12.5 (Fig. 4 b ,d ,e ), an d  expres­
sion was also detected in the interd ig ital spaces a t E14.5 (Fig. 4c). 
Transverse sections showed that F rasl was expressed in  cells ju st 
underlying the surface epithelium  o f  the entire  em bryo  (Fig. 4 d -g )  
and in  the linings o f  the  peritoneal cavity (Fig. 4f) an d  dorsal aorta
Figure 5 Kidney abnorm alities  in b lebbed  (bl/b l) m ice, (a) Kidney with 
gross cysts  from a b l/b l  m ouse a fte r weaning, (b) Transverse sec tio n  of 
E l 1 .5  b l/b l  em bryo a t level of lower limb. One m etan ep h ro s  is recognizab le  
(arrows) with condensing  m esenchym e (m) a d jacen t to  th e  u reteric  bud (u). 
The con tra la teral organ is rep resen ted  by a d ila ted  ep ithe lia l s tru c tu re  
(asterisk) surrounded  by poorly co n d en sed  m esenchym e. The neural tu b e  
(nt) is shown on th e  left, (c) E 1 3 .5  b l/b l  m e taneph ros  (m t) is sm all and  
poorly d ifferen tiated , g, developing gonad, (d) E 1 3 .5  m etan ep h ro s  (m t) 
from a wild-type em bryo with developing  gonad (g). (e) Higher 
m agnification of th e  b l/b l  m etanephros d ep ic ted  in c show ing m any d en se , 
irregular s tru c tu res  typical of apop to tic  nuclei, (f) Higher m agnification  of 
the  w ild-type m etanephros shown in d show ing developing  tu b u le s  (t) 
surrounded by m esenchym e an d  s trom a with norm al n u c lear morphology.
(g) Som e m etanephric  kidneys from b l/b l  m ice a p p ea r norm al; kidney from 
an E 1 5 .5  b l/b l  em bryo show ing form ation  of th e  first layers of glom eruli 
(arrows) s im ilar to  wild-type organs (d a ta  not show n). Bars are 7 0  pm  in b-d 
and g and  3 5  pm  in e and  f.
(data  no t show n). At E12, expression was also detected in the  
m esonephric  duct (Fig. 4f) and  in the  lens (Fig. 4g).
Som e observers have ascribed th e  fo rm ation  o f blebs to  epiderm al 
fragility o n  the  basis that the  back, head, tail and  lim b buds m ake 
physical contact w ith the u terine  w all10. T he lim b and  eyelid defects 
are th o u g h t to  be secondary to  m echanical interference w ith the  
developm ent o f  those structures. Some su p p o rt for this m echanism  
com es from  the asym m etrical na ture  o f  the  lesions and  inconsistency 
o f  the  digits involved in the  syndactyly. A lthough the presence o f  
grossly visible blebs (such as in Fig. le )  probably interferes w ith  
developm ent o f  surface structures and  causes m alform ation , such an 
exp lanation  canno t be invoked for the  renal abnorm alities. 
Additionally, h u m an  hereditary  skin blistering conditions affecting 
the basem ent m em brane zone result in post-nata l blistering and do  
no t have renal o r cardiac m alfo rm ations11. We therefore exam ined 
renal anatom y and  histology in bl mice.
M ost bl/bl m ice died  before b irth , bu t a few reached adu lthood  
where they, like hum ans w ith  Fraser syndrom e, show ed n o  signs o f  
skin b listering, such as those seen in  the  genoderm atoses. Cystic k id ­
neys did occur in som e bl/bl survivors (Fig. 5a). A lthough cystic dys- 
plastic kidneys occur in 12% o f  cases o f  Fraser syndrom e, the m ost 
co m m o n  u rin ary  trac t m alform ation  is renal agenesis (th a t is, the  
organ  can  n o t be detected radiographically  o r at autopsy), w hich 
occurs in 45%  o f  cases1. T he bl/bl em bryos had in tact m esonephric  
kidneys b u t from  E l 1.5 and  E l5.5 show ed a range o f defects in  the  
m etanephric  k idney (Fig. 5 and  data n o t show n). E11.5-E12.5 
em bryos had  a dilated ureteric bud  (Fig. 5b) w ith less b ranching th an  
in w ild -type m ice (data no t show n). By E13.5-E14.5, kidneys o f  
m u tan t m ice were developm entally delayed, being m uch  sm aller th an  
those o f  w ild-type m ice (Fig. 5c,d). In these mice, the m etanephric  
m esenchym e was poorly d ifferentiated w ith  m any cells having 
pyknotic  nuclei suggestive o f  apoptosis (Fig. 5e,f), which could result 
in renal agenesis later in developm ent. But 20%  o f  em bryos had rela­
tively norm al m etanephric developm ent, including the fo rm ation  o f  
glom eruli by E15.5 (Fig. 5g). O f 146 live-born  bl/bl survivors, 2 had 
grossly cystic kidneys and 20 had com plete unilateral agenesis.
The phenotype described above suggests that although m etanephric 
kidneys form , they are developm entally delayed and  later degenerate. 
From  this, we predicted th at in th e  h um an  condition  at equivalent 
stages (5 -10  weeks gestation), em bryos w ith m utations in FRAS1 
w ould have m alform ed kidney rud im ents undergoing apoptotic  
degeneration , as has been described in non-syndrom ic hum an  dys- 
plastic k idneys12. Therefore, FRASl probably has a role in 
m etanephric  differentiation and survival (for example, in the  genera­
tio n  o f  nephrons and  collecting ducts) bu t is probably n o t im plicated 
in the  form ation  o f  the m etanephric m esenchym e o r initial outgrow th 
o f the  ureteric  bud. The degeneration o f  early bl/bl m etanephric ru d i­
m ents resem bles that observed in mice w ith  m utations o f  a 8 p l  inte- 
g r in 13; o ther genes, including BCL2 (B-cell CLL lym phom a 2; ref. 14), 
BM P7  (encoding bone m orphogenetic p rotein  7) and  FGF2 (encoding 
fibroblast grow th factor 2; ref. 15), have been im plicated in  m ain tain ­
ing the  m etanephric kidney after it begins to form .
We interrogated protein  databases and  found that FRAS1 shares 
sequence sim ilarity w ith ECM3, a com ponent o f  extracellular m atrix  
fibers that undergo dynamic reorganization during  sea urch in  gastru- 
la tio n 16. In  the ECM3-like region, there is a dom ain  w ith  sequence 
sim ilarity to  the chondroitin  sulphate proteoglycan NG2, and  m o tif 
searches predict the presence o f  CALX-p dom ains, a transm em brane 
dom ain  and  short intracellular dom ain  (Fig. 6), as for ECM3. The 
function  o f  the CALX-p dom ains is entirely speculative, given th a t 
they are otherw ise found intracellularly; the NG2 proteoglycan binds
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L E T T E R S
Figure 6  P red icted  FRAS1 protein s tru c tu re . The 
protein is 4 ,0 0 7  am ino a c id s  in length  and  has 
an N -term inal signal p ep tid e  followed by VWFC 
dom ains, furin-like dom ains, an  NG2-like region, 
CALX-p m otifs, a  tran sm em b ran e  dom ain  an d  a 
cytosolic tail. The chordin-like dom ains  are 
overlapping th e  regions co n ta in ing  th e  VWFC and  
furin m otifs (dark bar). The four n onsense  
m uta tions identified  in exons 2 9 , 3 1 , 5 8  and  61  
and  th e  fram esh ift m utation  iden tified  in exon 
41  are positioned relative to  th e  protein 
dom ains, and  th e  equ iva len t position of th e  b l  
m utation  in F ra s l is ind ica ted .
Exon 29 31 41
X X  FS
I I I
(4,007 Amino acids)
Q  Signal peptide 
Q  VWFC dom ains
200 Amino acras
(bl M ouse) Exon 47
A CALX-p domain 
♦ NG2-like domain
T ransm em brane domain
Chordin dom ains
|  Furin-like dom ains I -I Cytosolic tail X, FS Stop, Frameshift mutation
bFGF and PDGF-AA17. At least part o f ECM3 is proteolytically cleaved 
after translation, raising the  possibility that a p ro p o rtio n  o f  FRASl 
becomes part o f  the ECM w ithout necessarily having direct cellular 
a ttachm en t16. At the  N term inus, there are m otifs no t found  in ECM3 
that have strong sim ilarity to a num ber o f  proteins contain ing the cys­
teine-rich furin  dom ains (som etim es term ed subtilisin /kexin/propro- 
tein convertase dom ains), von W illebrand factor type C (VW FC) 
dom ains, overlapped by chordin/kielin-like d o m ain s18. Furin 
dom ains have been associated with the m odulation o f  BMP and o ther 
TGFji-related p rotein  activity by endoproteolytic cleavage o r seques­
tra tio n 19,20. Five blebbed m utations have been described, and  four 
have chrom osom al localizations3. BLAST searches o f  the hu m an  and  
m ouse genomes identified several novel genes w ith significant s im ilar­
ity to F R A Sl, although none have the VWFC or furin  dom ains.
The position o f  the blister form ation resembles that seen in dys­
trophic epidermolysis bullosa, which is associated w ith dom inant and 
recessive m utations o f type VII collagen, some form s o f which involve 
traum a-induced blistering21. In hum ans with Fraser syndrom e and in 
blebbed mice, the lack o f any post-natal traum a-induced blistering and
® the resolution o f the m ouse blebs themselves during late gestation point to a requirem ent for FRAS1 during a specific window o f developm ent. 
This may be because FRAS1 is required for the initial establishm ent o f  
various epithelial structures but not required postnatally because, at 
later stages o f  developm ent, another protein compensates for lack o f 
FRASl. Skin w ound repair is a prime example o f a difference in the bio­
logical behavior o f  fetal and post-natal epithelium, as it is well docu­
m ented that fetal w ounds heal w ithout scarring whereas in later life 
tissues heal w ith fibrosis, contracture and imperfect reconstitution o f 
skin structures. It is known that scar-free healing is a property  o f  the tis­
sue itself rather than the intrauterine environm ent and that differences 
in m atrix deposition underlie the phenom enon, w ith tighter control o f  
TGFp isoform activity also having an influence22. It is conceivable that 
Frasl has a role in this differential healing response, and w ounding 
experiments in bl/bl em bryos could test this hypothesis.
O n  the basis o f  the  phenotype we observed in the m utan ts and  the 
predicted protein structure o f  FRASl and F rasl, we propose that there 
is a m id-gestational developm ental defect due to a defective ECM. This 
may be accom panied by a secondary d isrup tion  o f  signaling, p a rticu ­
larly o f TGF(3 family m em bers. A relationship betw een the  insoluble 
m atrix and soluble factors du ring  lim b pa ttern ing  has been show n in 
mice w ith knockouts o f  b o th  Fbn2 (encoding fibrillin 2) and  Bmp7, 
which develop syndactyly and  have reduced apoptosis23. In  the kidney, 
the m etanephrogenic m esenchym e defaults to  an apoptotic  fate unless
rescued by appropria te  signaling24. The sites o f m alform ation  in  Fraser 
syndrom e and  histology o f  diseased bl kidneys suggests a defect in 
apoptosis secondary to  the  m olecular m utation . A detailed study o f  
the sites and  tim ing  o f  apoptosis and any altered cellular proliferation 
in bl m u tan ts will be required to  investigate this m odel further. In  later 
em bryos, we p redict that these various abnorm alities lead to  a fragility 
o f  surface structures and subsequent b lebbing, w ith a secondary phys­
ical interference w ith  developm ent. Requirem ent for FRAS1 seems to 
be restricted to  the  em bryonic period; thus, the bl m ouse m odel 
should  provide insights in to  the developm ent o f  epithelial structures.
METHODS
Families. We obtained inform ed consent and extracted DNA from the periph­
eral w hole blood o f  family m em bers and controls using a standard protocol as 
described23. Inclusion criteria were the presence o f  cryptophthalm os and at 
least one other feature o f  Fraser syndrom e. The study was conducted under 
ethical approval from  Gt. O rm ond St. Hospital for Sick Children N H S Trust.
Genotyping and mutation screening. We used Research Genetics and ABI 
primers for STRP analysis, custom -m ade (Genosys) primers being synthesized  
for fine m apping. G enotyping was carried out on an ABI377 sequencer. We 
identified individual exons for both genes by BLAST analysis o f  the appropri­
ate genom e database and used these to  design intronic and, where required, 
exonic primers (sequence and PCR conditions available on  request). We 
sequenced am plim ers w ith an Amersham MegaBACE 500 and compared them  
to samples from an unaffected control and from  parents. We analyzed 
sequences using Sequencher v4.1 software.
Mouse breeding. We obtained +/bl m ice from  the MRC (Harwell). Live-born 
+ lbl m ice were initially typed for the linked Fgf5  (angora) m utation and later 
for the Frasl m utation. The work was carried out w ith UK H om e Office 
approval. We prepared DNA using standard m ethods. DNA from  strains AKR, 
CD 1, C3H, BALB/c, 101, CBA, C57BL/6, SWR and CAST were a gift from  P. 
Stanier (Imperial College, London, UK) and J. M urdoch (M edical Research 
C ouncil, Harwell, UK).
Expression analysis. We radioactively labeled hum an EST IMAGE 2815699 by 
random  prim ing and hybridized the probe to a Clontech M ultiple Tissue 
Array (#7776-1) according to the manufacturer’s instructions. We then 
stripped the probe from the filter and rehybridized it w ith ubiquitin as a 
housekeeping gene control. We used m ouse EST IMAGE 3496602 for w hole- 
m ount hybridization o f  m ouse embryos as described previously26. We post­
fixed em bryos after in situ  hybridization overnight in 4% paraformaldehyde 
and phosphate-buffered saline. We then dehydrated em bryos through an 
ethanol series ending with 100% ethanol. This was followed by two 30-m in  
incubations in Histoclear and one 20-m in incubation in 50:50 Histoclear:wax
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at 60 ~C. After three changes o f  wax for 20 m in each, we placed em bryos in 
m olds and allowed the wax to set. Sections were cut at 13 ,um and floated onto  
slides treated with 3-am inopropyltriethoxysilane before being counter-stained  
with eosin and m ounted in DPX m ountant (B D H ).
Photography. We viewed and photographed sections using a Zeiss Axioplan 2 
microscope.
Histology. We fixed embryos in form ol saline and dehydrated and em bedded  
them in paraffin wax. We cut 10-pm  serial sections and stained them  with 
Masson’s Trichrome.
Ultrastructural analysis. We removed limbs from embryos and fixed them  for 2 
h at 40 °C in half-strength Karnovsky fixative, rinsed them  in cacodylate buffer 
and post-fixed them in 1% osm ium  tetroxide. After a further rinse in buffer, we 
washed the specimens briefly in water and stained them  en bloc in 2% aqueous 
uranvl acetate. After dehydration through graded alcohols and finally propylene 
oxide, we polymerized the limbs in resin at 65 °C. We cut sem i-thin and ultra- 
thin sections using a Reichert-Jung Ultracut E ultratome and collected them  on 
copper grids. The grids were then stained with 2% aqueous uranvl acetate and 
1% aqueous phosphotungstic acid2'. We viewed sections using a JEOL 1010 
transmission electron microscope and analyzed the derm al-epiderm al junction 
as described2'. We carried out protein m otif predictions using the PFSCAN, 
TMHMM and RPSBLAST28 facilities at EC San Diego Supercomputer Center.
URLs. Ensembl server, http://w ww .ensem bl.org/H om o_sapiens/; BLAST 
search, http://www.hgm p. mrc.ac.uk/Registered/W ebapp/blast/index.htm l;
San Diego Supercomputer Center, http://workbench.sdsc.edu.
Accession numbers. F R A S l , AJ512501; FR ASl segm ents predicted by 
Ensembl, Q96JW7, 000 5 4 9 , Q 9H 6N9 and Q9P228.
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A direct functional link between the multi-PDZ domain 
protein GRIP1 and the Fraser syndrome protein Frasl
Kogo Takamiya1, Vassiliki Kostourou2, Susanne Adam s2, Shalini Jadeja3, Georges Chalepakis4, Peter J Scambler3, 
Richard L Huganir1 & Ralf H Adams2
Cell adhesion to extracellular matrix (ECM) proteins is crucial 
for the structural integrity of tissues and epithelial- 
mesenchymal interactions mediating organ morphogenesis1'2. 
Here we describe how the loss of a cytoplasmic multi-PDZ  
scaffolding protein, glutamate receptor interacting protein 1 
(GRIP1), leads to the formation of subepidermal hemorrhagic 
blisters, renal agenesis, syndactyly or polydactyly and 
permanent fusion of eyelids (cryptophthalmos). Similar 
malformations are characteristic of individuals with Fraser 
syndrome and animal models of this human genetic disorder, 
such as mice carrying the blebbed mutation (6/) in the gene 
encoding the Frasl ECM protein3 4. GRIP1 can physically 
interact with Frasl and is required for the localization of Frasl
to the basal side of cells. In one animal model of Fraser 
syndrome, the eye-blebs (eb) mouse, G rip l  is disrupted by a 
deletion of two coding exons. O ur data indicate that GRIP1 is 
required for normal cell-matrix interactions during early 
embryonic development and that inactivation of G rip l  causes 
Fraser syndrome-like defects in mice.
The g lu tam ate  receptor interacting proteins GRIP1 and GRIP2 form  a 
sm all fam ily o f cytoplasm ic p ro teins first isolated as in teractors o f  
AM PA-type g lu tam ate receptors'1. Both contain  seven PD Z dom ains, 
m odules o f  80 -90  am ino  acids th at m ediate heterophilic  and  
hom ophilic  p ro tein -p ro te in  b inding, w hich typically recognize short 
peptide  sequences at the C term in u s o f  their in teraction  partners.
Grip2 Grip 1 Grip2
Figure 1 G rip l m u tan ts  phenocopy m ice lacking th e  Fraser syndrom e protein F ra s l .  (a -c ) Prom inent b lebs (arrows) form ed over th e  h eads  and  lim bs of 
E 1 2 .5  (a) and E 1 3 .5  (b,c) em bryos, (d) Transverse section  of an E 1 3 .5  Gripl~'~  h ead  with hem orrhaging in a su b se t of b lis ters . (e,f) D eform ation of 
em bryonic G ripl~  limbs. Epiderm al d e tach m en t and  hem orrhaging  in a section  through a dista l E 1 3 .5  forelim b (e) and  ap p ea ran ce  of variable 
polydactylous or syndactylous m alform ations a t E 1 6 .5  (f). (g,h) Surviving G rip l  and  G r ip lG r ip 2  m u ta n ts  showed unilateral c ryp toph thalm os (arrows), 
w hereas G rip2  null m ice (h) appeared  norm al. WT, w ild-type, (i) Adult G rip lG r ip 2  double m u ta n t with syndacty lous fusion of d ig its in th e  h indlim b.
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Although the biological roles o f  m ulti-PD Z  proteins are poorly un d e r­
stood, they m ight control the assembly o f signaling complexes and the 
surface presentation and trafficking o f  transm em brane  pro teins6-8. 
Consistent with this function, GRIP1 associates w ith the kinesin heavy 
chain and is involved in synaptic vesicle tran sp o rt by steering m otor 
proteins to their targets9. To study the in vivo roles o f  GRIP1 and 
GRIP2, we inactivated the  corresponding genes in mice 
(Supplem entary  Fig. 1 online). D isruption o f Gripl led to  detachm ent 
o f epithelia in the oral and nasal cavities, form ation  o f large subepider- 
mal hem orrhagic blisters and lethality at m idgestation that was sim ilar 
to observations reported for an independently generated G ripl knock­
o u t10 (Fig. la -e ) . Blisters form ed underneath  the epiderm al basem ent 
m em brane o f  head, limb and back skin from  around  em bryonic day 
(E) 11.0 and were initially transparen t (Fig. la ) . At later stages o f 
em bryonic developm ent, blisters becam e increasingly hem orrhagic 
(Fig. lb -e ) ,  and most hom ozygotes in the original m ixed 129 x 
C56B1/6 background died around  E l3.5. Gripl*1* mice on  the C57B1/6 
background, however, developed to term , and this enabled us to study 
several aspects o f  the m utan t phenotype. The blistered skin recovered 
during late gestation and only few small hem orrhagic blisters were vis­
ible at E l6.5. M utant hindlim bs were affected by variable defects rang­
ing from com plete syndactyly o f all digits to polydactyly, w hich 
suggested that norm al m orphogenesis o f distal limbs m ight be com ­
prom ised in  areas w ith epiderm al detachm ent (Fig. If). In contrast, 
Grip2~'* mice appeared norm al and were born  in the expected statisti­
cal ratio (Fig. lh  and data not shown). We also obtained a few adult 
Gripl m utants (n  = 5) and Gripl Grip2 double m utants ( n =1 ) ;  these 
mice were devoid o f  externally visible blisters bu t showed perm anent 
fusion o f one o r both eyelids (Fig. lg ,h). We observed sim ilar fusion 
m alform ations in adult autopods (Fig. li).
On exam ination o f the internal organs o f  G ripl-/_ em bryos, we 
found that kidneys were completely absent. At E13.5, only u n stru c ­
tured  m esenchymal rudim ents rem ained, which were devoid o f 
m etanephric tubules and contained large num bers o f  apoptotic  cells 
(Fig. 2 a -d ). In the absence o f  GRIP1, even the earliest steps o f 
m etanephric developm ent failed: mesenchymal condensations did not 
assemble a round  the ureteric bud  and expression o f the W ilm s' tu m o r
a n tig e n -1 (encoded by W tl)  was not induced (Fig. 2 e -h ). C onsistent 
w ith the  m alform ation  observed in the m utants, im m unofluorescence 
w ith the  use o f antibody to GRIP1 labeled the em bryonic epiderm is, 
eyelids, epithelia o f  oral and nasal cavities and ureter o f  w ild-type mice 
(Fig- 3 a -g ).
Defects caused by the loss o f  GRIP 1 were markedly sim ilar to the phe­
notype o f Frasl-/~ mice, an anim al m odel o f the hum an congenital dis­
ease Fraser syndrom e, the sym ptom s o f which include blistering o f 
em bryonic but not adult skin, renal agenesis and cryptophthalm os3,4. 
To explore a possible connection betw een Frasl and GRIP1, we com ­
pared their spatial d istribution patterns by double im m unofluorescence 
and found that expression o f the two proteins overlapped in m any 
em bryonic tissues, including skin, oral and nasal cavities, ureteric bud 
and the gastrointestinal system (Fig. 3h,i and data not show n). At higher 
m agnification, we observed substantial colocalization o f Frasl and 
GRIP1 at the basal surface o f  epiderm al cells (Fig. 3j).
Frasl is a putative ECM pro tein  w ith  a large extracellular dom ain , 
tran sm em b ran e  region and a short C -term inal cytoplasm ic do m ain 3,4. 
The p rim ary  sequence o f  the Frasl C term inus presents a good co n ­
sensus for a class I PDZ d o m ain -b in d in g  m o tif (Fig. 4a), raising the  
possibility o f  a direct physical in teraction  w ith GRIP 1. Indeed, we were 
able to  precip itate  GRIP1 from  HEK293T cells w ith a fusion protein  
that con ta ined  the Frasl cytoplasm ic region. M utating the  C -term inal 
residue (V4010G ) to  d isrup t the  PDZ consensus in Frasl abolished 
GRIP1 b ind ing  (Fig. 4b). Frasl and the unnam ed  m ouse pro tein  
BAC27425 share considerable sequence hom olog)7 (35%  iden tity  over 
755 residues), suggesting that the two gene products m ight be a part o f 
the sam e family. Like F rasl, BAC27425 contains a tran sm em b ran e  
region and  a sho rt cytoplasm ic dom ain  w ith P D Z -bind ing  m otif, 
which in teracts w ith GRIP1 (Fig. 4a,b). We found that b o th  Frasl and 
BAC27425 can also b ind  GRIP2 in a PD Z -dependent m ode (Fig. 4d). 
PDZ dom ains 1-3 , bu t no t dom ains 4 -7 , o f  GRIP 1 o rG R IP 2  were suf­
ficient for Frasl binding (Fig. 4c,e). A lthough the biological role o f 
BAC27425, functional sim ilarities to Frasl and  the question  o f  its rele­
vance for Fraser syndrom e have n o t yet been addressed, o u r  results 
suggest th a t b o th  gene p roducts m ight be connected to  GRIP proteins 
in an  analogous fashion.
Wild-type G ripl knockout
Figure 2 Loss of G rip l leads to renal agenesis, (a.b) Kidneys were a b se n t in E 1 7 .5  G r/p l-d efic ien t em bryos, w hereas adrenal g lands (A) were of norm al size. 
(c,d) Only rudim entary and unstruc tu red  m etanephric  co n d en sa tio n s  (arrow) with num erous  apop to tic  cells, a s  shown by TUNEL sta in ing  (red nuclei in inset; 
all nuclei are s ta ined  blue by DAPI), were visible in transverse  sec tio n s  through th e  E 1 2 .5  m u tan t abdom en (d). Kidneys of control litte rm ates  show ed 
extensive epithelial b ranching  and  were devoid of apop to tic  cells  (c). (e-h) Early s tep s  of kidney m orphogenesis, such  as  th e  form ation of m esenchym al 
condensations around th e  distal u re te r (arrow heads in e,f) and  induction  of W tl expression (g,h) a t E l 1 .5 , require G rip l.  G rip l^ ~  distal u re te rs  are ind ica ted  
by arrows (f,h).
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Consistent with the p rotein-protein  interaction described above and 
the overlapping expression patterns in vivo, GRIP1 and  Frasl colocal­
ized in cytoplasmic vesicular structures o f cultured keratinocytes (Fig. 
4 f-h ), indicating that a direct link between the two gene products might 
be responsible for similar loss-of-function phenotypes.
This was fu rther confirm ed by the im m unofluorescence o n  tissue 
sections from  Gripl~'~ em bryos. In norm al epiderm is, the  Frasl 
im m unofluorescence signal is concentrated at the basal side o f  ker­
atinocytes and  overlaps w ith ECM proteins, such as lam in in -y l. Loss 
o f GRIP1 resulted in reduced Frasl expression and abnorm al retention  
o f the protein  in the keratinocyte layer (Fig. 5a,b). The defective local­
ization o f Frasl did not affect basem ent m em brane integrity  in gen­
eral, because lamina lucida and densa were visible by electron 
m icroscopy (S upplem entary  Fig. 2 online), and neither did it affect 
the expression o f the ECM proteins collagen IV, la m in in -a l,  -0.2, -a5 , 
-(3l, -yl or -y2 (Fig. 5b and data not show n). A central region o f  Frasl 
shows strong hom ology to the collagen V and V i-b in d in g  dom ain  o f 
the m em brane-spanning NG2/AN2 chondro itin  sulphate proteogly­
can (CSPG)3’4’11, which can also interact w ith GRIP1 th rough  its C- 
term inal PD Z-binding m otif1-.
Considering the potential relevance o f this connection, we analyzed 
the pattern  o f  NG2 expression in embryonic skin. W hereas NG 2 was 
concentrated at the epiderm al-derm al junction in norm al E13.5 
embryos, this accum ulation was markedly reduced in G ripl knockouts 
(Fig. 5c,d). The absence o f GRIP1 had similar effects on  the deposition 
of collagens V and VI, substrates for NG2 and possibly F rasl, so that the 
accum ulation o f  bo th  m atrix proteins was com prom ised in the m utant 
basem ent m em brane region (Fig. 5e,f). We observed com parable 
changes to expression o f Frasl, NG2 and collagens V and VI in  other 
tissues o f G r i p l embryos, which indicated that defective deposition 
o f these molecules is a com m on factor in areas w ith disrupted epithelial 
attachm ent (Supplem entary  Fig. 3 online). These findings indicated 
that G RIPl activity is necessary for correct Frasl presentation, which, 
in tu rn , m ight be required for the  recruitm ent o f NG2 CSPG and  colla­
gens V and VI from  the derm is to the basem ent m em brane region. This 
is also consistent w ith the accum ulation defects seen for collagen VI in 
Frasl-knockout embryos4 and for NG2 in bl m utants (data not shown). 
An im portan t role o f  dermis-derived structural proteins is fu rther sup­
ported by the occurrence o f blisters at the derm is-basem ent m em brane 
junction in bo th  Gripl (Fig. 5m  and Supplem entary  Fig. 2 online) and 
Frnsl knockouts3,4. During later embryonic developm ent, skin o f  Gripl 
m utants showed an alm ost complete recovery, leading to the disappear­
ance o f blisters in a m anner similar to that reported for surviving 
F rasl_/_ mice. O u r analysis showed that the skin o f G r i p l em bryos 
improved although Frasl localization remained com prom ised. In con­
trast, the accum ulation o f NG2 and collagens V and VI was largely 
restored by E l7.5 (Supplem entary  Fig. 4 online). Hence intact CSPG- 
m atrlx interactions m ight be sufficient for adhesion at the basem ent
Figure 3 The tissue  d istributions of GRIP1 and F ras l largely overlap.
(a-d) Cryosections of E 1 3 .5  skin s ta ined  with an tibod ies to  G R IP l. S ignals 
are prom inently seen  in developing hair follicles (arrow in a), th e  basal 
region of interfollicular keratinocytes (b) and in th e  eyelid (Ey) area  near the 
lens (Le; c). (d) A bsence of GRIP1 im m unofluorescence in G ripl~ ' skin (KO; 
arrow head), (e-g ) GRIP1 stain ing  in the  basal oral ep ith e liu m  of wild-type
(e) but not knockout (KO; arrow heads in f) E 1 3 .5  em bryos, (g) C onsisten t 
with a role in early m etanephric developm ent, GRIP1 is exp ressed  in th e  
E l l . 5 ureter. (It—j) GRIP1 (green) and F ra s l  (red) signals  overlap in E 1 3 .5  
epiderm is (h) and  oral epithelium  (i). Higher resolution show s colocalization 
of th e  GRIP1 and  F ras l signals a t th e  ep iderm al-derm al in te rface  (j). 
Epiderm is (Ep) and  derm is (De) a re  ind ica ted . Cell nuclei a re  s ta in ed  by 
DAPI (blue).
m em brane-m esenchym al interface, whereas the role o f  GRIP1 and 
Frasl seems to be transient bu t crucial.
We next exam ined the d istribu tion  o f endogenous Frasl pro tein  in 
cultured  em bryonic keratinocytes. C onfocal m icroscopy showed Frasl 
im m unofluorescence in perinuclear vesicular structures in the apical 
region o f b o th  contro l and Gripl~'~ cells (Fig. 5g,j). In basal sections 
Frasl was widely d istributed , extending alm ost to the  edge o f  wild- 
type keratinocytes; in con trast, th is peripheral stain ing was m arkedly 
reduced in the absence o f GRIP1 (Fig. 5h,i,k ,l). T hus, the  observed 
a lterations o f Frasl localization in GRIP 1-deficient skin and  cultured  
keratinocytes are consistent w ith  an essential role for the m ulti-PD Z  
dom ain  pro tein  in trafficking F rasl to the  basal side o f  cells.
The phenotype  o f G ripl m u tan ts resem bles the dystrophic form  o f 
epiderm olysis bullosa (DEB), a hu m an  blistering disease w ith skin 
ru p tu rin g  that results from  defects in the  gene encoding collagen VII 
(C O L7A1) that affect the anchoring  fibrils th a t link derm is and base­
m ent m em b ran e 10. Mice w ith  a targeted inactivation  o f  C ol7al, an 
anim al m odel o f  DEB, develop skin blisters postnatally  in areas 
exposed to m echanical stress13 in a m an n er that is d istinct from  
G R IP l-deficien t em bryos. A lthough collagen VII deposition  was co m ­
prom ised in som e regions o f  early G rip l-/~ em bryos, perhaps due to 
the d isrup ted  adhesive in teractions at the basem ent m em b ran e -d e r­
m al interface described above, anchoring  fibrils were fo rm ed in E l7.5 
skin (S u p p lem en ta ry  Fig. 2 online), arguing against a d irect connec­
tio n  w ith DEB.
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In contrast, our results indicate that GRIP1 m ight have a role in 
Fraser syndrome: GRIP m ulti-PD Z  proteins and Frasl directly in te r­
act and GRIP1 is essential for norm al Frasl localization. Gripl~'~ 
em bryos and adult survivors show phenotypes th a t are sim ilar to  a 
num ber o f m utant m ouse strains w ith em bryonic b listering (often 
described as ‘blebs’), which have been proposed to be anim al m odels 
o f hum an Fraser syndrom e14'15. O ne o f  these strains, called blebbed, 
carries a prem ature stop codon in Frasl (ref. 3). A different m u tan t, 
eye-blebs, has been m apped to m ouse chrom osom e 10 and  linked to  
the m arker D 10M itl87  (ref. 16). We found that D 1 0M itl87  physically 
overlaps with the Gripl locus and that a region o f Gripl is d isrup ted  in 
eye-blebs, so that the gene lacks coding exons 10 and 11 (Fig. 5n). 
There are several consanguineous Fraser syndrom e families w ith h e t­
erozygosity for m arkers at Frasl. H um an GRIP1 m aps to chrom osom e 
12ql4.3 and short tandem  repeat polym orphism s flanking the gene 
could be used to assess w hether any o f the phenotype o f  these ind iv id­
uals m ight be secondary to m utations in GRIPl.
Thus, we have provided evidence that GRIP1, a cytoplasm ic PD Z 
dom ain protein, m ediates cell-m atrix interactions th rough  a role in 
the trafficking o f cell surface-EC M  molecules and that its activity is 
essential for several m orphogenetic processes in the embryo.
M ETHODS
G eneration o f  G rip l  and G rip2  m utant mice. We isolated G ripl and Grip2 
clones from 129 genom ic phage libraries. We constructed gene targeting vectors
& or <7 <<r 92
m FrasI 4003NLQDGTEV*
h Frasl 4000NLQDGTEV*
BAC27425  866HYNDSSEV*
lvECM3 3096HFDDNTEV*
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<8 AL 
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'  J'rZ- 7*-EC-
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PDZ +  +  +  _  +  _
1,2,3
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by inserting PGK-neo cassettes into EroRI or BspEl sites in Gripl or Grip2 DNA, 
respectively, so that exons corresponding to PDZ dom ain 1 were disrupted. We 
electroporated linearized targeting constructs into R1 em bryonic stem  cells1 
and tested G418-resistant clones for hom ologous recom bination by PCR and 
Southern-blot analysis. Blastocyst injection produced several chimeric m ice, 
which were backcrossed to C57B1/6 w ild-type mice. The genotype was deter­
m ined by Southern-blot analysis and then by PCR screening. We confirm ed the 
absence o f  GRIP proteins in hom ozygous mutants by W estern-blot analysis.
All the m ice used had a mixed 129 x  C56B1/6 genetic background. After six 
generations o f  backcrossing to C56B1/6 m ice, we observed that hom ozygous  
G ripl~f~ em bryos survived beyond E13.5 and developed to term. We obtained  
Grip2-deticient mice with the expected m endelian ratios, indicating norm al 
survival o f  these mutants.
All m ouse experim ents were done in com pliance w ith the relevant laws and 
institutional guidelines and were approved by the Johns Hopkins University 
Anim al Care and Use C om m ittee and the Cancer Research UK Anim al Ethics 
C om m ittee.
Stain ing o f  tissue sections. We fixed freshly isolated em bryos in 4% 
paraformaldehyde, dehydrated them , embedded them  in paraffin and prepared 
5 -|im  sections. We then rem oved the paraffin from the sections and analyzed 
them  by staining w ith hem atoxylin and eosin. We detected apoptotic cells w ith  
the ApopTag In Situ A poptosis Detection Kit (O ncor), according to the m an u­
facturer’s instructions.
Im m unofluorescence staining was done on acetone-fixed 5 pM  cryosections 
w ith primary antibodies directed against GRIP1 (ref. 5; BD Pharm ingen), Frasl 
(ref. 4 ), N G 2 (C hem icon), collagens V and VI (Rockland) and lam in in -yl (rat 
m onoclonal 3E10). Secondary antibodies were coupled to Alexa Fluor-488 or 
Fluor-546 (M olecular Probes).
We generated the digoxigenin-labeled W tl  antisense RNA probe by in vitro  
transcription from a linearized DNA template and hybridized it at 70 °C 
overnight to pretreated 5-p m  tissue sections, which we then washed extensively  
and incubated w ith antibody to DIG-AP Fab fragment (Roche). We used 
NBT/BCIP substrates (Roche) to develop the signal.
A nalysis o f  protein -protein  interactions. We constructed GFP-GRIP1 by fus­
ing green fluorescent protein (GFP) to the C term inus o f  rat G ripl cDNA. 
Similarly, we fused GFP with PDZ dom ains 1-3 , 4 -6  and 7. For GRIP1 and 
GRIP2 expression vectors, we subcloned rat G ripl and Grip2  into pBK-CM V  
(Stratagene) and pRK-5 (BD Pharm ingen), respectively.
We amplified D N A  fragments encoding the C term inus o f w ild-type Frasl 
(m F rasl), Frasl TEG mutant and BAC27425 by PCR and fused them  to GST by 
subcloning into the pGEX-4T vector (Amersham Pharmacia Biotech).
Figure 4 PDZ dom ain -m ed ia ted  interaction betw een GRIP1 and F ra s l. (a) The 
C te rm inus  of hum an (hF ra sl)  and  m ouse F ras l (m F rasl) con tains a potential 
PDZ b inding  site  (shown in green). C-terminal PDZ recognition m otifs also 
occur in th e  predicted  m ouse protein B A C 27425 and in the  sea  urchin ECM3 
protein (lvECM3). (b) Direct physical interaction of F ras l and  B A C 27425 
proteins with GFP-tagged GRIP1 in vitro. The W estern blot shows GFP-GRIP1 
protein th a t was precip itated  from H EK293T cells with G ST-Frasl and  GST- 
B A C 27425 but not GST alone. M utation of the  C-terminal valine in F ras l 
abo lishes th e  interaction completely. A GST fusion of G luR2, a known 
in teractor of GRIP1, was used as  positive control. Input GST fusion protein 
levels are visualized by colloidal Coom assie blue (CBB) staining, (c) F rasl 
b inding is m ediated  by PDZ dom ains 1, 2  and 3  in the  N-terminal region of 
GRIP1, w hereas GST-Frasl did not im m unoprecip itate G FP-PD Z4,5,6 and 
GFP-PDZ7 proteins. M utation of the  F ras l C te rm inus (TEG) abolished  the  
in teraction. Input protein levels are shown on the  left side, (d) F ras l and 
B A C 27425 also show direct binding to GFP-tagged GRIP2. (e) The interaction 
betw een th e  cytoplasm ic region of F ras l and GRIP1 PDZ dom ains 1, 2  and  3 
was confirm ed in the  yeast two-hybrid assay. Yeast double transform ants were 
selec ted  on double dropout p lates (Trp- , Leu- ) and  tested  for physical 
interaction of the  fusion proteins by growth on triple dropout selection  p la tes 
(Trp- , Leu- , His- ). The GluR2 cytoplasm ic region in teracts with GRIP1 PDZ 
dom ains 4 , 5 and 6 . Deletion of the  C-terminal TEV motif in F ras l (F raslA 3) 
abolished b inding to GRIP1. (f-h) GFP-GRIP1 (green) and  antibody to  F ra s l
(red) signals colocalize in keratinocytes (a single cell is shown).
1 H
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We produced GST fusion recombinant proteins in Escherichia coli strain 
BL21 transformed with each GST fusion construct according to standard pro­
cedures. We incubated lysates o f  HEK293T cells transiently transfected with rat 
GRIP1 or GRIP2 expression constructs with 10 pg o f GST fusion protein 
attached to glutathione Sepharose beads for 4 h at 4 °C. After GST im m unopre- 
cipitiation, we processed the samples for Western blotting w ith antibodies to 
GRIP1, GRIP2 (ref. 5) or GFP (Molecular Probes).
We used the yeast two-hybrid system to identify the PDZ dom ains interact­
ing with the C-terminal sequence o f Frasl. Fragments encoding GRIP1 PDZ  
dom ains, the C terminus o f  Frasl, a mutant version carrying a deletion o f the 
TEV m otif (A3) and the GluR2 C-terminal dom ain were amplified by PCR and 
cloned into pPC86 (GAL4 AD) or pPC97 (fusion with GAL4 DB). We cotrans­
formed constructs into yeast strain CG1945 and grew them on double dropout 
medium  (Trp- , Leu- ) to select the double transformants. Growth on triple 
dropout m edium  (Trp- , Leu- , His-  + 50 mM  3-am inotriazole) indicated pro- 
tein-protein interactions, that is formation o f the active GAL4 transcriptional 
activator complex.
Frasl localization in cultured cells. We isolated primary keratinocytes from  
Gripl knockout and wild-type embryos (E17.5) containing the temperature- 
sensitive (ts) A58 ‘im m orto’ allele18 and maintained them as reported for 
neonatal keratinocytes19. For immortalization, we cultured em bryonic ker­
atinocytes at 33 °C in the presence o f IFN-y as described18. To study the cellular 
localization o f  Frasl, we plated keratinocytes on collagen VI—coated coverslips, 
cultured them overnight, fixed them in acetone-methanol (1:1) and stained
them  with primary antibody to Frasl (1:80 dilution) followed by secondary 
antibody to rabbit Alexa Fluor-488 (M olecular Probes).
For the GRIP1 colocalization studies, we transfected keratinocytes w ith the 
GFP-GRIP1 expression vector or the control EGFP-C1 plasmid (BD Clontech) 
with the use o f  Lipofectamine 2000 (Invitrogen) according to manufacturer’s 
instructions. After 24 h, we stained the transfected cells for Frasl with sec­
ondary antibody to rabbit Alexa-546 (M olecular Probes). The GFP-GRIP1 pro­
tein was visualized w ith A lexa488-conjugated antibody to GFP (M olecular 
Probes). We acquired optical sections (Z  series) and analyzed them  with an 
LSM510 confocal laser scanning m icroscope (Zeiss).
PCR analysis o f  the eb  m utant G rip l  gene. We amplified individual G ripl 
exons from  genom ic DNA. Primer sequences and PCR conditions are available 
on request. Products were directly sequenced and run on  an Amersham  
MegaBACElOOO automated sequencer before analysis w ith Sequencer software 
(G eneC odes) or separated by electrophoresis on a 2% w /v agarose gel.
We obtained D N A  from  the ATEB strain segregating the eb m utation from  
the Jackson laboratories (strain num ber 000277). The m utation arose sponta­
neously in a noninbred strain o f  the hairless m ouse and had previously been 
m apped to 77cM  on M M U10 (ref. 20). We designed primers for am plification  
o f  individual exons to conduct m utation screening by direct sequencing. 
Exons 10 and 11 repeatedly could not be am plified from ATEB D N A  but could  
be am plified from C57/B16 DNA (Fig. 5n) and from  four other strains o f  
m ou se (data not show n). All other exons amplified norm ally and no putative  
m utations were detected. Our data suggested a deletion o f  exons 10 and 11,
i 'J k
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Figure 5 GRIP1 is required for normal trafficking and  biological activity  of F ra s l .  (a-f) D efects a t the  G rip l m u tan t ep iderm al-m esenchym al in terface. Green 
fluorescence ind ica tes expression of F ras l (a,b), NG2 (c.d) and  collagen VI (e,f) in G r ip l+,+ (a .c.e) and  G r ip l-*- (b,d,f) skin. B asem en t m em brane  is labeled 
by stain ing  with antibody to lam in in -y l (red) and cell nuclei by DAPI (blue). P ane ls  a ' - f  show green  ch an n e ls  for rep resen ta tive  a re as  from a-f, respectively. 
Position of the  basem en t m em brane is indicated  by an arrow in b', d' and f . Note m islocated  F ra s l in th e  G r/p l-d efic ien t ep id e rm is  (arrow heads in b).
(g-l) Cellular distribution  of F ras l in apical (g,j) or basal (h,i,k,l) optical sec tio n s  of cu ltu red  w ild-type (WT; g -i) and  G rip l- '-  keratinocy tes (j-l). (g,h,j,k) 
Phase con trast is shown; cell borders are ind icated  by arrow heads, (m) Model show ing G R IP l-d ep en d en t transpo rt of F ra s l to  th e  basal ep id e rm is  and the  
proposed in teractions with collagens V and VI (green) and  NG2. F ra s l  localization is abnorm al in ab sen ce  of GRIP1 an d  th e  derm is sep a ra te s  from th e  
basem ent m em brane, (n) PCR identified a deletion in G rip l in eye-b lebs (eb) genom ic DNA. Diagram of th e  genom ic region con ta in ing  G rip l exons 9 - 1 1 ,  
not to scale and with exon num bering  based  on th e  refGene N M _ 0 2 8 7 3 6  seq u en ce . D ow nward-pointing arrows labeled  a -k  ind ica te  th e  locations of the  
corresponding PCR am plim ers shown in th e  agarose gel; th e  upw ard-poin ting  arrow ind ica tes  th e  position of D 1 0 M i t l8 7 ,  w hich was previously reported  as 
failing to am plify in e b  (ATEB inbred stra in) DNA. The approxim ate  position of the  de le tion  (ebA) is shown. The bottom  p anels  show the  am p lim ers  ob ta ined  
from control and eb  DNA after agarose gel e lectrophoresis . M, 1 0 0 -b p  ladder.
1 7 6 VOLUME 36 | NUMBER 2 | FEBRUARY 200 4  NAT URE G E N E T I C S
<£>
 
20
04
 
N
at
ur
e 
P
u
b
li
sh
in
g
 
G
ro
up
 
h
tt
p
:/
/w
w
w
.n
at
u
re
.c
o
m
/n
at
u
re
g
en
et
lc
s
L E T T E R S
which was corroborated by the failure to amplify a region from intron 10 and 
four other sequences 5' o f exon 10 and 3' o f exon 11. The deleted segm ent is 
3.22-5.38 kb in length. Conceptual translation o f  the deleted G ripl gene  
results in a protein o f 353 am ino acids, the last six o f  which (AAHEEP) are 
novel, as a result o f a frame shift and premature term ination. Assum ing no 
nonsense-mediated decay, the resultant protein would lack the C-terminal 
four PDZ domains.
Note: S u p p lem en ta ry  in form ation  is ava ilab le  on the N a tu re  G en etics website. 
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Identification of a new gene mutated in Fraser syndrome 
and mouse myelencephalic blebs
Shalini Jadeja1, Ian Smyth1,2, Jolanta E Pitera3, Martin S Taylor4, Mieke van H aelst1, Elizabeth Bentley5,
Lesley McGregor1, Jason Hopkins5, Georges Chalepakis6, N icole Philip7, A ntonio Perez Aytes8, Fiona M Watt2, 
Susan M Darling5, Ian Jackson9, Adrian S W oolf3 & Peter J Scam bler1
Fraser syndrome is a recessive, multisystem disorder presenting 
with cryptophthalmos, syndactyly and renal defects1'2 and 
associated with loss-of-function mutations of the extracellular 
matrix protein FRAS1. Frasl mutant mice have a blebbed 
phenotype characterized by intrauterine epithelial fragility 
generating serous and, later, hemorrhagic blisters. The 
myelencephalic blebs (my) strain has a similar phenotype. We 
mapped my  to Frem2, a gene related to Frasl and Freml, and 
showed that a Frem2 gene-trap mutation was allelic to my. 
Expression of Frem2 in adult kidneys correlated with cyst 
formation in my  homozygotes, indicating that the gene is 
required for maintaining the differentiated state of renal 
epithelia. Two individuals with Fraser syndrome w ere homo­
zygous with respect to the same missense mutation of FREM2, 
confirming genetic heterogeneity. This is the only missense 
mutation reported in any blebbing mutant or individual with 
Fraser syndrome, suggesting that calcium binding in the CALXfl- 
cadherin motif is important for normal functioning o f FREM2.
Extracellular m atrix  molecules are im portant for cell adhesion and 
migration, basem ent m em brane integrity and epithelial-mesenchymal 
interactions during development. We recendy identified the proto- 
typic m em ber o f  a new family o f putative ECM proteins, FRAS1, and 
showed that loss o f  FRAS1 function resulted in Fraser syndrom e in 
hum ans and the blebbed phenotype in mice (bl)iA . In ~ 5 0 %  o f 
families w ith Fraser syndrome, however, disease was no t linked to  
FRAS1, and four o ther blebbing loci in mice have been reported5. 
Gripl is m utated in  the m ouse eye blebs (eb) strain6, and  Freml (Frasl 
related extracellular m atrix 1) is m utated in  the head bleb (heb) 
strain7, but neither o f these genes is m utated in the families w ith 
Fraser syndrome that we studied (data not shown).
To investigate the cause o f Fraser syndrome n o t linked to  FRAS1, 
we carried out linkage analysis in the my  strain. The original m y  
m utation arose in mice irradiated with X-rays8 and m apped  to  m ouse
chrom osom e 3. A nother allele, m yUc\  was identified during  the 
creation o f  an unrelated transgenic strain, although no  trace o f  
transgene sequence could be found later (E.B. and S.M.D., u n p u b ­
lished data). The m yUcl strain shows epithelial blebbing, first detect­
able at em bryonic day (E) 11.5, and has a similar gross pathology 
to  the bl strain3’3 (Fig. 1). O n  the NM RI background, hom ozygotes 
have a semilethal phenotype, with approxim ately half the expected 
num ber o f  hom ozygotes surviving and som e hom ozygotes being 
fertile. We observed cutaneous syndactyly typical o f  the blebbed 
m utan ts in  myUcl mice, occasionally accom panied by bony syndactyly 
and polydactyly (Fig. 1).
We undertook  an initial backcross yielding 146 progeny, which we 
further bred to  yield 1,030 mice to  finely m ap the region o f chrom o­
some 3 segregating with myVc\  In this region, bordered by D 3M itl84  
proximally and  D3Mit275 distally, we detected two recom binants with 
D3M it66  (in the gene Trpc4), placing m y  proximal to  D3M it66  
(Fig. le ) . TRPC4 m aps to  hum an  chrom osom e 13ql3.3. Analysis of 
the m ouse genomic region flanked by D 3M itl84  and  D3M it66  led to 
the identification o f a gene encoding a Frasl-like protein 500 kb 
proxim al to  Trpc4 and 400 kb distal to D3M itl84. C om putational 
analysis and  subsequent validation by RT-PCR indicated that this gene 
is com prised o f 28 exons and potentially encodes a protein o f 3,160 
am ino acids; exon 4 was large, encoding 1,655 am ino acids. The 
predicted protein has an arrangem ent o f dom ains identical to  the sea 
urchin ECM3 protein9: an N -term inal signal peptide followed by 13 
tandem ly arranged chondroitin sulphate proteoglycan dom ains, five 
tandem ly arranged CALXP dom ains, a transm em brane helix and a 
short cytoplasmic tail with a consensus PDZ interaction motif. In 
addition  to  being structurally similar to Frasl and ECM3, this protein 
is related to  Frem l, as previously reported7, and is called Frem2. 
Phylogenetic analysis o f this gene family showed that Frem2 can be 
considered orthologous to  ECM 3 (ref. 7).
To test the hypothesis that m utations in Frem2 underlay m yVc\  we 
directly sequenced each exon and flanking intronic sequences, b u t we
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Figure 1 M apping the  locus to m ouse chrom osom e 3  (MMU3). A 
m y Ucl//T7yUcl m ouse showing unilateral cryptophthalm os (a) and syndactyly 
(b). Alizarin red stain ing  of lim bs from m y Ucl/m y Ucl m ice showing a clubbed 
paw appearance  secondary to bony fusion (c) and polydactyly (d). Linkage 
analysis localized the  /n y Ucl locus between th e  m arkers D3MH184 and 
D3Mit66\ d is tan ces  betw een marker pairs are given in cM and are derived 
from the  backcross (e).
substantial expression o f the gene from  E10 in the m esoderm al core o f 
the branchial arches, developing lens, otic vesicle and lim b apical 
ectoderm al ridge. Later, expression initiated in the vibrissae and 
vibrissae pad, eyelids, ear and pelage follicles and, at low  levels, the 
epidermis. We observed expression in the caudal somites and, in later 
embryos, in facial, lim b and intercostal muscles. Both the sites and 
tem poral initiation o f Frem2 expression in developing epithelial 
structures was reminiscent o f  that o f  Freml (ref. 7). But we did not 
detect Frem2 expression at other sites o f Freml expression in the 
developing m am m ary  glands or, specifically, in the caecum  (Frem2 
is broadly expressed in gastrointestinal m esothelium ). Furtherm ore, 
sectioning o f  stained em bryos showed that Frem2 expression was 
restricted to  the epithelia in a pattern com plem entary to  that o f  Freml 
(which is generally expressed in the derm is and m esenchym e7), 
suggesting that coordinate expression o f  the two genes is functionally 
im portan t in m aintaining epiderm al adhesion.
Frasl, on the o ther hand, is broadly and strongly expressed 
th roughout the epiderm is3,4. Because renal adysplasia is a character­
istic o f bo th  Fraser syndrom e and a variable p roportion  o f m y  mice 
(depending on  genetic background), we exam ined expression o f
Figure 2  Expression of Frem2 during mouse 
development, (a) Frem2 expression initiates at 
- E 1 0 .5  when the  gene is expressed in the 
ectoderm  and m esoderm al cores of the  branchial 
arches, endoderm  of the  pharyngeal pouches, otic 
vesicle, lens and lim b apical ectoderm al ridge.
(b,c) At E 12 .5  and E 1 3 .5 , expression is noted in 
the differentiating epiderm is, vibrissae and 
jvibrissae pad, developing ear, apical ectoderm al 
'ridge, eyelids, corneal epithelium , pelage 
follicles, som ites of the  tail and skeletal m uscle 
elem ents in the  lim bs and elsew here in the  body.
(d) E14 m yUcl/m y KST em bryos develop 
hemorrhagic epiderm al blebs (arrowheads) with a 
frequency and severity indistinguishable from 
that of m yUcl/m y Ucl homozygotes, illustrating that 
the two are allelic. S taining for [f-galactosidase 
activity, which derives from Frem2 promoter- 
m ediated transcrip tion  of the  gene-trap vector, 
indicates a pattern of expression identical to 
Frem2. The better penetration of fi-galactosidase 
substrates (relative to labeled riboprobes) m eans 
that Frem2 expression in skeletal m uscle is more 
easily resolved. (e,f) Frem2 expression in the 
developing limb is dynam ic. Expression initiates 
and is m aintained a t the apical ectoderm al ridge 
and later develops in the  epiderm is on the  apical and basal su rfaces  of each  digit, (g) Analysis of gene-trap  fusion transcrip ts  in + /m y KST em bryos ind ica tes
strong expression of Frem2 in different epiderm al s truc tu res including  th e  eyelids, vibrissae and hair follicles. (h,i) Sections of E 14  em bryos show stain ing  
for Frem2 expression in the  eyelid and corneal ep ithelia  (arrowheads) and in th e  placode of the  developing hair follicles (dashed  line ind icates th e  epiderm al 
basem ent m em brane). Unlike Freml expression in th ese  locations, Frem2 expression is restric ted  to the  epiderm is rather than  the  m esenchym e and derm is, 
(j-n) During kidney developm ent, Frem2 is expressed in th e  ureteric  ep ithelia  of the  m etanephros a t E l 1 .5  (j) with h ighest expression in th e  tip s of the  buds 
(arrows). Frem2 is also expressed in the  m esonephros (arrow in k). The ureter tip s  induce a m esenchym al-to-epithelial transition around E 1 2 .5  with
concom itant expression of Frem2 in th e se  vesicles (arrows in I and m). Expression of Frem2 persists  in epithelial com ponents  of the  kidney a t E 1 4 .5  (n).
AER, apical ectoderm al ridge; BL, bleb; EC, ectoderm ; EL, eyelid; LE, lens; MC, m esoderm al core; PF, pelage follicles; S, som ite; SKM, skeletal m uscle 
elem ent; V, vibrissa.
MMU3
20 cM
D3MH227 
D3MH134 
D3MH119 
D3MH183 
D3MU67 
D3MH184 
U r■ my
■ D3MiW6 Trpc4 
D3MH275 
D3MH208 
D3MH334
D3Mit170. 172. 173 
D3Nds38
found no m utations. Database interrogation showed that Frem2 had 
been m utated by a gene trap created at BayGenomics. We injected the 
relevant em bryonic stem cells (KST252) into blastocysts and obtained 
germline transm ission o f norm al viable heterozygotes. We then bred 
these mice {Frem2YS[2' 2, subsequendy called my^s 11 to  mice carrying 
the myUcl allele. This cross failed to complement the m utation , 
indicative o f allelism. We examined expression o f Frem2 both  by 
whole-m ount in situ  hybridization o f CD1 embryos from  E8.5-E15 
and by LacZ staining o f m y ^ 1 embryos (F ig . 2 ). We first noted
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Figure 3 Analysis of the  epiderm al basem ent 
membrane in wild-type and m yUcl/m y Ucl 
m utants. A cryosection of lesional tissue  in lim b 
bud of an m yUcl/m y Ucl E 14 .5  embryo stained 
with a panlam inin antibody de tec ts  th is 
m em brane com ponent (green) in the  roof of the  
blister (a) and in the  derm al-epiderm al junction 
of a heterozygote (b). Collagen IV (green) is 
present a t th e  basem ent m em brane zone of wild- 
type (c) and m yUcl//n y Ucl (d) em bryos a t E 14 .5  
but absent in equivalent cryosections of limb 
buds of b l/b l em bryos (e). (a-e) Sections are 
counterstained with propidium iodide.
Transmission electron microscopy confirm s tha t 
the disruption occurs below th e  epiderm al 
basem ent m em brane in m yUcl/m y Ucl em bryos (ff), 
som etim es within the  m esenchym al cell layer (h).
BC, blister cavity; MES, m esenchym al cell layer; EP, epithelial cell layer. Arrowheads indicate  m esenchym al cells a t th e  roof of th e  bleb. Normal struc tu re  is 
illustrated in g (tissue from a + /b l  heterozygote), (i) Collagen VI (red) is p resen t in th e  epiderm al basem en t m em brane of m yUcl/m y Ucl em bryos (section is 
counterstained with DAPI).
Frem2 in the developing kidney. At E l 1.5, we detected Frem2 in  the 
mesonephric and m etanephric epithelia, and expression was highest at 
the tips o f the developing ureteric buds. At E12.5 and E13.5, expres­
sion persisted throughout the epithelial components o f  the kidney, 
including epithelia fated to  form nephrons, which are induced by the 
ureter tips to differentiate from the mesenchymal condensations that 
surround them . The renal expression at these stages was rem iniscent o f 
that o f Frasl (ref. 3), and complementary to that o f Freml (ref. 7), 
which is expressed in the stroma.
O ur ultrastructural and im m unohistochem ical analysis o f  myUcI/ 
myvd  embryos showed both similarities and differences com pared 
with Frasl~'~ m utants. Electron microscopy o f lesional skin at E l4.5
indicated that the plane o f  separation o f the skin in  m yud/m yvd  
em bryos was below the basem ent m em brane, as in Frasl m utants, and 
could som etim es occur w ithin the m esenchymal cell layer (Fig. 3). 
Lam inin was present in  the basem ent m em brane o f  bo th  m utants, 
associated w ith the roo f o f  the blister (Fig. 3). W hereas collagen VI is 
absent (o r greatly reduced) from  the cutaneous basem ent m em brane 
o f nonlesional skin o f  E14.5 F r a s l m utant em bryos4, however, it 
was preserved in  m yvd/m yvd  embryos (Fig. 3). Targeted m uta tion  o f  
Col4al and  Col4a2 showed that collagen IV is essential for the 
structural integrity o f  basem ent m em branes during embryogenesis10. 
We found that cutaneous basem ent m em brane collagen IV was absent 
or reduced in  Frasl em bryos bu t not in m yvd /m yvd  embryos
Figure 4 Double m utant b l/b l m y^V m y1^ 1 m ice 
are viable, (a) Bilateral cryptophthalm os in a b l/b l 
myUcl/n7yUcl m ouse, (b-d) Adult m ice (2 0  weeks) 
homozygous with re spec t either, or both, of th e  b l 
tend m y  a lleles developed renal cysts (asterisks), 
particularly in th e  cortex. Sections (magnification 
lO x ) stained  with periodic acid Schiff and 
hematoxylin, (b) + /b l  + /+ . (c) + /b l myUcl//n y Ucl.
(d) b l/b l myUcl/m y Ucl. Transheterozygote kidneys 
(+ /b l + /m y) were normal (not shown), (e-j)
Kidney sections from adu lt b l/b l myUcl/m y Ucl 
mice, (e—i) Nuclei are counterstained blue with 
hematoxylin, (e) Im m unostaining with 
proliferating cell nuclear antigen (brown) shows 
proliferating cells  (arrowheads) in cystic epithelia.
(f) TUNEL stain ing  of cyst (asterisk) showing 
apoptosis in th e  cyst epithelium , (g) A cyst 
(asterisk) that binds D. biflorus lectin (green), a 
collecting duct marker. White arrowhead 
indicates a normal collecting duct, (h) A cyst 
(asterisk) tha t im m unostains (brown) with THP 
antibody, a m arker of th e  thick ascending limb of 
loop of Henle (normal caliber tubu les indicated 
by arrowheads), (i) Cystic epithelia  (asterisks) do not im m unostain  (brown) for AQP-1, which is expressed by nearby proximal tubu les (black arrowhead) and 
descending th in  lim bs of loops of Henle. Periodic acid Schiff m arks th e  brush border of proximal tubu les (pink, black arrow head). W hite arrow head indicates 
a distal tubule negative for both m arkers, (j) U pper panel, F rem 2-driven p-galactosidase  expression in a section  of adu lt renal cortex. Lower panel, th e  sam e 
section labeled with D. biflorus lectin (falsely colored red) and coun terstained  with DAPI, indicating  F rem 2  expression in collecting ducts, (k) Dual f$- 
galactosidase and THP im m unostaining of an adu lt + /m yKST m ouse kidney cortico-m edullary junction , showing F rem 2  expression in collecting  d u c ts  (black 
arrowheads) and proximal tubu les (gray arrow heads) but not in th e  loops of Henle (purple THP staining). (I) Section of an adu lt + /m yKST m ouse kidney 
stained for a-SMA to  identify the  vascula ture  sm ooth m uscle. Frem 2-driven p-galactosidase expression is seen  in th e  collecting duc ts  (black arrow heads) and 
the a-SM A-staining vessels.
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Figure 5 Mutation of FREM 2  in Fraser syndrome. (a,b) Proband from 
family 1, showing cryptophthalm os, syndactyly and am biguous genitalia, 
(c-e) Sequence analysis of control (c), proband (d) and parental (e) DNAs 
showing the  5914G -> A  m utation in the  affected individual, (f) The position 
of the  corresponding E 1972K  m utation is indicated (arrow) in a schem atic  
of th e  FREM2 protein, showing the  predicted domain structure.
(Fig. 3). We also analyzed collagen staining in myKST/myK;ST embryos, 
which was indistinguishable from that in m yvd/m yvd  (data not 
shown). Freml m utants also have norm al localization o f collagen VI 
in the epidermis7, indicating that although loss o f this protein m ay 
have a role in the phenotype, its absence is not the cause o f the 
blebbing process.
The blebs in both Frasl and Frem2 m utant embryos usually resolve 
by late gestation. We determined whether double m utants had a m ore 
severe phenotype or a new early embryonic phenotype. Double 
homozygotes were viable (observed at 50% of the expected m endelian 
frequency, similar to myUcVmyud) and even fertile and had birth  
defects similar to those observed in single homozygotes, including 
syndactyly, cryptophthalm os and renal dysplasia (Fig. 4a-d ). Surviving 
mice homozygous at either o r both loci had renal cortical cysts as 
adults (from 12 weeks). Staining with proliferating cell nuclear antigen
d  a TUNEL assay showed both increased proliferation and apoptosis 
in these cysts com pared with neighboring normal epithelia (Fig. 4e,f). 
Some cysts were o f collecting duct origin (i.e., they bound  Dolichos 
biflorus lectin), whereas others were derived from the thick ascending 
limb o f the loop o f Henle (i.e., they immunostained with Tam m - 
Horsfall protein (THP) antibody; Fig. 4g,h). Cysts were negative for 
proximal tubule markers (Fig. 4i). Notably, we observed Frem2 
expression in adult kidney, with expression in the collecting ducts, 
proximal convoluted tubules and arterioles o f wild-type mice, or, in the 
case o f gene-trap embryos, heterozygotes (Fig. 4j—1). But the con­
gruence o f Frem2 expression in collecting ducts and cyst staining with 
collecting duct markers suggests a function for Frem2 in the m ain­
tenance o f the quiescent, differentiated state o f m ature renal epithelia.
A hum an transcript encoding a protein o f 3,098 am ino  acids 
orthologous to Frem2 is located 800 kb distal to  TRPC4. We used 
four short tandem  repeat markers covering 1.6 M b (1.7 cM) o f 
chromosome 13ql3.3 and flanking FREM2 to  screen families with 
Fraser syndrome not linked to  FRAS1 for evidence o f  linkage. We 
identified three families, each potentially identical by descent at each 
locus, and directly sequenced the FREM2 coding exons. We identified 
the nucleotide transition 5914G -»A  in two unrelated families, which 
results in the am ino acid substitution E1974K (Fig. 5); the parents in 
family 1 were heterozygotes. Family 1 is o f Spanish gypsy origin, and
family 2, though originating in France, has a family nam e som etim es 
seen in this population. Alleles at two o f the four linked loci were no t 
shared. Sequencing o f intronic DNA in the two affected individuals 
identified a SNP 64 bp in to  in tron  10, 62 kb 3 ' o f 5914G-> A; database 
searching indicated that this was identical to  rs9548503. The two 
affected individuals were hom ozygous with respect to  different alleles. 
Therefore, 5914G->A probably arose independently and does no t 
represent an  ancestral m utation. We screened 300 Spanish chrom o­
somes, 40 Spanish gypsy chromosomes, 160 other ‘Caucasian’ chro­
m osom es and  the other families w ith Fraser syndrom e no t linked to 
FRAS1 and found no instances o f  5914G-»A. Family 3 is also o f  
Spanish gypsy origin, but the affected individual in  this family did no t 
share a haplotype with either o f the other families and  carried ou t no  
m utation  in  FREM2.
The E1972K m utation  occurs in  the second o f  five consecutive 
CALXP dom ains and substitutes a residue that is conserved in  all 
know n CALX(3 dom ains. A lthough there is no  representative structure 
available for the CALXP fold, ou r sequence sim ilarity searches showed 
that CALXP is related to  cadherin dom ains (M.S.T. et a l ,  unpublished 
data). Tandemly arranged cadherin dom ains intercalate m ultiple Ca2+ 
ions in  a negatively charged pocket between consecutive dom ains11,12. 
The intercalation o f  Ca2+ induces m ajor conform ational shifts in  the 
protein , and  in  the case o f  E-cadherin, Ca2+ is required for hom o- 
dim erization and norm al cell adhesive function11. CALXP dom ains 
are also know n to b ind  Ca2+ with high affinity and undergo a m ajor 
conform ational shift upon b ind ing13,14. We undertook  sequence to  
structure alignm ents and found that G lul972 is located in  the Ca2+ 
binding pocket at the interface o f CALXf) dom ains 2 and  3 and  
corresponds to  a conserved position that is directly involved in the 
coordination o f Ca2+ (Supplem entary  Fig. 1 online). The m utation  
E1972K reverses the charge o f this residue and  is expected to  reduce or 
abolish the intercalation o f Ca2+ ions in  this pocket. These data 
suggest that calcium  binding is required for function o f FREM2. 
In this regard, it is notable that one o f the individuals carrying the 
E1972K m uta tion  was severely affected, with genitourinary abnorm ­
alities, presum ably responsible for prem ature delivery and perinatal 
death. This is the first missense m utation  to  be detected in any blebbed 
strain o r individual with Fraser syndrome.
The phenotype o f individual II.3 in  family 3 is similarly severe, and  
despite hom ozygosity across the region, we found no  m uta tion  in  
FREM2. In  th is case, and in the case o f  the m yvd  mice, there may be a 
regulatory region m utation  o r coding exons no t included in o u r 
analyses, even though gene prediction algorithms and o u r RT-PCR 
experim ents (data no t shown) d id  n o t detect any. Either o r bo th  o f  the 
gene trap  an d  hum an  missense m utations m ay be hypom orphic.
In sum m ary, we identified a second gene m utated  in  Fraser 
syndrom e and  extend the Fras-Frem family o f genes, which are 
expressed widely during development. We found that Frem2 is 
required for m aintenance o f the integrity o f  the skin epithelium  
in utero, for renal development and for the m aintenance o f renal 
epithelial structure in  adult mice. The expression pattern  o f Freml 
(ref. 7) is, in som e aspects, reciprocal to  that o f  Frem2 o r Frasl, and 
Frem l m ay interact with one o r both  o f these proteins. It will be 
interesting to  examine com pound m utations o f  Freml w ith Frem2, 
Frasl or  bo th  to  detect epistasis in this new developm ental pathway.
M ETHODS
Clinical data: family 1. The proband was born at 32 weeks of gestation to 
parents who were first cousins, once removed; weighed 1.34 kg; and died within 
1 h of respiratory failure. The child had cryptophthalmos, nasal dysplasia with 
hypoplastic alae nasi, multiple skin syndactyly in all four extremities and
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short thorax with abdominal distension. Autopsy showed that the right 
kidney and ureter were absent, the left kidney was small and dysplastic and 
the ureter was directly connected to the vagina, the bladder was absent and the 
vagina was dilated with external genitalia o f  male appearance. The child had 
karyotype 46XX.
Clinical data: family 2. The proband was bom  at 35 weeks o f  gestation 
to parents who were second cousins after a normal pregnancy and weighed 
2.39 kg. There was complete cryptophthalmos o f the right eye and a malformed 
left globe, a small mouth and an abnormally low hair line. There was also 
cutaneous syndactyly o f  the left and right hands and left foot. The external 
genitalia were ambiguous.
Clinical data: family 3. Ultrasound findings at 18 weeks o f  gestation included  
severe oligohydramnios and renal and bladder agenesis. A macerated fetus was 
delivered, preventing further pathological examination. Individual II.2 was 
miscarried at 12 weeks o f  gestation with no obvious abnormalities. Ultrasound 
examination o f  individual II. 3 at 19 weeks o f  gestation showed oligohydram­
nios, renal agenesis and absence o f  bladder. Autopsy after termination o f  the 
pregnancy showed cryptophthalmos and microphthalmia, a hypoplastic 
broad nose, low-set and small dysplastic ears with atresia o f  left ear canal, a 
short and oedematous neck, skin syndactyly o f all four extremities, ambiguous 
external genitalia and imperforate anus. Internal organs had hypoplasia o f  the 
epiglottis and thymus and dysplastic larynx and upper trachea with macro­
scopic absence o f thyroid cartilage and thymic gland. The intestine was 
malrotated, and there was bilateral renal agenesis with hypoplastic bladder 
and rectal atresia with a probable fistula to cervix. Parental chromosomes were 
normal. The maternal grandfather was a Spanish gypsy; the parents o f  the 
father were North African gypsies.
Controls. All controls were unrelated. Fifty Spanish control samples came from  
the same city as family 1. We obtained 100 additional samples from elsewhere 
in Spain. The other ‘Caucasian’ controls were from the UK. We also used 18 
samples from Spanish gypsies and 2 samples from Portuguese gypsies.
Mapping backcross. We established an intersubspecific backcross segregating 
the myvd mutation using the wild-derived Mus musculus castaneus strain. We 
crossed hom ozygous mutant mice (myUcl/myUcl) on an NMRI background with 
M. musculus castaneus mice to give +cast/myUcl Fj progeny. We then backcrossed 
these Fi progeny to hom ozygous mutant mice to generate N 2 backcross 
progeny. We genotyped the initial 146 backcross progeny with markers 
spanning a substantial part o f  mouse chromosome 3. We analyzed data using 
kMap Manager and ordered the loci by minimizing the number o f  recombina­
t io n  events. We typed 1,030 additional progeny with the markers D3Mit227 and 
D3Nds38 to identify progeny with recombinations in the critical mapping 
region. We identified 75 such progeny and used them to generate a fine genetic 
map o f  the region.
Human linkage and mutation analysis. Primers for human short tandem  
repeat analysis (D13S1491, D13S218, D13S139 and D13S1253) and SNP screen­
ing were custom made (Qiagen), and genotyping was carried out on  an 
Amersham MegaBACElOOO using conditions taken from the G enom e Data­
base. For sequence analysis o f  Frem2 and FREM2, we used genom ic sequences 
from the Ensembl server and designed intronic and, where appropriate, exonic 
primers to amplify the coding regions and flanking intronic sequences o f  both  
genes (primer sequences are given in Supplementary Table 1 online). We 
carried out direct sequencing o f  amplimers on an Amersham MegaBACElOOO 
and analyzed sequences versus controls using Sequencher 4.1 software.
Expression and ultrastructural analysis. We carried out in situ hybridization 
of the digoxigenin-labeled Frem2 riboprobe on  staged embryos and dissected 
embryonic kidneys using a standard protocol15. We generated a Frem2 probe 
comprising nucleotides 5,083-5,796 by RT-PCR amplification from C57BL6/J 
skin RNA. We embedded stained embryos and kidneys in OCT and cut 10-pm  
sections on a cryostat.
For P-galactosidase staining, we fixed whole embryos in 2% paraformalde­
hyde in phosphate-buffered saline (pH 7) with 2 mM  MgCl2 for 30 m in at 
room temperature. We then incubated embryos in a P-galactosidase solution
containing 20 mM  potassium ferricyanide, 2 mM  MgCl2, 0.01% DOC, 0.02% 
Nonidet-P40 and 2% X-gal overnight at 37 JC and postfixed them in 2% 
paraformaldehyde. For light microscopy, we dehydrated the embryos, cleared 
them  in Histoclear and embedded them  in paraffin wax. We cut sections at 
10 pm  and counterstained them with eosin.
For immunohistochemistry, we fixed whole embryos in 4% paraformaldehyde 
in phosphate-buffered saline and embedded them in OCT for cryosectioning at 
10 pm. After incubation with primary antibody for 2 h at room temperature, we 
used a fluorescendy labeled secondary antibody. We counterstained cell nuclei 
out with DAPI, propidium iodide or hematoxylin. To characterize renal cysts, we 
used the following markers: periodic acid Schiff (Sigma) to stain brush borders o f 
proximal tubules; aquaporin-1 antibody (Chemicon) to detect terminal sections 
o f proximal tubules and thin descending limbs o f  loops o f Henle; THP antibody 
(Biodesign) to detect thick ascending limbs o f  loops o f  Henle; fluorescein 
isothiocyanate-conjugated D. biflorus lectin (Vector Labs) applied to frozen 
sections to stain collecting ducts. For TUNEL staining, we used the Roche in situ 
cell death detection fluorescein kit in accordance with the manufacturer’s 
instructions, and we used proliferating cell nuclear antigen antibody (Pharmin­
gen) as a marker for cycling cells. Collagen IV antibody was from Chemicon 
International; panlaminin antibody was from Collaborative Biomedical Products; 
and collagen VI antibody was from Rockland. Horseradish peroxidase- 
conjugated antibody to a-sm ooth muscle actin (a-SMA; monoclonal 1A4) 
and secondary fluorescein isothiocyanate-conjugated goat antibody to rabbit 
IgG were from Dako. Images were taken on a Zeiss Axioplan 2 microscope. 
We carried out ultrastructural studies as previously described for Frasl (ref. 3).
Ethics. Hum an work was done by informed consent under the ethical approval 
o f Great Orm ond Street Hospital for Sick Children NHS Trust and ICH 
Research Ethics Com m ittee (approval number 1350). M ouse work was done 
under the auspices o f  a UK H om e Office project license and with ethical 
approval from University College London.
URLs. The Genom e Database is available at http://gdbwww.gdb.org/gdb/. 
BayGenomics is available at http://baygenomics.ucsf.edu/cgi-bin/BayDbAccess. 
py?TYPE—blast.
Accession numbers. Riken database: Frem2 protein gene annotation, 
6030440P17Rik. TPA: human FREM2 transcript, BN000687. GenBank: Frem2, 
AJ833643.
Note: Supplementary information is available on the Nature Genetics website. 
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APPENDIX D
CD (attached to back cover) containing 3 OPT movies showing Frem2 expression in 
E10.5 myKst/+ embryos by X-gal staining. OPT was carried out by Rob Watson at 
the MRC-Human Genetics Unit in Edinburgh. The three movies show the embryos 
through different virtual planes.
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